






Structural and Functional Characterization of the Retinol-Binding Protein Receptor  
Stimulated by Retinoic Acid 6 
 














Submitted in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy 
under the Executive Committee 

















































Structural and Functional Characterization of the Retinol-Binding Protein Receptor Stimulated 
by Retinoic Acid 6 
Brianna K Costabile 
 
 Vitamin A is an essential nutrient; it is not synthesized by mammals and therefore must 
be obtained through the diet. During times of fasting or dietary vitamin A insufficiency, retinol, the 
alcohol form of the vitamin is released from the liver, its main storage tissue, for circulation in 
complex with retinol-binding protein 4 (RBP) to provide an adequate supply to peripheral tissues. 
Stimulated by Retinoic Acid 6 (STRA6), the transmembrane RBP receptor, mediates retinol 
uptake across blood-tissue barriers such as the retinal pigment epithelium of the eye, the placenta 
and the choroid plexus of the brain. Our understanding as to how this protein functions has been 
greatly enhanced by the high-resolution 3D structure of zebrafish STRA6 in complex with 
calmodulin (CaM) solved by single-particle cryogenic-electron microscopy. However, the nature 
of the interaction of STRA6 with retinol remains unclear. Here, I present the high-resolution 
structures of zebrafish and sheep STRA6 reconstituted in nanodisc lipid bilayers in the presence 
and absence of retinol. The nanodisc reconstitution system has allowed us to study this protein 
in a close to physiological environment and examine its interaction with the cell membrane and 
relationship with its ligand, retinol. We also present the structure of sheep STRA6 in complex with 
human RBP. The structure of the STRA6-RBP complex confirms predictions in the literature as 
to the nature of the protein-protein interaction needed for retinol transport. Calcium-bound CaM 
is bound to STRA6 in the RBP-STRA6 structure, consistent with a regulatory role of this calcium 




and during interaction with retinol – provide unique insights into the mechanism of STRA6-
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She showed through retinol-binding protein (RBP) deficient mouse models that RBP, although 
the prominent form of vitamin A transport in the bloodstream (in the fasting state), is not absolutely 
essential to maintaining whole organism retinoid homeostasis when dietary vitamin A is sufficient 
as was previously thought. Its importance comes more in the context of the visual process, whose 
vitamin A needs must be met by a source that is both quick to respond and precise. In 2007, the 
RBP receptor in the eye responsible for retinol uptake, was identified as the transmembrane 
protein, STRA6. The work presented here illuminates for the first time, the high-resolution 
structure of the mammalian STRA6 in complex with the retinol carrier protein, RBP. The structure, 
as is par for the scientific course, begs more questions than it answers, but in light of Dr. Quadro’s 
work, we can begin putting this protein into the physiological context she laid the groundwork for. 
 I am extremely grateful for the opportunity to work on this fascinating protein. I did not 
know at the time when Dr. Quadro showed me the first low-resolution density map of the zebrafish 
STRA6 structure (and made me promise not to tell anyone) that it would be the subject of my 
dissertation project. It is not lost on me that I began studying the transport of this nutrient at an 
organ level in my undergraduate days and have focused in on its cellular transport mechanism in 





and biochemistry experimentation. During the long hours of writing this thesis, I was often uplifted 
by the quote from Thomas Moore “It may be an inspiring thought…that Man’s knowledge of the 
existence of the stars and the vast universe which appears in the heavens each night, comes in 







Chapter 1: Literature review on the biological importance of 
vitamin A 
Vitamin A is an essential nutrient obtained from the diet, either as preformed vitamin A 
from animal products or provitamin A from fruits and vegetables. Vitamin A metabolites play a 
myriad of roles in the body; they are indispensable to the visual cycle, critical for embryonic 
development and essential for immunity. In the cell they mediate transcription of hundreds of 
genes, regulating processes such as cell proliferation, differentiation and death. With such critical 
roles in the body, it is clear that vitamin A deficiency is a serious issue, however excess retinoid 
can also be toxic and teratogenic. This chapter will present an overview of the importance of 
vitamin A and what is currently known about how different tissues maintain adequate amounts of 
this vital nutrient. 
 
1.1 The discovery of vitamin A 
 The ancient Egyptians (circa 1550 BC) are credited with the first description of night 
blindness (nyctalopia), a condition in which the patient has difficulty seeing in dim light [1], 
resulting from nutritional vitamin A deficiency [2, 3]. Although the Egyptians were not aware of the 
existence of this micronutrient, they prescribed the application of ox liver to the eye as treatment 
[4, 5]. This would suggest an early understanding of the curative properties of a vitamin A rich 
organ, however the topical application of the tissue would not provide effective treatment for night 
blindness [4]. The first record of consumption of liver as treatment for night blindness came some 
hundreds of years later from the ancient Greeks (around 200 AD) [4, 6]. In the late 1850s and 





blindness [7-9]. Both the physical corneal defects and night blindness were found to be reversed 
by consumption of vitamin A rich cod liver oil in the early 1900s [10]. Today, high-dose vitamin A 
supplementation is the most commonly used treatment for these conditions [11].  
 “Fat soluble A” was discovered by several groups at the same time as a constituent of 
certain fats that was necessary for proper growth and development in rats [12]. In 1912, Frederick 
Hopkins, who would later be awarded the Nobel Prize in Physiology or Medicine for his discovery, 
described the existence of “accessory factors” in food. Rats on a minimal diet of starch, lard and 
sugar grew but did not flourish. The addition of milk to this diet however rescued this effect [13]. 
The following year, McCollum and Osborne separately demonstrated that it was possible to 
extract lipid from butter or egg yolk and transfer it to fats that did not promote proper growth and 
thus imbue these lesser fats (such as lard or olive oil) with the ability to foster growth [12, 14]. The 
structure of this “fat soluble A” (retinol) as McCollum referred to it was reported in 1931 by Paul 
Karrer [15] and earned him the Nobel Prize in Chemistry in 1937 [16].  
 Evidence of vitamin A metabolic derivatives, later named retinoids, and their pleiotropic 
roles in support of a number of biological processes such as embryonic development, vision, 
immunity and spermatogenesis to name a few came over the course of the 20th century. The 
essential role of the aldehyde form in the visual process was reported by George Wald who was 
later awarded the Nobel Prize in Physiology or Medicine in 1967 [16]. The discovery of 
transcription factors that bind retinoic acid was postulated and later confirmed in the 1980s, 
beginning to answer many questions as to how the vitamin A acid form is able to control such a 
variety of physiological processes [17]. Indeed, retinoic acid has been shown to mediate 
transcription of over 500 different genes [18]. Retinol, the alcohol form, is the main transport form 
of vitamin A, although it has recently been shown to exert effects on gene expression and 





importance of vitamin A has undoubtedly come a long way since the ancient Egyptians, although 
we are still uncovering novel roles for this nutrient and insights into its metabolism, transport and 
function. 
 
1.2 The threat of vitamin A deficiency 
Despite our understanding of the importance of vitamin A in preventing disease, deficiency 
of this nutrient is still a global public health concern. In developed countries, vitamin A rich foods 
and supplements are in such surplus that deficiency of this nutrient is rare (see Table 1.1 for a list 
of common vitamin A rich foods) [21]. However, in certain countries where meat products are not 
readily available or produce naturally rich in vitamin A is not commonly grown, the populations 
are at risk of deficiency [22]. Children and pregnant women are especially at risk given the high 
level of nutrients required during development, adequate vitamin A supplementation during 
pregnancy is critical for proper development of the fetus and also to support the mother’s 
increased metabolism during this period [23]. Generally, the first sign of vitamin A deficiency is 
night blindness caused by xerophthalmia (dryness of the cornea and conjunctiva) [24], if 
supplements are not added to the diet, the person can completely lose their eyesight.  
UNICEF has classified 82 countries as vitamin A scarce based on the prevalence of 
vitamin A deficiency, defined as more than 2% of the population having serum level of vitamin A 
below 0.7 µmol/L [24, 25]. Serum level of 1.4 µmol/L has been shown to protect against night 
blindness in 95% of cases [26] and the current median level in the US is between 1.7 and 2.2 
µmol/L [27]. Although vitamin A supplementation has been shown to decrease all-cause 
childhood mortality by 12-24% [25], in 2013, an estimated one third of the world’s preschool age 





affected regions (south Asia and sub-Saharan Africa) were attributed to this insufficiency [28]. 
The vitamin A deficiency-related  mortality rate is mainly due to an increased susceptibility to and 
severity of infection [29], indeed vitamin A is vital to normal immune system functioning as it 
maintains the epithelial cell barrier, induces T cell response and regulates immune cell maturation  
[30].  In these countries, the WHO recommends a supplement regimen every six months of 30 
mg RAE (Retinol Activity Equivalents – see section 1.3) delivered as retinyl esters in soft gel 
capsules for children 6-11 months old and 60 mg RAE for children 12-59 months of age [31, 32]. 
This high dose intervention therapy has been shown to decrease childhood blindness and 
mortality related to micronutrient deficiency. Although these doses constitute an extremely high 
amount of vitamin A, children receiving this treatment appear to tolerate it well and maintain 
vitamin A serum levels over the following 4-6 months [32, 33]. UNICEF instituted a program to 
reach these children in 2000 and provide these high doses of vitamin A. Only 61% of children at 
risk received supplements in 2018, leaving over 100 million children still at risk of malnutrition [34] 
(Figure 1.1). Another WHO supplementation program utilizes sachets of mixed essential 
micronutrient powders. The sachets are premeasured and can be mixed into any semi-wet food, 
but must be taken daily rather than every 6 months [35]. Biofortification of commonly grown crops 
such as maize with vitamin A through genetic modification and selective breeding is a third method 
of providing this nutrient to developing countries. The success of introducing such crops as 
orange-fleshed sweet potatoes or orange (vitamin A fortified) maize has been mixed as crop yield 
and acceptability by the community is often low [36, 37]. Vitamin A (in these cases, in the form of 
beta-carotene) is also an unstable molecule and tends to oxidize during storage and food 
processing, further decreasing its bioavailability in these crops [38, 39]. Despite this, compared 
to the powders and capsules currently in use, biofortification is a more sustainable method of 





Without supplementation, vitamin A deficiency can lead to severe outcomes such as loss 
of vision entirely, stunted growth and child mortality [34]. Clearly, the global community requires 




Figure 1.1 Vitamin A deficiency prevalence.  
Success rate of vitamin A supplementation for children 6-59 months of age by two high doses per year 
indicated by color. Image from [40]. 
 
 
1.3 Nutritional sources of vitamin A 
 Vitamin A can be obtained through the diet either as preformed vitamin A, retinoids, or 
provitamin A, carotenoids. Meat and dairy products are high in readily available retinol and retinyl 





made more bioavailable by heating or homogenization to release them from complexes with 
proteins, High heat however can result in oxidation or isomerization which tends to decrease 
bioavailability [41, 42]. A number of studies have demonstrated that synthetic beta-carotene tends 
to be more bioavailable than carotenoids from food sources likely due to the complexes they exist 
in in plant matter [43]. Additionally, enzymatic processing of the ingested beta-carotene, alpha-
carotene and beta-cryptoxanthin is needed to form active retinoids [44-49]. Provitamin A 
carotenoids, once ingested, are packaged into chylomicrons in the intestine and transported 
through the lymphatic system for uptake into tissues such as the liver where they can then be 
metabolized [43, 50]. Beta-carotene for example, can be cleaved by beta-carotene 15,15’ 
oxygenase-1 to form two molecules of retinaldehyde, which can then be further converted to 
retinol and retinyl esters [51].  
 
 
Figure 1.2 Cartoon depiction of carotenoid and retinoid food sources.  
Provitamin A carotenoids from fruits and vegetables can be enzymatically cleaved to form retinaldehyde 
which can be further metabolized to other retinoids. Meat and dairy products contain high concentrations 







 Because of the carotenoid cleavage step and higher potential for clearance compared to 
ingested retinoids, the term Retinol Activity Equivalent (RAE) was developed to simplify and 
combine the pre and provitamin A content of foods. By this system, 12 µg of beta-carotene is 
equal to 1 µg RAE [27]. Vitamin A supplements usually contain 750-3000 µg RAE in the form of 
a mix of pre and provitamin A, well over the recommended daily intake of 700 µg RAE for adult 
(non-pregnant or lactating) women and 900 µg RAE for adult men [21, 27]. Western countries 
obtain approximately 75% of their vitamin A as preformed vitamin A from animal sources and the 
rest as provitamin A, mainly in the form of beta-carotene from red-orange and dark green fruits 
and vegetables [27]. The most common food source of beta-carotene in the US being carrots, 
followed by broccoli, cantaloupe and squash (see Table 1.1 for a list of example foods and vitamin 
A contents) [27]. During WWII, Britain began a carrot campaign, persuading people that eating 
them would improve their night vision. This propaganda was aimed at hiding the British Airborne 
Interception Radar – blaming the increased downed German planes not on new technology, but 
on carrot-powered super soldiers [52]. This of course is a fallacy, eating carrots indeed helps to 













Table 1.1 List of vitamin A contents of example foods 
Food Micrograms RAE per serving Percent DV 
Beef liver, pan fried, 3 oz 6582 731 
Sweet potato, baked in skin, 1 whole 1403 156 
Spinach, frozen, boiled, ½ cup 573 64 
Carrots, raw, ½ cup 459 51 
Cheese, ricotta, part skim, 1 cup 263 29 
Cantaloupe, raw, ½ cup 135 15 
Egg, hard boiled, 1 large 75 8 
Broccoli, boiled, ½ cup 60 7 
Salmon, sockeye, cooked, 3 oz 59 7 
Chicken, breast meat and skin, ½ breast 5 1 
RAE: Retinol Activity Equivalents, DV: Daily Value. Adapted from [21]. 
 
1.4 An overview of retinoid metabolism: from ingested retinoid to secreted retinol 
After a meal of meat or dairy products, retinol for the most part appears to be freely 
absorbed by the enterocytes of the intestine through passive diffusion (Figure 1.3) [53-55]. There 
is also data to suggest a saturable carrier-mediated process of retinol uptake into the enterocytes, 
although not confirmed. The transmembrane liver and intestine specific retinol-binding protein 
receptor 2 (RBPR2) may be responsible for this uptake, it would however require binding of retinol 
to RBP prior to uptake [56, 57]. Ingested retinyl esters however, must be converted by the luminal 
hydrolases PTL (Pancreatic Triglyceride Lipase) and PLRP2 (Pancreatic Lipase-related Protein 
2) to retinol before being taken up by the enterocytes [58, 59]. Once in the enterocyte, Cellular 
Retinol-Binding Protein II (CRBPII) binds retinol and shuttles it to the enzyme Lecithin Retinol 
Acyltransferase (LRAT), which esterifies the retinol to retinyl esters [54, 60]. Recent studies of 





can also function as an acyl-CoA:retinol acyltransferase and esterify retinol [61, 62]. Once 
esterified, these retinyl esters can then be incorporated into chylomicrons composed of 
phospholipids and triacylglycerol and secreted from the enterocytes into the lymphatic system 
[63, 64]. A cell-based study on Caco-2 cells showed that free retinol can also be secreted under 
vitamin A deficient condition, not requiring packaging into lipoproteins [64]. The chylomicrons are 
then broken down into chylomicron remnants and taken up into the hepatocytes mainly by low-
density lipoprotein receptors (LDLr) [65]. Retinyl esters are then hydrolyzed to retinol by retinyl 
ester hydrolases (REHs) so that they can bind retinol-binding protein 4 (RBP) located on the 
endoplasmic reticulum (ER). Transthyretin (TTR) which serves to prevent clearance of the retinol-
bound RBP forms a complex with RBP in the ER with the help of the chaperone, calnexin [66, 
67]. Binding of retinol to RBP triggers migration of the now holo-RBP-TTR complex from the ER 
to the Golgi apparatus and is then secreted from the cell [68]. The rest of the retinol meanwhile is 
converted to retinyl esters by LRAT and stored in the hepatic stellate cells (HSCs), although the 
mechanism of transport of retinol from the hepatocytes to the HSCs is still unclear [69-71]. Some 
of the chylomicrons do travel directly from the enterocytes to peripheral tissues such as the 







Figure 1.3 Simplified digestion of retinoids.  
Ingested retinyl esters (REs) must be converted to retinol (ROL) before uptake by the enterocytes in the 
intestine. REs formed in the intestine are secreted into the lymphatic system in chylomicrons which can 
directly travel to tissues such as the kidney, bone marrow or adipose tissue or to the liver. In the liver, REs 
are converted to ROL then either bound to RBP and secreted into the bloodstream or converted back to 
REs which can be stored in the hepatic stellate cells. Pancreatic triglyceride hydrolase (PTL), Pancreatic 
lipase-related protein 2 (PLRP2), Cellular Retinol-binding protein II (CRBPII), Lecithin retinol 
acyltransferase (LRAT), Low-density lipoprotein receptor (LDLr), Retinyl esters hydrolases (REHs). Figure 
made using BioRender and adapted from [73] and [74]. 
 
 
Once inside the cell, retinol is converted to retinaldehyde by retinol dehydrogenases 
(RDHs) [75]. Retinaldehyde can then be further oxidized by retinaldehyde dehydrogenases 
(RALDHs) to retinoic acid, which is considered the active form of vitamin A as it serves as a 





genes implicated in a variety of physiological processes (Figure 1.4) [18]. Three cytochrome P450 
enzymes can degrade retinoic acid, eliminating it from the cell and preventing toxic accumulation 
of these metabolites [77, 78]. The reciprocal reaction of RDHs catalyzed by retinaldehyde 
reductases (RALRs) such as DHRS3, can also serve to prevent retinoic acid accumulation by 
decreasing the amount of available precursor, retinaldehyde [79].  This sequence of events of 




Figure 1.4 Overview of retinoid metabolism.  
Retinaldehyde is converted to the transcription factor ligand, retinoic acid by retinaldehyde dehydrogenases 
(RALDHs). Cytochrome P450 enzymes (CYPs) degrade retinoic acid to polar metabolites that can be 
removed from the cell, preventing retinoid toxicity. Retinaldehyde and retinol can be interconverted by 
retinol dehydrogenases (RDHs) and retinaldehyde reductases (RALRs). Retinol and retinyl esters can be 
interconverted by lecithin retinol acyltransferase (LRAT) and retinyl ester hydrolases (REHs). REs are the 
major storage form of vitamin A, mainly in lipid droplets in the hepatic stellate cells. Figure made in 






1.5 The essential role of vitamin A in rod photoreceptor vision 
Mammalian rod and cone photoreceptor vision utilize a monostable pigment that must be 
constantly regenerated and whose precursors and derivates must be carefully transported 
between cell types to maintain visual cycling [81]. The pigment, 11-cis retinal binds rhodopsin and 
is photoisomerized by a photon of light hitting the retina. The product of this reaction, all-trans 
retinal is released from opsin and must then be converted back to 11-cis retinal through a series 
of reactions (Figure 1.5). All-trans retinal is transported from the luminal to the cytosolic side of 
the disc membrane by ABCA4 and once there is converted to the most common vitamin A 
transport form, all-trans retinol by RDH. All-trans retinol must then be exported out of the 
photoreceptor into the retinal pigment epithelium (RPE) for further recycling by the 
interphotoreceptor retinol-binding protein (IRBP). Once in the RPE, all-trans retinol is converted 
to retinyl ester by LRAT then to 11-cis retinol by RPE65 and then finally back to 11-cis retinal by 
RDH [82]. Retinyl esters can be stored in retinosomes, serving as a store of retinoid in the RPE 
[83]. The regenerated pigment can then be transported back across the interphotoreceptor space 
to the rod photoreceptor by IRBP. This specifically tuned system of pigment regeneration begins 
in the first place with all-trans retinol taken into the RPE from the circulation [84, 85]. Rod 
photoreceptors are mainly needed for vision under low light conditions (as compared to cones 
which function under bright light and do not rely on the RPE for a supply of retinoid), therefore it 








Figure 1.5 Rod photoreceptor visual cycle schematic.  
The choroid supplies all-trans retinol (atROL) bound to RBP to the RPE where it can be metabolized to the 
photopigment needed for vision. atROL is esterified to retinyl esters (REs) which are then converted to 11-
cis retinol (11cisROL) by RPE65. 11cisROL is then converted to 11-cis retinoaldehyde (11cisRAL) by retinol 
dehydrogenase before it can be transported across the interphotoreceptor matrix by IRBP 
(interphotoreceptor retinol binding protein). Once in the rod photoreceptor, the opsin can bind the 
photopigment. Light hitting the retina photoisomerizes 11cisRAL to atRAL (all-trans retinaldehyde). atRAL 
is then converted back to atROL which can cross the interphotoreceptor matrix and begin the cycle again. 
Figures made in BioRender and adapted from [86]. 
 
 
1.6 Evidence supporting the existence of an RBP receptor  
 In the fasting state, 95% of vitamin A in the blood is retinol bound to RBP [87]. It was 
hypothesized that this form of circulating vitamin A functioned to maintain retinoid homeostasis in 
the body. Indeed, examples of vitamin A toxicity typically occur when retinoids are delivered to 





were able to obtain retinol from circulating RBP was highly debated for many years; was an RBP 
endocytosis mechanism responsible? Was retinol first released from RBP before internalization? 
Or was it some combination of the two? In the 1970s, evidence of an RBP receptor in the RPE 
began to accrue when binding of iodinated RBP to bovine RPE was observed with high affinity 
[90, 91]. This binding was specific to the RPE (no binding was detected in rod photoreceptor outer 
segments) and uptake of retinol without endocytosis of the RBP was observed [85, 90]. RBP 
receptor binding was detected in a variety of other tissues but most highly in blood-tissue barriers 
such as the choroid plexus of the brain, the placenta and the RPE. In 1998, transport of retinol 
from extracellular retinol to intracellular CRBP was demonstrated by a receptor expressed in 
placenta membranes. This receptor only responded to retinol-bound RBP and did not accept 
retinol from albumin or beta-lactoglobulin, proteins also known to transport retinol in the circulation 
[92-94]. A number of other studies further demonstrated uptake of retinol from RBP without 
endocytosis of the protein in intestinal mucosal cells [95], placental membranes [96],  Sertoli cells 
of the testes [97] and macrophages [98]. Using crosslinking and pull-down methods, scientists 
were able to purify a 63 kDa protein that recognized RBP from bovine RPE cells [99], rat yolk sac 
[100], and human placental membranes [96] and presumed it to be this mysterious receptor.   
 In 1995 Bouillet and colleagues identified Stimulated by Retinoic Acid 6 (STRA6) as a 
gene whose expression responded to changes in retinoic acid level [101]. They showed high 
tissue expression during development and found that it is mainly expressed in blood-tissue 
barriers with tight junctions, suggesting a potential transport function [102]. In 2007, Dr. Hui Sun’s 
group at UCLA identified through an unbiased crosslinking approach the RBP receptor natively 
expressed in bovine RPE cells to be this previously classified gene, STRA6 [103]. They 
demonstrated both binding of RBP to STRA6 and also retinol uptake in RPE cells and COS-1 





not block retinol uptake and the process was specific to RBP. Following this landmark study, Dr. 
Sun’s group, through a variety of cellular and “cell-free” (solubilized cell-membrane) assays, 
characterized the topology and function of this novel protein, which had no sequence homology 
to any known protein at the time. The protein had a molecular weight of around 65 kDa, was 
predicted to have 9-11 transmembrane helices and a large intracellular C terminal domain [103, 
104]. This number of transmembrane helices was indicative of a transport pore through which 
retinol could pass and TMs 6 and 7 were later shown to be part of this putative pore [104, 105]. 
The details of these comprehensive experiments will be examined in section 1.8 and revisited in 
chapters 3 and 4 in relation to the mammalian STRA6 protein structures reported here. 
 
1.7 Evidence of a role of STRA6 in tissue-specific retinol uptake 
 STRA6 is highly expressed in the RPE and other blood tissue-barriers such as the 
placenta and the choroid plexus of the brain [102]. Below is a brief description of the evidence 
surrounding STRA6 function in each of these tissues.  
 
1.7.1 STRA6 in the eye 
 STRA6 is expressed on the basolateral membrane of the RPE which provides nutrients 
from the circulation to the photoreceptors, but especially all-trans retinol [106]. The canonical 
visual cycle begins with STRA6-mediated uptake of all-trans retinol from the circulation into the 
RPE, where it is converted to 11-cis-retinol and transferred across the interphotoreceptor matrix 
to the rod photoreceptor where photoisomerization occurs [107]. In Stra6-/- mouse models, 
animals maintained on vitamin A sufficient diet had few effects with the exception of shortened 





stores in the eye in addition to deteriorating photoreceptors and visual responses [108]. 
Interestingly, a different study of Stra6-/- mice showed that animals when maintained even on a 
vitamin A sufficient diet, had poor visual responses and developed PHPV (persistent hyperplastic 
primary vitreous), a congenital malformation often caused by vitamin A deficiency during 
development [109]. These studies indicate that other pathways can compensate for a lack of 
STRA6 in the eye, but they may not be sufficient to permit normal visual function.  
 
1.7.2 STRA6 in the placenta 
 Vitamin A is crucial to mammalian embryonic patterning and development, but can also 
be teratogenic if in excess. Therefore strict regulation of vitamin A crossing the maternal-fetal 
barrier to the developing tissues is of the utmost importance [110, 111]. Some of the earliest 
binding kinetic studies of RBP to its receptor were performed using membrane vesicles from 
human placenta given its high expression in this tissue [112, 113]. RBP-bound retinol has been 
shown to be the primary source of vitamin A for the developing fetus, although lipoprotein 
incorporated retinyl esters can contribute to embryonic retinoid stores as well [114]. Using 
radiolabeled retinol-bound RBP, Quadro et al. demonstrated that only retinol, but not RBP crosses 
the placenta to reach the developing tissues, suggesting the existence of a receptor specific to 
this process [115].  
 
 1.7.3 STRA6 in the choroid plexus 
 The choroid plexus of the brain is a barrier of epithelial cells, protecting the cerebrospinal 
fluid from the peripheral circulation [116]. It is responsible for mediating transfer of various 





choroid plexus accepts retinol from RBP in the circulation, bringing it into this epithelial cell barrier 
where it is loaded back onto RBP and secreted into the cerebrospinal fluid for transport in the 
brain [117]. Mouse models of vitamin A deficiency, whether diet or genetic ablation induced, show 
severe defects in brain patterning [114, 118].  Although animal models of vitamin A deficiency 
during development clearly depict a role for retinoic acid in modulating development of the brain, 
the role of this nutrient in the mature brain remains unclear. Metabolic retinoid enzymes are 
expressed in different regions as are retinoic acid receptors indicating the importance of this 
nutrient in maintaining brain function [119]. There is however some evidence from rodent models 
for a role of vitamin A in regulation of synaptic plasticity [120] and cortical synchrony during sleep 
[121]. It is clear that new functions for vitamin A in the brain are still being uncovered [122].  
 
1.8 STRA6 function  
 A variety of biochemical and cell-based studies in the early 2000s have illuminated 
properties of the mechanism of how STRA6 transports retinol. STRA6 is a unique protein in that 
it accepts a neutral lipidic molecule bound with high affinity to an extracellular soluble protein and 
brings it into the cell without the need of a chemical gradient or activating force [123]. There is no 
known toxin or chemical inhibitor of STRA6, suggesting that the protein likely lacks a distinct pore 
or binding site that can be blocked to prevent retinol uptake [105]. In 2011, Dr. Sun’s and also Dr. 
von Lintig’s groups demonstrated that STRA6 is able not only to mediate cellular uptake of retinol, 
but also efflux, loading retinol onto extracellular apo-RBP (Figure 1.6 AB) [124, 125]. In addition, 
STRA6 was also shown to mediate exchange of retinol between RBP molecules and between 
extracellular RBP and intracellular CRBPs (Figure 1.6 C) [124]. In the bloodstream, more than 





of STRA6 is the majority reaction, but efflux occurs at the same time, potentially in order to 
replenish intracellular retinol stores and prevent oxidation due to long term storage [124].  
 In general, mechanisms that block retinol loading onto RBP increase retinol uptake. 
STRA6 retinol uptake was shown to couple to intracellular vitamin A storage proteins, CRBP-I, 
LRAT and RDH (retinol dehydrogenase). Transport of retinol out of the membrane and to 
enzymes that convert it to other retinoid metabolites effectively blocks retinol efflux and therefore 
increases uptake. Small molecules such as beta-ionone [127] and other retinoids that can 
compete with retinol for loading onto RBP have also been demonstrated to increase retinol uptake 
[128]. Fenretinide, all-trans retinaldehyde, all-trans retinoic acid, and 13-cis retinoic acid were 
shown to block retinol loading and promote retinol release from RBP via STRA6 in a dose 
dependent manner and also to increase cellular retinol uptake [128]. 9-cis retinol however had no 
effect on all-trans retinol loading or release, despite the fact that it can be transported by both 
RBP [129] and CRBP-I [130] suggesting that this retinoid cannot pass through STRA6 and 
pointing to the importance of the double bond arrangement of the retinoid in facilitating STRA6 
interaction. Additionally, retinol with an siRNA tail was able to increase retinol release from RBP 
in a membrane system, suggesting that the beta-ionone ring end of retinol is needed for STRA6 
interaction, and that the alcohol tail is less essential. Indeed, retinol is carried in RBP with the 
beta-ionone ring innermost of the binding pocket with the alcohol end interacting with the exit 
loops [131], so this potential orientation aligns with the data. The interaction of the alcohol group 
with the exit end of RBP appears to be less essential for binding compared to the beta-ionone 
ring as evidenced by binding of retinoids such as fenretinide and 13-cis retinoic acid to RBP [132]. 
Excess free retinol has in some cases been shown to prevent retinol uptake from RBP, however 
in an experiment in which cells are treated with unlabeled free retinol and also labeled retinol 





 In 2013, Dr. Sun’s group proposed the existence of a pore in the STRA6 protein through 
which retinol could be internalized into the cell (Figure 1.6 D). After large-scale random 
mutagenesis the group failed to find a point mutation that would allow cell-surface expression and 
RBP interaction, but block retinol uptake by STRA6. They were however able to decrease retinol 
uptake by chemically modifying introduced cysteines in a specific region of the structure while still 
maintaining RBP interaction. Addition of MTSEA-biotin to cysteines introduced into predicted TMs 
6 and 7 was the most effective in preventing uptake, suggesting that this putative pore is bounded 
by these TMs [105]. A high-resolution 3D structure of the protein at this point would be vital to 







Figure 1.6 STRA6 functional and topological characterization.  
A) STRA6 (blue rectangles) mediates influx of retinol from extracellular RBP (in rainbow coloring above the 
membrane). Influx is coupled to CRBP-I (in rainbow coloring below the membrane) and LRAT (in teal) 
located on the endoplasmic reticulum. B) STRA6 mediates retinol efflux onto RBP and exchange of retinol 
from CRBP-I to RBP. C) STRA6 mediates exchange of retinol between RBP molecules. D) Topology of 
STRA6, residues in blue are implicated in RBP binding, residues in red are thought to be part of the pore 
through which retinol passes through STRA6. Figures made in BioRender and adapted or taken from [123]. 







1.9 STRA6 role in disease 
1.9.1 Matthew-Wood Syndrome 
 Mutations in the Stra6 gene have been implicated in Matthew-Wood Syndrome (MWS) 
which results in severe congenital malformation. The syndrome is characterized by 
microphthalmia or anophthalmia in combination with pulmonary agenesis, but it is quite pleiotropic 
with some patients having diaphragmatic effects, cardiac deficiencies as well as general stunted 
growth [133-135]. Patients with truncating, frameshift and missense mutations in Stra6 have been 
reported [136, 137]. From cell-based assays, we have learned that most of the missense 
mutations prevent cell-surface expression of the protein and are in essence null mutations. In one 
case, the patient had two mutations, T321P on its own coded for functioning protein, but in 
combination with P90L, the protein was not surface expressed [138]. It is of interest to note the 
severe effects of this syndrome are more closely aligned with zebrafish models of Stra6-/- than 
mouse models which essentially develop without issue with the exception of visual defects; 
perhaps the STRA6 protein plays a more significant role in trafficking retinoic acid in the 
developing human and zebrafish embryos as compared to mouse [109, 125]. 
 
 1.9.2 STRA6 in cancer 
 Retinoic acid is known to use transcriptional regulation to influence three factors often 
aberrant in cancer, namely, cell proliferation, differentiation and apoptosis. Promyelocytic 
leukaemia is often treated with retinoic acid as differentiation therapy; this retinoid promotes 
differentiation of malignant cancer cells into more mature cell forms that lose their ability to self-





and has been implicated in cancers in which aberrant retinoic acid signaling is present. Colorectal 
cancers in which Wnt-1 signaling is impaired were found to have elevated expression of STRA6 
although at the time, the function of the protein was unknown [140]. In a more recent study, 
upregulated STRA6 in breast and colon cancers was linked to the protein’s ability to transduce a 
JAK/STAT signaling cascade [141, 142]. The retinoid analog, fenretinide, is a cancer drug that 
can induce apoptosis. The mechanism as to how this is achieved is unclear, although Dr. Sun 
postulated that fenretinide’s ability to block retinol loading serves to overload the cell with 
retinoids, resulting in transcriptional effects that can then lead to apoptosis [128, 143]. 
 
 1.9.3 Diabetes/Insulin signaling 
 The potential role of RBP in type 2 diabetes was first reported in 2005 when it was found 
that serum RBP levels are increased in obese people with type 2 diabetes [144]. In 2011, Berry 
and colleagues reported that holo-RBP interaction with STRA6 transduces an insulin signaling 
cascade through interaction of the phosphorylated STRA6 C terminus with JAK2 and STAT5 
proteins [145, 146]. Upon interaction of retinol-bound RBP with STRA6, a tyrosine in the C-
terminal SH2 domain of STRA6 is phosphorylated, recruiting JAK2 and STAT5 (Figure 1.7) [147]. 
STAT5 is then directed to the nucleus where it induces transcription of the suppressor of cytokine 
signaling 3 (SOCS3) and peroxisome proliferator-activated receptor gamma (PPARγ). SOCS3 
then inhibits insulin signaling [148], resulting in phosphorylation of Akt and subsequent 
translocation of GluT4 to the membrane where it can increase glucose uptake [149]. PPARγ 
meanwhile increases lipid accumulation [150] and the combination of these two effects increases 
adiposity and insulin resistance [151, 152]. Decreasing circulating RBP could be a potential 
therapeutic target (the data is mixed on this [153]). for this syndrome, although it is clear that off-





The data from Dr. Noy’s lab however must be examined cautiously as it was later found that the 
antibody they utilized to detect STRA6 expression and interaction with JAK2 and STAT5 does not 
actually recognize human STRA6  [123, 124, 154]. In a study of preadipocytes expressing 
transfected STRA6, holo-RBP did not induce STAT5 phosphorylation, nor did it increase 
transcription of PPARy or SOCS3 [154]. Further studies to confirm this STRA6-mediated signaling 
cascade are needed. 
 
 
Figure 1.7 Proposed STRA6/JAK/STAT signaling cascade. 
holo-RBP interacts with STRA6 (1) triggering the phosphorylation of the C terminus of STRA6 (2) which 
then recruits JAK2 (3) and STAT5 (5). STAT5 can then migrate to the nucleus (5) where it activates 
transcription of SOCS3 and PPARγ (6). SOCS3 inhibits insulin receptor signaling (7), resulting in Akt 
activating GluT4 translocation (8). PPARγ triggers lipid accumulation in the cell (9). Human holo-RBP image 







1.10 Structure of STRA6 from Danio rerio  
 STRA6 was predicted to have 9-11 transmembrane helices, a large C terminal cytosolic 
domain and a small extracellular domain required for interaction with RBP [104, 138]. Other than 
this basic knowledge of the predicted topology of the protein, little else was known of the protein’s 
structure until 2016 when Dr. Mancia’s lab reported the full-length structure of STRA6 from 
zebrafish [155]. The protein was expressed in insect cells, purified in detergent and then 
reconstituted in amphipol A8-35, a membrane mimetic that maintains transmembrane proteins in 
a detergent-free environment and is amenable to single-particle cryogenic-electron microscopy 
(cryo-EM) analysis. The structure of the zebrafish homolog revealed that the protein is a dimer 
with 9 transmembrane helices and one intramembrane helix (Figure 1.8 A). It has a bundle of 5 
N-terminal transmembrane helices that contain two hydrophobic cavities, one on either side of 
the membrane. The function of these cavities, referred to as the inner and outer pockets, has not 
been explored (Figure 1.8 C). Perhaps these cavities are binding sites for ligands that can mediate 
STRA6 function [127]. The residues forming the essential ligand-binding domain as described by 
Dr. Sun [138] are located between TMs 6 and 7 at the extracellular apex of the protein, 25 Å 
above the membrane. This location appears to be optimal for interaction with RBP circulating in 
the bloodstream. Between the two protomers is a large hydrophobic cleft that seems to be lipid 
filled, as evidenced by a shell of density lining the extracellular face of the cavity (Figure 1.8 B). 
TMs 8, 9 and the intramembrane helix form a triangular lateral portal that appears to open from 
this cavity directly to the membrane. At the C terminus of the protein, STRA6 is in complex with 
one molecule of calmodulin (CaM). Three peptides of STRA6 interact with CaM and are referred 
to as CaMBP0, CaMBP1 and CaMBP2. All four binding sites of CaM appear to be calcium bound 





from the structure how STRA6 is able to mediate the translocation of retinol between extracellular 
RBP and intracellular CRBP-I. Given the lipid-filled nature of the central cavity and the large size 
of the lateral window, we hypothesize that upon interaction of RBP with the extracellular RBP 
interacting loops, retinol is released from RBP into the central cavity and diffuses through the 
opening directly into the membrane. This mechanism would not require direct interaction of 
CRBP-I with STRA6, which is in line with functional studies demonstrating that retinol uptake still 
occurs independent of this transport protein [127]. The mechanism also does not require a distinct 
RBP binding site which so far is not obvious in the structure. There are two densities interacting 
with the intramembrane helices that were tentatively identified as cholesterol either from the insect 
cells the protein was expressed in or the cholesteryl hemisuccinate that was used during 
purification. The alcohol tail of retinol could potentially interact similarly with N519 and T515 as 
the hydroxyl tails of the cholesterol molecules are in the structure (Figure 1.8 D). The nature of 
the direct interaction of RBP with the extracellular loops also remains unclear. Does the interaction 
mimic that of RBP with TTR? What sort of conformational changes in each of the players is 
needed for release or loading to RBP? Or does the proximity of retinol to the lipid-filled cavity 
favor release, thus triggering conformational changes? Perhaps the most surprising finding from 
this structure was the complex of STRA6 with calcium-bound CaM, which begs the question as 










Figure 1.8 Structure of zebrafish STRA6 reconstituted in amphipol.  
A) Front model of STRA6 in rainbow spectral coloring. Membrane indicated by yellow rectangle. N terminal 
transmembrane helices 1-5 in purple, TMs 6 and 7 and the RBP interacting peptide in green, TMs 8, 9 and 
intramembrane helix in yellow and orange, CaM in cyan and CaMBP0 in blue, CaMBP1 and CaMBP2 in 
red. B) Front model of STRA6, amphipol density indicated by yellow spacefill. C) STRA6 side and front 
models, protomers in black and red, CaM in silver and gold, central hydrophobic cavity in blue spacefill, N 
terminal TM bundle hydrophobic cavities in purple (outer pocket) and pink (inner pocket). D) Cholesterol 
densities in green shown interacting with residues T515 and N519 of the intramembrane helices. From 












1.11 STRA6-CaM interaction 
 Although the direct interaction of STRA6 with CaM was an unexpected finding, the 
importance of calcium during phototransduction was well-known and therefore a connection 
between calcium level in the photoreceptor and STRA6-mediated retinol uptake may exist [149]. 
In an upcoming publication (submitted to Journal of Molecular Biology) in collaboration with Dr. 
Weber’s group at the University of Maryland, we detail the biophysics of the interaction of CaM 
with CaMBP2 of zebrafish STRA6 [156]. CaMBP2 appears to be the major peptide out of the 
three (CaMBP0, 1 and 2) that governs the interaction with CaM. It binds the hydrophobic groove 
of the C lobe of CaM while CaMBP0 and CaMBP1 interact with the N lobe of CaM. Dr. Weber’s 
group found through ITC, NMR and Quin-2 calcium chelator competition studies that the affinity 
of CaM for CaMBP2 is increased in the presence of calcium from a Kd of 6800 nM in the absence 
of calcium to 0.9 nM in the presence, suggesting a calcium dependent interaction of these proteins 
(Figure 1.9). We also report that CaMBP2 increases the calcium binding affinity of CaM to a 
different extent in each of the CaM lobes. The Kd of the C lobe of CaM for calcium when bound 
to CaMBP2 is 60 nM whereas the affinity of the N lobe of CaM for calcium is 1000 nM. This 
suggests that calcium is bound to the C lobe of CaM when in complex with STRA6 under normal 
physiological conditions (<100 nM), and during a calcium signaling event when intracellular 
calcium concentration rises, the N lobe binds calcium as well [157]. In the zebrafish STRA6 
structure, calcium is bound in all four sites of CaM despite not having added any exogenous 
calcium during the purification of the protein. As will be detailed in chapter 2, the addition of EGTA 
to the purified protein did not allow us to capture the putative state in which calcium is only bound 
in the C lobe of CaM but not the N lobe, suggesting that the full calcium-bound state of CaM in 





 In 2020, in collaboration with Dr. Sun’s group we published a paper detailing evidence 
supporting the role of calcium in modulating mammalian STRA6 affinity for RBP and subsequent 
retinol uptake in a cell-based system [158]. Dr. Sun’s group showed that increased calcium level 
in the cell increased affinity of STRA6 for apo-RBP over holo-RBP, thus decreasing retinol uptake 
by promoting retinol efflux. It is of note that in their cell system it appeared that CaM completely 
dissociated from STRA6 under low calcium conditions; we would expect based on our biophysical 
studies that the C lobe of CaM would remain bound to STRA6. This may be a species difference 
as our CaMBP2 was from zebrafish and is not 100% conserved in bovine which is the homolog 
used in Dr. Sun’s studies. We are just beginning to decipher the modes of interaction and role of 
CaM in STRA6-mediated retinol uptake. How the visual process is affected by this interaction is 
a major topic to be addressed in the future. 
 
 
Figure 1.9 Cartoon schematic of CaM in complex with STRA6 CaMBP2. 
Under physiological conditions, the intracellular calcium concentration is under 100 nM, with an affinity of 
60 nM for calcium while in complex with CaMBP2 (yellow bar), this would mean that the C lobe of CaM is 
constitutively bound to CaMBP2. When a calcium signaling event occurs, the N lobe of CaM binds calcium 







1.12 Principal findings in this thesis  
 The structure of zebrafish STRA6 has provided immense insight into the potential 
mechanism of function of the protein, however many outstanding questions remain. Although the 
visual cycle mechanism is generally conserved between mammals and zebrafish, the moderately 
low sequence identity of STRA6 from these species (approximately 40% amino acid sequence 
identity) would suggest potential structural differences that may lead to functional variability. How 
related are the zebrafish and mammalian homologs of STRA6? Are the overall features similar 
enough to suggest a conservation of retinol uptake mechanism? The second major question 
regards the nature of the RBP interaction. Although the essential ligand binding domain of STRA6 
has been determined through cellular studies, what is the nature of the interaction needed for 
transfer of retinol from RBP into the membrane?  
 In this thesis I will present 3 experimental chapters: the first on zebrafish STRA6. I will 
share improved high-resolution structures of zebrafish STRA6 reconstituted in nanodisc in the 
presence of calcium and also loaded with retinol. The second will detail methods of structure 
solution of mammalian STRA6. The third will focus on the complex formation and structural study 
of RBP and STRA6. The final chapter will describe ongoing functional studies on mammalian 
STRA6 aimed at elucidating the nature of its interaction with RBP and the relationship of vitamin 









Chapter 2: Zebrafish STRA6 structure and function 
The structure of zebrafish STRA6 reconstituted in amphipol was solved by single particle 
cryo-EM in 2016. The published structure reached 3.9 Å resolution, allowing us to visualize the 
full-length protein in complex with calcium-bound CaM for the first time. Given the lipidic nature 
of the ligand and the central hydrophobic cavity in the protein, we surmised that the membrane 
must play a significant role in STRA6 retinol uptake function. We therefore aimed to solve the 
structure of this protein in a lipid bilayer formed by nanodiscs in order to provide insight into the 
nature of the protein’s interaction with the cell membrane. Nanodisc reconstitution provided us a 
close to native milieu in which we could study the interaction of STRA6 with its ligand, retinol. The 
protein purifications and data collections in this chapter were performed in collaboration with post-
doc Yunting Chen and Dr. Oliver B. Clarke.  
 
2.1 Zebrafish STRA6 introduction 
STRA6, as described in 1.10 (Figure 1.8), has 9 transmembrane helices with one 
intramembrane helix and a large hydrophobic cavity that appears to be lipid filled between the 
two protomers (Figure 1.8 C). TMs 8, 9 and the intramembrane helix form an opening that seems 
large enough for retinol to freely pass through. Based on the structure of the protein and taking 
into consideration the biophysical data on STRA6-mediated retinol uptake from previous studies, 
we postulate that retinol once released from RBP is deposited into this central cavity and can then 
directly partition into the membrane [155]. Cell-based and membrane-based assays of retinol 
uptake (by mammalian STRA6) do not support the existence of a specific retinol-binding site in 
the protein [105]. Indeed, the nature of the protein’s function is to quickly respond to low tissue 





large hydrophobic pore through which retinol could directly partition into the membrane would in 
theory be more efficient than docking and undocking in a specific ligand binding site before 
partitioning into the membrane or binding to an intracellular CRBP. The mechanism of retinol 
uptake may in part be regulated by the calcium-bound state of the CaM in complex with the 
STRA6 C-terminus [158]. As Dr. Sun has postulated, STRA6 may function as the “homing device” 
for RBP to blood-tissue barriers, but calcium may function as the dimmer switch of this device 
[20]. The hypothesis in regards to retinol uptake supposes a vital role of the lipid bilayer in the 
protein’s putative functional mechanism. 
In order to better study the interaction of the protein with its ligand, we aimed to solve the 
structure of STRA6 reconstituted in nanodisc. Amphipol, although an effective detergent-free 
solubilization technique for membrane proteins, does not allow for visualization of the protein in a 
lipid bilayer. The amphipathic surfactant is composed of a hydrophilic backbone with hydrophobic 
groups that tightly associate with the transmembrane regions of the protein [159]. Nanodiscs, 
however reconstitute the protein in a lipid bilayer formed by exogenously added lipids and a 
membrane scaffolding protein which forms a belt around the protein surrounded by the lipid [160]. 
This technology effectively solubilizes the protein in a lipid bilayer at the single molecule level, 
allowing for both functional and structural study.  
The nanodisc system provides a closer to native milieu and therefore could be more useful 
in investigating the interaction of STRA6 with its ligand from a structural standpoint. We present 
here high-resolution structures solved by single particle cryo-EM of zebrafish STRA6 






2.2 Methods  
 In lieu of Methods sections describing the purification of zebrafish STRA6 and its 
reconstitution in amphipol and nanodisc, I will here present our Methods in Enzymology 
manuscript published in 2020. This paper explains the benefits of each of these techniques and 
also details the liposome-based assay of retinol uptake I developed for zebrafish STRA6. The 
chapter will continue with Methods sections describing the RBP-mediated retinol loading of 
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STRA6 (stimulated by retinoic acid 6) is a 75kDa polytopic transmembrane protein
that facilitates cellular retinol uptake from retinol-binding protein (RBP). Structural char-
acterization of STRA6 from Danio rerio purified in detergent and reconstituted in
amphipol A8-35 was achieved by single-particle cryo-electron microscopy (cryo-EM).
This provided the first high-resolution snapshot of this protein, showing a novel topol-
ogy of a tightly assembled homodimer, and an unexpected physiological association
with calmodulin in addition to insights into its potential mechanism of function.
Specifically, a large hydrophobic cavity in the center of STRA6 linked to the known
site of interaction with RBP suggested a route of retinol entry into the cell by diffusion
into the membrane through a lateral opening of the cavity directly into the bilayer.
Moreover, the capability to produce pure and homogeneous protein has allowed pre-
viously unattainable functional characterization of STRA6 in a reconstituted system.
Here, we describe detailedmethods for Danio rerio STRA6 expression in insect cells, puri-
fication in detergent and reconstitution in amphipol for structural characterization by
cryo-EM. Furthermore, we show reconstitution of the protein in liposomes for an
in vitro proteoliposome-based assay of STRA6-mediated retinol uptake. Finally, we pre-
sent methods and preliminary cryo-EM data for STRA6 incorporated in lipid-filled
nanodiscs, a close to native milieu to study membrane protein structure and function.
1. Introduction
Retinoids, vitamin A derivatives, have diverse roles throughout the
body including vision, immune response and embryonic development
(Blomhoff & Blomhoff, 2006). Within the cell, each retinoid form has a
specific function. Retinoic acid for example, functions as a ligand for the tran-
scription factors retinoic acid receptors (RARs) and retinoid X receptors
(RXRs) (Allenby et al., 1993; Giguere, Ong, Segui, & Evans, 1987;
Mangelsdorf, Ong, Dyck, & Evans, 1990; Petkovich, Brand, Krust, &
Chambon, 1987). Photoisomerization of 11-cis-retinaldehyde to all-trans-
retinaldehyde meanwhile, is a key step in the vision cycle (Wald, 1935,
1968). During times of vitamin A deficiency, retinol, the alcohol form of
vitamin A, can be mobilized from storage tissues, predominantly the liver,
for delivery to peripheral tissues (Paik et al., 2004; Quadro et al., 1999).
Retinol, which is intrinsically water-insoluble, is secreted from the cell bound
to its sole specific transporter retinol-binding protein (RBP, also called
RBP4) and circulates in the bloodstream, solubilized by this protein carrier
(Blaner & Olson, 1994; Kanai, Raz, & Goodman, 1968). Once it reaches
a target cell, the transmembrane (TM) receptor STRA6—the product of a






previously reported gene responsive to retinoic acid (Bouillet et al., 1997),
and identified as the cellular receptor for RBP in a landmark study
(Kawaguchi et al., 2007)—facilitates the release of retinol from RBP
and the subsequent translocation of this hydrophobic molecule across the
plasma membrane into the cell through an as yet undetermined mechanism
(Kawaguchi et al., 2007). STRA6 was found to be expressed to particularly
high levels in blood-tissue barriers where a regulated delivery of an ade-
quate supply of retinol is most crucial, including the brain, eye and placenta
(Amengual et al., 2014; Bouillet et al., 1997; Kelly, Widjaja-Adhi,
Palczewski, & von Lintig, 2016).
To begin to understand how STRA6-mediated translocation of retinol
across the membrane occurs at a molecular level, we determined the struc-
ture of STRA6 from Danio rerio (zebrafish) reconstituted in amphipol by
single-particle cryo-EM (Fig. 1) (Chen et al., 2016). We chose to work
on the protein from zebrafish as, of the orthologs we screened, this was
the highest expressing and most stable one in detergents compatible with
Fig. 1 Danio rerio STRA6 structure reconstituted in amphipol and determined by single-
particle cryo-EM to 3.9Å resolution. (A) Protomers are colored in gray and red, one mol-
ecule of CaM is associated with each protomer in green and blue, respectively. The
membrane is indicated by a yellow rectangle. The residues of STRA6 known to interact
with RBP protrude above the membrane on the extracellular side and are labeled
accordingly. The N- and C-terminal domains are labeled (NTD and CTD) and the central
domain is labeled (CD). (B) A central hydrophobic cavity is indicated by the purple
spacefill and its direct opening to the bilayer as defined by TM helices 8 and 9, and
by the IM helix is labeled as lateral window. The volume model was created using
the Voss Volume Voxelator (Voss & Gerstein, 2010).






structural studies. We learned from this structure and from related biochem-
ical work, that (i) the protein is an intrinsic homodimer displaying a previ-
ously unobserved fold consisting of nine TM and an intramembrane (IM)
helix, comprising an N-terminal penta-helical TM bundle (TM helices
1–5), a central domain along the dimer interface (TM helices 6–9 and IM
helix) and a C-terminal cytoplasmic domain; (ii) that each protomer is
tightly—albeit unexpectedly—associated with calmodulin (CaM) at the
C-terminal domain, posing a potential link between calcium homeostasis
and retinol metabolism; (iii) that the central domains of the two protomers
form a striking central hydrophobic cavity spanning from !25Å above the
putative membrane at the previously identified site for interaction with RBP
(Fig. 1B) (Kawaguchi, Yu, Wiita, Honda, & Sun, 2008), to approximately
mid-bilayer as delineated by the two (one for each protomer) long IM heli-
ces that lie essentially parallel to the membrane itself. We hypothesized that
interaction of RBPwith the loop at the apex of this central cavity, where the
residues involved in RBP interaction are located (Kawaguchi et al., 2008)
may trigger the release of retinol into the hydrophobic milieu of the cavity
itself. Retinol could in turn diffuse into the bilayer through a triangular lat-
eral opening of the cavity delineated by TM helices 8 and 9 on the sides and
the IM helix on the bottom. Indeed, in the amphipol structure, the cavity
appeared to be lipid filled likely taking lipids from the Spodoptera frugiperda
(Sf9) cell membrane where it was expressed before purification in detergent
and reconstitution in amphipol. We surmised from this result that the
membrane itself might play a role in the interaction of STRA6 and retinol,
necessitating a lipid bilayer in which to study the purified protein.
Here, we present methods for expression and purification of STRA6 in
detergents, reconstitution of this protein in amphipol and nanodisc for struc-
tural analysis, as well as reconstitution in liposomes for assays of STRA6-
mediated retinol uptake in a proteoliposome-based reconstituted system.
These methods may also be useful to the study of other retinoid-interacting
transmembrane proteins such as ABC transporters (Tarapcsák et al., 2017) or
retinoid-linked G protein-coupled receptors like rhodopsin (Zhao et al.,
2019), if not integral membrane proteins, transporters in particular, at large.
2. Purification of the STRA6 protein in detergent
and reconstitution in amphipol
STRA6 from zebrafish was chosen as a structural target after screening
nine orthologs for expression and monodispersion in detergents using a GFP






tag at either the N- or C-terminus. We performed anti-GFP western blot
analysis on HEK293 cells transiently transfected with STRA6 GFP fusion
DNA constructs to compare expression and subsequent fluorescence-
coupled size exclusion chromatography (FSEC) to further probe expression
and also measure protein stability—assessed from the height, sharpness and
symmetry of the elution peak—in detergents amenable to structural analysis
(Kawate & Gouaux, 2006). Initial screening of the orthologs was performed
utilizing dodecyl-!-D-maltopyranoside (DDM; Anatrace) with and without
the addition of cholesteryl hemisuccinate (CHS; Anatrace) to further stabi-
lize the protein (Weiss & Grisshammer, 2002). The results of these screening
experiments are described further in our publication (Chen et al., 2016).
After settling on the zebrafish STRA6 ortholog, which was by far the best
expressing and most stable of those screened, we also tested lauryl maltose
neopentyl glycol (LMNG; Anatrace) as a detergent for solubilization and
purification with and without the addition of CHS using size exclusion
chromatography (SEC). LMNG in the presence of CHS in a 10:1 ratio
(w/w) LMNG:CHS produced the sharpest and most symmetric peak by
SEC. We scaled up expression by switching to the baculovirus expression
system, following standard protocols. We purified the protein following
a two-step purification consisting of metal-affinity chromatography (taking
advantage of a genetically-engineered deca-histidine tag at the C-terminus
of the protein) followed by SEC. We first attempted crystallization exper-
iments. Crystals were formed from a preparation of STRA6 in DDM/CHS,
using standard vapor diffusion conditions. However they were not suffi-
ciently ordered for structure determination by X-ray crystallography.
Despite extensive rounds of optimization, the crystals never diffracted
past 14 Å.
During purification of STRA6 from Sf9 cells, we noticed that it formed a
hard to dissociate association with a low molecular weight protein, which
was initially thought to be a recalcitrant contaminant. N-terminal sequenc-
ing and mass spectrometry of the proteolytic peptide fragments of the low
molecular weight extra band excised from an SDS-PAGE denaturing gel,
informed us that the supposed “contaminant” was CaM from the expression
host. Through co-immunoprecipitation studies from zebrafish membranes,
we later determined that this interaction was physiological (Chen et al.,
2016). Dynamic light scattering experiments coupled to SEC showed
unambiguously that STRA6 in solution was of approximately 180kDa.
We surmised that the protein was a dimer (75kDa!2"150kDa) and
that each monomer was associated with one molecule of CaM






(CaM 15kDa!2"30kDa). This molecular weight put us in the realm
(although on the smaller side) of what was achievable by cryo-EM in terms
of atomic resolution (Merk et al., 2016). In initial attempts, the protein
structure could not be solved by cryo-EM using detergent as this masked
the structural features of the protein, resulting in a lack of fiducial markers
with which to align particles. The protein was then reconstituted in
amphipol A8-35 from LMNG/CHS and the structure was analyzed by
single-particle cryo-EM. Amphipol has become a commonly used molecule
for membrane protein reconstitution after detergent purification as it
stabilizes membrane proteins while showing minimal background for
cryo-EM experiments (Tribet, Audebert, & Popot, 1996). Reconstitution
of STRA6 using this amphipathic molecule allowed us to solve the
STRA6 structure to 3.9 Å resolution (Chen et al., 2016). We present here
a detailed method for detergent purification of STRA6 and reconstitution in
amphipol A8-35.
2.1 Materials: Purification of STRA6 protein in detergent
1. Baculovirus expression system of STRA6 in Sf9 cells.
2. Sorvall RC 30 Plus centrifuge, rotor and 800mL volume collection
buckets for large-scale cell collection.
3. 1! Phosphate-buffered saline (PBS).
4. Beckman Coulter Optima L-90K Ultracentrifuge, 45 Ti rotor
and tubes.
5. 100mL Dounce homogenizer.
6. Low salt buffer: 10mM Hepes pH 7.5, 10mM KCl, 10mM MgCl2,
1mM phenylmethylsulfonyl fluoride (PMSF), cOmplete mini EDTA-
free protease inhibitor cocktail, DNase and RNase.
7. High salt buffer: Same as low salt buffer with the addition of 1MNaCl.
8. Storage buffer: 20mMHepes pH 7.5, 200mMNaCl, 1mMPMSF and
cOmplete mini EDTA-free protease inhibitor cocktail.
9. Rotator kept at 4 °C.
10. 3% Lauryl maltose neopentyl glycol/0.3% cholesteryl hemisuccinate
tris salt detergent solution in water (LMNG and CHS both from:
Anatrace).
11. LMNG detergent buffer: 20mM Hepes pH 7.5, 200mM NaCl, 1%
LMNG/0.1% CHS.
12. Wash buffer: 20mMHepes pH 7.5, 200mMNaCl, 60mM imidazole,
0.1% LMNG/0.01% CHS.






13. Elution buffer: 20mM Hepes pH 7.5, 200mM NaCl, 200mM
imidazole, 0.05% LMNG/0.005% CHS.
14. Ni-NTA agarose (Qiagen).
15. Poly-Prep chromatography column (Bio-Rad).
16. Amicon 100kDa centrifugal concentrator (Millipore).
17. Ultra-free-MC centrifugal micro-filter, GV 0.22!m, 0.5mL volume
(Millipore).
18. Tabletop centrifuge (Eppendorf 5415R).
19. AKTA system—Superdex 200 Increase 10/300 GL column.
20. AKTA buffer: 20mM Hepes pH 7, 150mM NaCl.
2.2 Protocol: Purification of STRA6 protein in detergent
1. Produce a recombinant baculovirus that expresses zebrafish STRA6
with a C-terminal 10! Histidine tag (Chen et al., 2016; Goehring
et al., 2014). Amplify the virus to P4 following the procedures detailed
in Goehring et al. (2014).
2. Use P4 of the baculovirus to scale up expression of STRA6 in Sf9 cells.
Virus potency is not always consistent; a titration to determine the opti-
mal infection concentration in small scale is recommended before
scaling up expression.
3. Grow cells for 72h in shaker flasks at 27 °C.
4. Harvest cells:
a. Centrifuge the cultures at 2400 RPM for 17min in the Sorvall
centrifuge.
b. Pour off the supernatant and gently wash the centrifuged cell pellet
in ice-chilled 1! PBS.
c. Transfer each resuspended cell pellet to a 50mL Falcon tube and
centrifuge for 17min at 2400 RPM.
d. Pour off the supernatant and store the pellets at "80 °C until use.
5. Isolate the membranes of the collected cells:
a. Thaw one frozen cell pellet, suspend the pellet in low salt buffer—
use 40mL buffer per cell pellet from one 800mL SF9 culture.
Pellets can range in weight from 12 to 20g depending on the cell
growth.
b. Lyse the pellet by homogenization in a Dounce homogenizer.
c. Centrifuge the lysate at 34,000 RPM for 30min.
d. Pour off the supernatant and resuspend the pellet in 40mL high
salt buffer.






e. Homogenize the pellet in a 100mL glass homogenizer.
f. Centrifuge the lysate at 34,000 RPM for 30min.
g. Repeat steps d–f—the supernatant should be clear after the second
high salt wash.
h. Resuspend the final pellet in ice-chilled storage buffer. Store the
pellet at !80 °C until ready to use.
6. To solubilize the prepared membranes, add 4mL LMNG/CHS deter-
gent buffer per 1g of original cells so that the final membrane protein
concentration is around 2mg/mL.
7. Rotate 1.5h at 4°C.
8. Centrifuge 34,000 RPM for 30min.
9. Add solubilized protein to Ni-NTA resin along with 30mM imidazole
and rotate overnight at 4°C.
10. The next day, settle the resin on ice.
11. Wash the resin with 10 column volumes of wash buffer.
12. Elute the protein from the resin using 3.5 column volumes of
elution buffer.
13. Concentrate the protein using a 100kDa cutoff centrifugal concentrator.
14. Filter the protein using an ultra-free MC centrifugal filter.
15. Perform size exclusion chromatography on the filtered protein
by injecting the sample on an AKTA system with a Superdex 200
Increase 10/300 GL column to analyze the protein.
16. Run an SDS-PAGE gel of the injected protein and collected peak
fractions to confirm that the molecular weight of the protein from
the chromatogram peak matches that of STRA6.
2.3 Materials: Reconstitution of STRA6 in amphipol
1. Disposable PD-10 Desalting column with Sephadex G-25 resin
(GE Healthcare).
2. Desalting buffer: 20mM Hepes pH 7.5, 200mM NaCl.
3. NanoDrop Microvolume Spectrophotometer (ThermoFisher).
4. Amphipol A8-35 (Anatrace).
5. Prepared Bio-beads SM-2 Resin (Bio-Rad).
2.4 Protocol: Reconstitution of STRA6 in amphipol
1. Purify the STRA6 protein in detergent following steps 1–15 of the 2.1
Protocol.
2. Desalt the protein to remove imidazole.






3. Measure the protein concentration using a Nanodrop.
4. If necessary, concentrate the protein to 0.5mg/mL or higher using an
Amicon centrifugal concentrator with a 100kDa cutoff.
5. Add Amphipol dissolved in 200!L desalting buffer in a 1:3 (w/w) ratio
of STRA6:amphipol to the protein sample.
6. Rotate at 4°C for 4–5h protected from light.
7. Equilibrate 0.2g of Bio-Beads per 1mL of sample in desalting buffer.
8. Add Bio-Beads to the sample and rotate at 4°C overnight protected
from light.
9. The next day remove the sample from the Bio-Beads.
10. Concentrate to 500!L or less if necessary using an Amicon 100kDa
cutoff concentrator.
11. Filter the sample using an Ultra-free-MC centrifugal filter.
12. Inject the filtered sample on the AKTA system with a Superdex 200
increase 10/300 column (Fig. 2A).
13. Collect the peak fractions and run an SDS-PAGE gel to confirm correct
size of STRA6 protein (Fig. 2B).
3. Reconstitution of STRA6 in nanodisc
Numerous structures of membrane proteins in detergent have been







































Fig. 2 Danio rerio STRA6 purification and reconstitution in amphipol. (A) Representative
SEC profile of recombinant zebrafish STRA6 purified from Sf9 cells in LMNG/CHS and
reconstituted in amphipol. (B) SDS-PAGE gel of purified STRA6. First lane is a molecular
weight marker and lanes 2–5 are eluted fractions from the AKTA purification system
showing the protein after a two-step purification.






(Efremov, Gatsogiannis, & Raunser, 2017). However, advances in nanodisc
protein reconstitution using membrane scaffolding proteins (MSPs) or
styrene maleic acid (SMA) copolymers have made it possible to study mem-
brane proteins in soluble lipid bilayers at the single-particle level, in a close to
native environment (Bayburt, Grinkova, & Sligar, 2002; Knowles et al.,
2009). These tools have allowed us to study membrane proteins in a more
physiologically relevant environment compared to reconstitution using
amphipol, which—and the same being true for detergents—is not a partic-
ularly good mimic of a lipidic bilayer in a membrane (Bayburt & Sligar,
2003; Boldog, Li, & Hazelbauer, 2007). Setting up a system to reconstitute
STRA6 in nanodisc became most relevant here given the hydrophobic
nature of retinol, and our mechanistic hypothesis involving its direct inter-
action with the membrane bilayer. Indeed, as discussed above, we observed
in the amphipol structure of STRA6 a large hydrophobic cavity at the inter-
face between the two protomers of the dimer that appeared to be lipid-filled
(presumably lipids from the SF9 cells in which the protein was originally
expressed). We hypothesized that retinol may be deposited into this cavity
from RBP as part of the STRA6-mediated retinol uptake process, for direct
diffusion into the membrane through a lateral opening of the cavity directly
into the bilayer. Although the cavity appeared to be lipid filled in the
amphipol structure, we knew that in order to further study this interaction,
we needed to analyze the protein in a membrane environment. We present
here methods to reconstitute zebrafish STRA6 in MSP nanodiscs to study
this interaction.
Efficient nanodisc reconstitution conditions are specific to the protein
target and as such each new protein target must be tested in relation to a
number of conditions including choice of detergent, MSP length, lipid spe-
cies and ratio of the three components (protein solubilized in detergent,
MSP and lipid) (Ritchie et al., 2009). In brief, nanodisc reconstitution pro-
tocols consist of initial membrane protein purification in detergent followed
by addition of lipid and MSP. Nanodisc formation is then initiated by
removal of the detergent solubilizing the protein by polystyrene beads
(Rigaud, Levy, Mosser, & Lambert, 1998) or dialysis, resulting in embed-
ding of the protein in a lipid bilayer formed by the added lipid and bound
by the MSP (Bayburt & Sligar, 2010).
We utilized FSEC to determine the optimal reconstitution parameters
and subsequent SDS-PAGE gel to confirm presence of the protein and
MSP in the elution peak from SEC (Bayburt & Sligar, 2010). FSEC has been
often used in screening of protein purification conditions including






temperature and choice of detergent (Kawate & Gouaux, 2006). We
decided to take advantage of a C-terminal GFP tagged STRA6 to screen
MSP and lipid species for efficient nanodisc reconstitution conditions. To
screen nanodisc conditions it may be useful to start with lipids closely related
to the membrane composition of the cell type where the protein is naturally
expressed. Once a lipid species and MSP length is chosen, relative ratios of
protein, MSP and lipid must be tested. Starting ratios should take into
account the size of the protein and weight of the lipid species. We screened
two MSP lengths and two lipid species by FSEC and SDS-PAGE gel. Once
the MSP and lipid parameters were determined, we used SEC and SDS-
PAGE gel analysis of the peak fractions to optimize the ratio of the three
components for optimal protein reconstitution. The following is a protocol
specific to the incorporation of zebrafish STRA6 in POPG filled nanodiscs
bound by MSP1E3D1. MSP1E3D1 is a variation of the original MSP1D1
which has three 22-mer helices added in the center of the apolipoprotein A1
sequence (Denisov, Grinkova, Lazarides, & Sligar, 2004). POPG lipid was
purchased in powder form from Avanti. In our hands, we have found that
the optimal nanodisc incorporation molar ratio is 1:5:300 (STRA6 in
DDM/CHS:MSP1E3D1:POPG).
3.1 Materials: Reconstitution of STRA6 in nanodisc
1. Purified MSP1E3D1 protein (Bayburt et al., 2002).
2. Prepared Bio-beads SM-2 Resin (Bio-Rad).
3. POPG (1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)])
lipid sodium salt (Avanti).
4. DDM detergent buffer: 20mM Hepes pH 7.5, 200mM NaCl, 1%
DDM/0.1% CHS
5. Wash buffer: 20mMHepes pH 7.5, 200mMNaCl, 60mM imidazole,
0.1% DDM/0.01% CHS.
6. Elution buffer: 20mM Hepes pH 7.5, 200mM NaCl, 200mM imid-
azole, 0.03% DDM/0.003% CHS.
7. Detergent-free wash buffer: Same as wash buffer minus the DDM/
CHS.
8. Detergent-free elution buffer: Same as elution buffer minus the
DDM/CHS.
9. AKTA buffer: 20mM Hepes pH 7, 150mM NaCl.
10. Probe sonicator (Fisher Scientific Sonic Dismembrator F60).






3.2 Protocol: Reconstitution of STRA6 in nanodisc
1. Prepare zebrafish STRA6 protein following the 2.1 protocol steps 1–15
using the modified buffers containing DDM/CHS instead of LMNG/
CHS. In our experience, nanodisc incorporation is not easily accom-
plished from LMNG compared to DDM detergent.
2. Prepare POPG lipid by suspending powder in AKTA Buffer to a final
concentration of 20mM. Sonicate the solution using a probe sonicator
until the solution is slightly opaque rather than white. Do not over-
sonicate; a completely clear solution indicates that the lipid may have
oxidized and is unlikely to form nanodiscs.
3. Add appropriate amount of MSP1E3D1 to the protein (1:5M ratio
STRA6:MSP1E3D1).
4. Add appropriate amount of POPG lipid to the protein andMSP1E3D1
(1:5:300 STRA6:MSP1E3D1:POPG molar ratio).
5. Rotate at 4°C in dark for 2h.
6. Equilibrate 0.2g Bio-Beads per 1mL of protein sample in AKTA bffer.
7. Add protein/MSP/lipid mix to the equilibrated Bio-Beads.
8. Rotate in dark 4°C overnight.
9. Equilibrate 300!L of Ni-NTA resin in AKTA buffer.
10. Carefully pipette the protein off of the Bio-Beads and apply it to the
equilibrated Ni-NTA resin.
11. Rotate 4 °C overnight protected from light.
12. Wash the resin using 10 column volumes of detergent-free wash buffer.
13. Elute the protein from the Ni-NTA resin using 3.5 column volumes of
detergent-free elution buffer.
14. Concentrate the protein to less than 500!L.
15. Filter the protein using an Ultra-free-MC centrifugal filter at top speed
in a tabletop centrifuge for 1min.
16. Inject the protein on gel filtration AKTA system with a Superdex 200
Increase 10/300 column attached (Fig. 3A).
17. Collect peak protein fractions and run an SDS-PAGE gel to confirm
correct size of STRA6 protein and presence of MSP1E3D1 (Fig. 3B).
4. Single-particle cryo-EM analysis of STRA6
reconstituted in nanodisc
Freezing conditions were identical to those used for structure deter-
mination of STRA6 protein reconstituted in amphipol (Chen et al., 2016).



















































































































































































































































































































































We were able to obtain 2D class averages of the STRA6 protein rec-
onstituted in nanodisc by single-particle cryo-EM (Fig. 3C). The structure
of the protein in nanodisc as judged from the 2D class averages is similar
overall to the protein in amphipol (Chen et al., 2016). The TM region
is surrounded by the circular nanodisc; the C-terminus of each protomer
bound to CaM can be seen protruding from one side of the nanodisc while
the RBP binding loop protrudes from the opposite side of the nanodisc
lipid bilayer. This resemblance supports the relevance of our amphipol-
reconstituted structure, at least to first approximation. Further 3D and
high-resolution analysis of the structure of STRA6 in nanodisc is
needed to determine whether reconstitution in a lipid bilayer results in
subtle changes in the protein conformation compared to in amphipol.
Indeed, a number of proteins including bacteriorhodopsin (Etzkorn
et al., 2013) and the TRPV1 channel (Gao, Cao, Julius, & Cheng, 2016)
showed similar overall structural features in amphipol versus nanodisc with
slight differences that did not affect the overall protein conformation.
5. Liposome-based assay of STRA6-mediated
retinol uptake
To study STRA6 function by probing structure-based mechanistic
hypotheses in a tightly-controlled reconstituted system as well as to confirm
the functionality of recombinant, detergent-purified STRA6, we devel-
oped an assay of liposome-based STRA6 retinol uptake. A number of
studies have utilized crude membranes or membrane vesicles from cells
expressing STRA6 (or unknown RBP receptor at the time) to demons-
trate retinol incorporation into a lipid bilayer (Kawaguchi et al., 2007;
Sivaprasadarao & Findlay, 1988a, 1988b). Retinoid incorporated liposomes
have also been characterized and used as a retinoid delivery tool for ther-
apeutic purposes (Mehta, Estey, & Lopez-Berestein, 1998; Pedersen et al.,
2010; Sinico et al., 2005). Utilizing STRA6 reconstituted in brain polar
lipid liposomes (Anderson, Frase, Michaelis, & Hrycyna, 2005), we dem-
onstrated STRA6-dependent retinol uptake from purified RBP refolded
with retinol (prepared as described in Chen et al., 2016). Previous studies
have demonstrated that RBP can transfer retinol to liposomes composed of
egg phosphatidylcholine and that retinol can be translocated between
liposomes in the absence of a retinol receptor or other exchange protein
(Fex & Johannesson, 1987, 1988; Rando & Bangerter, 1982). Our data
show some incorporation of retinol directly into liposomes from RBP,






but uptake is highly increased in liposomes with reconstituted STRA6. Our
studies were made possible by the availability of purified, structure-
determination quality, homogeneous protein.
The liposome-based assay of retinol uptake described here essentially
recapitulates the assays using membrane vesicles, but allows us to study func-
tion in a controlled system using purified protein, absent endogenous cellu-
lar components. Furthermore, detergent purification has often been shown
to negatively impact membrane protein function. Given that our solved
structures of the STRA6 protein in amphipol requires an initial detergent
purification step, we wanted to develop a method of assaying retinol uptake
of the protein after this potentially detrimental step (Seddon, Curnow, &
Booth, 2004). In brief, STRA6 protein is purified in detergent as described
above and reconstituted in liposomes formed from porcine brain polar
lipid extract (Avanti) (Anderson et al., 2005) in an 80:1 ratio of lipid to
STRA6 (w/w). Purified RBP refolded with retinol (Chen et al., 2016) is
incubated with the STRA6-reconstituted liposomes in a 1:10M ratio of
STRA6:RBP for 1h at room temperature. The liposomes are collected
by centrifugation and washed through a series of centrifugation and buffer
resuspension steps in order to remove background RBP ( Julkowska,
Rankenberg, & Testerink, 2013). The retinol content of the liposomes is
then measured by reverse phase high-performance liquid chromatography
(HPLC) (Kim & Quadro, 2010; Perduca, Nicolis, Mannucci, Galliano, &






















Fig. 4 Proteoliposome-based uptake assay. (A) Schematic of the proteoliposome-based
assay of STRA6-mediated retinol uptake. On the left, empty liposomes treated the
same as the STRA6-incorporated liposomes on the right. (B) STRA6-incorporated
proteoliposomes showed increased retinol uptake from RBP compared to empty lipo-
somes, demonstrating that the assay works, as well as functionality of the detergent-
purified protein reconstituted in an artificial bilayer.






functionality of our detergent-purified STRA6 protein and provides us a
tool to study factors that may influence STRA6-mediated retinol uptake
in a controlled system.
5.1 Materials: Preparation of brain polar lipid liposomes
1. Porcine brain polar lipid extract (Avanti).
2. Chloroform.
3. 50mL glass beaker.
4. Desiccator.
5. Argon gas.
6. Liposome formation buffer: 20mM Hepes pH 7.5, 150mM NaCl,
2mM !-mercaptoethanol, 1.5% octylglucoside.
7. Slide-a-lyzer dialysis cassette.
8. Dialysis buffer: 20mM Hepes pH 7.5, 150mM NaCl, 2mM
!-mercaptoethanol.
9. 1L glass beaker.
10. Magnetic stirrer and stir bar.
11. Liquid nitrogen for rapid freezing.
12. Avestin LiposoFast basic extruder and 100nm filters.
5.2 Protocol: Preparation of brain polar lipid liposomes
1. Weigh out 100mg of brain polar lipid extract into a 50mL glass beaker.
2. Suspend the lipid extract in 1mL chloroform, gently swirl until
completely dissolved.
3. Dry the lipids under a steady stream of argon gas until the chloroform
has completely dried and an even layer of dried lipid is formed on the
bottom of the beaker.
4. Dry the lipids overnight by placing the beaker in the desiccator attached
to a vacuum.
5. The next day, resuspend the dried lipids in 5mL of liposome formation
buffer by pipetting and swirling the beaker (Mimms, Zampighi, Nozaki,
Tanford, & Reynolds, 1981; Woodle & Papahadjopoulos, 1989).
6. Using a needle and syringe, inject the resuspended lipids into a 3–12mL
Slide-a-lyzer dialysis cassette.
7. Dialyze the lipids overnight in a 1L beaker of dialysis buffer stirring
overnight (Alpes et al., 1986).
8. The next day remove the lipids from the dialysis cassette, using needle
and syringe and aliquot 500"L each into 10 1.5mL tubes.
9. Flash freeze the lipids in liquid nitrogen then thaw at RT.






10. Extrude the liposomes using the Avestin LiposoFast basic extruder
with a 100nm filter, following the manual (Elorza, Elorza, Sainz, &
Chantres, 1993; MacDonald et al., 1991).
5.3 Materials: Reconstitution of STRA6 in liposomes
and liposome uptake assay
1. Porcine brain polar lipid liposomes prepared as described.
2. LMNG/CHS-purified STRA6 as described above.
3. Triton-X 100.
4. Protein incorporation buffer: 20mM Hepes pH 7 and 150mM NaCl.
5. Prepared Bio-beads SM-2 Resin (Bio-Rad).
6. Biofuge Sorvall Centrifuge (Thermo Fisher).
7. Purified zebrafish RBP (Chen et al., 2016).
5.4 Protocol: Reconstitution of STRA6 in liposomes
1. Purify STRA6 in LMNG/CHS detergent as described above.
2. Pipette 160!L of 20mg/mL prepared brain polar lipid liposomes into
a tube.
3. Add 10% Triton-X 100 so that the final volume is 0.11%, vortex briefly
to mix.
4. Add 40!g of STRA6 and however much extra buffer is needed so that
the final volume of the reaction is 320!L and therefore the liposomes
are diluted to a final concentration of 10mg/mL.
5. Rotate in dark at RT 15min.
6. Add 60mg semi wet bio-beads per 1mL reaction (in this case 19.2mg)
to remove the detergent (L!evy, Bluzat, Seigneuret, & Rigaud, 1990).
7. Rotate another 1h RT.
8. Add another 19.2mg semi wet bio-beads.
9. Rotate 1h RT.
10. Add double the amount of bio-beads (38.4mg) and rotate overnight at
4 °C.
11. The next day carefully pipette the liposomes away from the bio-beads
and into a new tube.
12. Centrifuge the liposomes at 22,000 RPM for 20min at 4°C.
13. Resuspend the pellet in buffer
5.4.1 Protocol: Liposome-based assay of retinol uptake
1. Add 100!L of prepared STRA6 liposomes to an eppendorf tube.
2. Add a 10-fold molar excess of purified holo-hRBP (Chen et al., 2016).
3. Incubate rotating in the dark 1h RT.






4. Collect the liposomes by hard spin at 4 °C 22,000 RPM in a Biofuge
Stratos Centrifuge (44,910! g) for 20min.
5. Wash the liposomes by resuspending them in buffer.
6. Repeat steps 4 and 5 a second time, then transfer the resuspended lipo-
somes to a new eppendorf tube.
7. Spin the liposomes a final time at 22,000 RPM.
8. Remove the supernatant and store the pellet at "80 °C until HPLC
analysis.
5.5 Materials: HPLC analysis of the liposome retinol content
1. Retinoid standards (retinol and retinyl acetate, Sigma) prepared in
ethanol (ACS grade).
2. Phosphate-buffered saline (PBS).
3. Probe sonicator (Branson).
4. Extraction solvent: Hexane.
5. Nitrogen gas.
6. HPLC system (Ultimate Thermo Fisher).
7. HPLC column, Denali reverse C18, 250mm!4.6mm, 5!M (Grace)
and HPLC guard column (PerkinElmer).
8. HPLC mobile phase: Acetonitrile 70%: Methylenechloride 15%:
Methanol 15% (HPLC grade solvents).
5.6 Protocol: HPLC analysis of the liposome retinol content
1. Add 200!L of PBS to the liposome pellet.
2. Sonicate and vortex the pellet until no clumps are visible.
3. Transfer the pellet suspension into a borosilicate glass tube.
4. Add 20!L of retinyl acetate (1ng/!L) as an internal standard and 180!L
of ethanol—bringing the volume to 200!L, equivalent to the PBS and
vortex well.
5. Add 3mL of hexane and vortex (30 s!2) to extract retinol from the
liposome.
6. Collect the supernatant containing retinol by centrifugation at 3000
RPM in a tabletop centrifuge for 3min.
7. Wash the extract by adding 0.4mL of HPLC grade water and vortex.
8. Repeat step 6, then transfer the supernatant to a new borosilicate
glass tube.
9. Completely dry the extract under stream of nitrogen gas.
10. Resuspend the extract in 50!L HPLC mobile phase and vortex.






11. Inject 20!L into the HPLC system with the mobile phase flowing at
1.8mL/min.
12. Analyze the retinol content by comparing retention times and the peak
spectra with those of the authentic standards (Kim & Quadro, 2010).
6. Summary
Membrane protein reconstitution tools such as nanodiscs and lipo-
somes have made it possible to study STRA6 structure and function in a
purified system while maintaining a close to native lipid bilayer environ-
ment. This chapter details our developed methods of STRA6 purification
and reconstitution in amphipol and nanodisc for structural studies of the pro-
tein. The similarity of the nanodisc to the original amphipol structure of
STRA6 as could be judged by 2D class averages, supports the significance
of the nanodisc reconstitution technique and suggests the relevance of
artificial environments such as those created by amphipols to a physiological
setting. We also describe a liposome-based assay of retinol uptake in which
STRA6 is reconstituted in liposomes composed of brain polar lipid and
treated with purified RBP to assess retinol uptake. This liposome assay
has provided us a cell-like environment in which we can specifically study
the factors governing STRA6 function. Liposomes in functional study have
indeed been invaluable and their use in cryo-EM protein structural studies is
progressing rapidly, adding a potentially exciting component to the field
(Wang, 2018). With these tools at our disposal, it is now possible to begin
answering the longstanding questions as to how STRA6 directly interacts
with retinol in a membrane environment, and what role CaM might have
in this process.
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Interactions of retinoids with the ABC transporters P-glycoprotein and breast cancer
resistance protein. Scientific Reports, 7(1), 41376. https://doi.org/10.1038/srep41376.
Tribet, C., Audebert, R., & Popot, J. L. (1996). Amphipols: Polymers that keep
membrane proteins soluble in aqueous solutions. Proceedings of the National Academy of






Sciences of the United States of America, 93(26), 15047–15050. https://doi.org/10.1073/
pnas.93.26.15047.
Voss, N. R., & Gerstein, M. (2010). 3V: Cavity, channel and cleft volume calculator
and extractor. Nucleic Acids Research, 38, W555–W562. https://doi.org/10.1093/nar/
gkq395. web server issue.
Wald, G. (1935). Carotenoids and the visual cycle. The Journal of General Physiology, 19(2),
351–371. https://doi.org/10.1085/jgp.19.2.351.
Wald, G. (1968). The molecular basis of visual excitation. Nature, 219(5156), 800.
Wang, L. (2018). Random spherically constrained single-particle (RSC) method to study
voltage-gated ion channels. Methods in Molecular Biology, 1684, 265–277. https://doi.
org/10.1007/978-1-4939-7362-0_20.
Weiss, H. M., & Grisshammer, R. (2002). Purification and characterization of the human
adenosine A(2a) receptor functionally expressed in Escherichia coli. European Journal of
Biochemistry, 269(1), 82–92. https://doi.org/10.1046/j.0014-2956.2002.02618.x.
Woodle, M. C., & Papahadjopoulos, D. (1989). [9] liposome preparation and size character-
ization. In Vol. 171, Methods in enzymology (pp. 193–217). Academic Press.
Zhao, D. Y., Poge, M., Morizumi, T., Gulati, S., Van Eps, N., Zhang, J., et al. (2019). Cryo-
EM structure of the native rhodopsin dimer in nanodiscs. The Journal of Biological
Chemistry, 294(39), 14215–14230. https://doi.org/10.1074/jbc.RA119.010089.





2.2.1 Preparation of the retinol-loaded STRA6 nanodisc sample  
 The retinol-loaded sample was prepared by incubating the STRA6 in nanodisc (prepared 
as in [161]) with purified zebrafish holo-RBP (RBP purified as described in [155]). RBP was added 
in a 1:10 molar ratio (STRA6:RBP) for one hour rotating at room temperature. Size exclusion 
chromatography (SEC) was used to separate the RBP from the STRA6. Two peaks were 
observed during gel filtration, the earlier peak corresponded to zebrafish STRA6 in nanodisc, and 
the latter one to purified RBP. The STRA6 peak was collected and concentrated down to 100 µl, 
half of which was sent to Rutgers for HPLC analysis to quantify the amount of retinol present in 
the nanodisc as a ratio to total protein. The retinol extraction and HPLC analysis is detailed in 
[161]. The other half was further concentrated to 0.75 mg/ml for cryo-EM grid preparation. A 
negative control of empty nanodisc was also incubated with RBP and sent for retinoid 
quantification by HPLC analysis. Empty nanodiscs were prepared following the zebrafish STRA6 
nanodisc incorporation protocol with use of buffer in place of purified protein.  
 
2.2.2 Cryo-EM grid preparation and data collection  
 Each of the protein samples in nanodisc were concentrated to approximately 0.75 mg/ml 
for cryo-EM grid preparation. 3 µl of the protein sample was applied to plasma cleaned holey gold 
R 0.6/1 grids from Quantifoil. The sample was blotted for 3.5-4 seconds with blot force 3 using 
Whatman ashless filter paper before plunge cooling into liquid nitrogen-cooled liquid ethane using 
a Mark IV Vitrobot (FEI). Data were collected on a Titan Krios microscope at the New York 
Structural Biology Center (NYSBC). 1486 micrographs were collected for the no retinol data set. 
4845 micrographs were collected for the retinol loaded dataset. The accelerating voltage of the 





used for each collection. The total exposure dose rate of the collections was 71 e/Å2 over 50 
frames at a rate of 8 e- per pixel per second.   
 
2.2.3 Processing and model building of STRA6 in nanodisc datasets 
 All datasets were imported into Relion for motion correction using the CPU-based 
implementation of motioncor2 and for CTF estimation using Gctf. 2D classification of the picked 
particles using Relion Auto-pick was then completed. 2D classes showing the characteristic CaM 
densities (as seen in the amphipol dataset) were used for the 3D ab initio reconstruction. Several 
rounds of heterogeneous refinement to remove empty nanodisc particles were completed to arrive 
at the final set of particles for non-uniform refinement, achieving a nominal resolution of 3.3 Å. 
Bayesian polishing followed by a second round of non-uniform refinement in Relion allowed us to 
achieve 3.1 Å resolution. CTF refinement, taking into account beam tilt and defocus was then 
performed before arriving at a final resolution of 3.0 Å resolution. Models were built in Coot using 
the amphipol STRA6 structure as a starting template for building. Real space refinement and 
validation of the final structures was performed in Phenix. 
 
2.3 Results  
2.3.1 Zebrafish STRA6 structure comparison in amphipol vs nanodisc  
 Upon comparison of the zebrafish STRA6 reconstituted in nanodisc and amphipol, the 
structures appeared in general quite similar with some minor shifts in specific regions (Figure 2.1 
A). Some of these differences may be the result of better resolution of the density map. The 
resolution of the zebrafish STRA6 structure in nanodisc was 3.0 Å as compared to the published 





the protein are closer together in the nanodisc vs the amphipol structure. The distance between 
the alpha carbon of residue F319 from each protomer measures 9.8 Å in the nanodisc compared 
to 13.1 Å in the amphipol structure (Figure 2.1 B) This may be in part due to an increased width 
of the central cavity as suggested by the increased distance between TMs 6 and 7 of the two 




Figure 2.1 Comparison of zebrafish STRA6 reconstituted in nanodisc vs. amphipol. 
A) Structure of STRA6 reconstituted in nanodisc. Protomers in chartreuse and CaM in blue. Structure of 
STRA6 reconstituted in amphipol in dark magenta with CaM in gold, PDB ID 5SY1. B) Views of the RBP-
interacting loops of STRA6 from above. Distances measured between alpha carbon of F319 on each 





 The N terminal bundle when overlaid is entirely conserved between the two structures 
reconstituted differently (amphipol vs nanodisc), with the exception of the N terminus. The 
disordered N terminal sequence prior to the start of TM 1 is longer in the nanodisc structure. More 
specifically, the alpha helix begins at E37 as compared to D32 in the amphipol structure. This tail 
is also shifted closer to the loop connecting TMs 4 and 5, bringing C31 within range of forming a 
disulfide bond with C171 in this loop. In the amphipol structure, the distance between the sulfide 
atoms is 3.57 Å, outside the range for a disulfide bridge to form (Figure 2.2 B). Two loops 
connecting TMs in the N terminal bundle are also shifted. Residues R69-L74 in the loop 
connecting TMs 1 and 2 (labeled TM1-2 Loop) is shifted closer to the bundle in the nanodisc 
structure compared to the amphipol counterpart (Figure 2.2 A). Residues S107-V117 form a loop 
that dips down from TM 2, forming a side of the outer pocket, before coming back up to connect 
to the extracellular end of TM 3 (labeled TM2-3 Loop). This loop is shifted outwards away from 
the bundle in the amphipol structure as compared to that in nanodisc. In the nanodisc structure, 
all residues face the outer pocket, but the shift in the loop in the amphipol is such that only residues 







Figure 2.2 Zebrafish STRA6 in nanodisc vs amphipol overlay of N-terminal TM bundle.  
A) Full side view of N terminal bundle, nanodisc STRA6 in chartreuse and amphipol STRA6 in dark 
magenta. Loops connecting TMs 1 and 2 and also TMs 2 and 3 are shifted away from the bundle in the 
amphipol structure compared to the nanodisc. B) Top view of the TM bundle showing the movement of the 
TM2-3 loop. C) Side view of the top of the N terminal bundle depicting the disulfide bond that forms between 
C31 and C171 in the nanodisc structure, but not the amphipol structure. Figure made in BioRender. 
 
 
 Another differing region is the juxtamembrane helix (JM) which connects CaMBP0 to TM 
6. The helix in the amphipol structure angles downwards towards the cytosolic side of the 





helix lies more parallel with the membrane, however the loop connecting CaMBP0 to this JM in 
the nanodisc structure is missing from the density map – residues K236-L254 (Figure 2.3 D). The 
CaMBP0 itself is also slightly different, in the amphipol structure, the helix extends S223 to K240, 
whereas in the nanodisc, the helix becomes disordered after K234. The loop connecting TMs 7 
and 8 is disordered in the nanodisc structure making a comparison with the amphipol structure 
where the loop contains a very short alpha helix unrealistic (Figure 2.3 C).   
 The CaM binding peptides appear to be conserved as does the conformation of the 
calcium-bound CaM. The slight offset of TMs 6 and 7 in one structure vs. the other (Figure 2.3) 
causes the CaM to initially appear different, but if the structures are superimposed on the CaM, 
the differences are rectified. Some of these differences may be the result of better resolution of 
the density map (3.0 Å for the nanodisc structure and 3.9 Å for the amphipol). The nanodisc 
structure actually allowed us to view ordered lipids interacting with protein, a few of them in the 
central cavity, supporting the notion that the central hydrophobic cavity first viewed in the 










Figure 2.3 Zebrafish STRA6 nanodisc vs amphipol overlay highlighting shifted loop regions.  
A) Top view of the STRA6 RBP-interacting loops. Overlay depicts the distance difference between loops 
as evidenced by measurement shown in figure 2.1 B. B) Side view of the RBP-interacting loops. Structural 
alignment was performed using the loop on the left and allowed us to observe a shift in the opposing 
protomer. C) Close-up of the loop connecting TMs 7 and 8 in the amphipol structure. This loop is missing 
in the nanodisc structure. D) The juxtamembrane helix (JM) is at a sharper angle in the amphipol structure 
as compared to the nanodisc. The loop connecting CaMBP0 to the JM is missing in the nanodisc structure. 







Figure 2.4: Model of STRA6 in nanodisc with ordered lipids interacting with the TM helices.  
A) Front view of STRA6, one protomer in black, the other in red, one CaM in silver and the other in gold. 
Calcium ions in green. Ordered lipids indicated in orange. B) Top view of STRA6 looking down on the RBP-
interacting loops to show some lipids in the hydrophobic cavity of the protein. Figure made in BioRender 
 
 
2.3.2 Zebrafish STRA6 structure in nanodisc in the presence and absence of retinol 
 After incubation of the SEC-purified nanodisc-reconstituted STRA6 with the purified 
retinol-bound RBP, the components were separated by a second round of gel filtration. HPLC 
analysis revealed that STRA6 in nanodisc contained 4.94 ng of retinol per 100 µl of sample 
whereas the empty nanodisc contained 0.84 ng/100 µl of sample.  
 STRA6 in nanodisc loaded with retinol overlays with the calcium-bound structure 
precisely, the major exception being the RBP binding peptide. In the retinol-loaded structure, the 
loops of each protomer are shifted such that they have more of a parallel interface composed of 
residues L315-G318 (Figure 2.5). This is due to a shorter alpha helix (E310-F319 in the retinol 





loop in the retinol-absent structure whereas N320 is the center in the retinol-loaded structure. The 
essential ligand-binding residues in the mammalian protein as defined in [138] are Y336, G340 
and G342. These correspond to F314, G318 and N320 in the zebrafish ortholog. F314 is not 
drastically shifted in the retinol-loaded compared to unloaded structure, the side chain faces 










Figure 2.5 Comparison of the RBP-interacting loops of zebrafish STRA6 reconstituted in nanodisc 
in the presence and absence of retinol.  
A) STRA6 RBP-interacting loops absent retinol. F314 residues face upwards away from the membrane. 
F319 faces into the central hydrophobic cavity. B) Retinol-loaded STRA6 RBP-interacting loops. F314 in a 
similar position in A and F319 facing away instead of toward the opposite protomer. C) Overlay of the retinol 
present and absent structures in A and B. D) Top view of C looking down on the RBP-interacting peptides. 




 The structure of zebrafish STRA6 reconstituted in nanodisc allowed us for the first time to 





in amphipol confirms that amphipol is an effective detergent mimetic for studying this protein. This 
is something we could not be sure of as we were unable to develop a functional assay for the 
protein in this state. The lipid bilayer formed by the nanodisc however provided us the ability to 
correct this. Indeed, we were able to confirm retinol uptake from RBP by zebrafish STRA6 when 
reconstituted in the nanodisc.  
 Reconstitution of STRA6 in nanodisc allowed us to reach much higher resolution – 3.0 as 
compared to amphipol 3.9 Å. Studies of the TRPV1 channel in amphipol vs nanodisc in general 
showed that nanodisc reconstitution yielded higher quality density maps. Loops that appear to 
interact with the membrane in particular were of higher quality. Like our structures, they were also 
able to reach high enough resolution to observe ordered lipids interacting with the protein [162, 
163]. Overall the structures solved using both membrane mimetics were largely the same, and 
thus matched our previously obtained results. An NMR study of bacteriorhodopsin found that the 
protein had the greatest functional activity when reconstituted in nanodisc compared to amphipol 
or detergent. The core of the protein was unaffected by the lipid environment, but they did observe 
chemical shift changes in outward facing residues that would interact with the detergent, 
amphipol, or lipid. In particular, a TM loop of the protein in amphipol had large chemical shift 
changes, indicative of nonspecific interactions with this surfactant [164]. It is likely that the 
changes we observed in the N terminal tail, N terminal bundle TM connecting loops and the JM 
helix could be due to a similar effect. The core of the protein was unchanged, but the 
surfactant/lipid interacting residues appeared to shift. A third example is the V-ATPase where the 
structure solved in nanodisc provided higher quality data than the amphipol one and allowed the 
group to view the directionality of key functional residues [165, 166]. 
 One of the main differences we observed between the amphipol and nanodisc structures 





the cavity. It is assumed that the cavity in the amphipol structure is occupied by lipids derived 
from the SF9 cell membrane during detergent solubilization. This could also be the case for the 
nanodisc structure as the protocol begins with the same detergent solubilization step from the 
same membranes. The difference is the reconstitution in a homogeneous lipid bilayer composed 
of purified POPG. It is unknown however whether this pocket is full of POPG. The sample was 
sent for native mass spectrometry to determine what lipids remained attached, but the results 
were inconclusive as the dimer did not stay together during the procedure, and the peaks were 
too noisy to discern potential protein masses bound to lipid. It is however possible that the noise 
in the data may be indicative of a variety of endogenous lipids present in the sample, more than 
just POPG.   
 Retinol loading of STRA6 in nanodisc did not appear to trigger dramatic conformational 
changes with the exception of the RBP interacting peptide. The mammalian protein has been 
shown to interact with apo-RBP and mediate efflux of retinol in addition to influx [124]. The 
structures of human RBP in the presence and absence of retinol were shown to be highly similar 
with the exception of one loop that appears shifted [131]. It is therefore possible that the 
conformational change observed confers higher affinity to STRA6 for apo over holo-RBP after 
retinol loading. TTR has lower affinity for apo (Kd of 1.2 µM) compared to holo-RBP (Kd of 0.2 
µM), the STRA6 RBP-binding peptide conformational change could similarly change the affinity 
of STRA6 for one form of RBP over the other [131, 167]. It might be worth mentioning that another 
more recent paper measured these affinities using SPR to be 2.2 µM for apo and 0.9 µM for holo-
RBP [168]. The fact that no other gross conformational changes were observed further supports 
our hypothesis that STRA6 may serve as a pore for retinol to partition into the cell membrane 
quickly and efficiently. The RBP interacting loop is likely to be the vital structural component of 





 We attempted to determine the structure of zebrafish STRA6 in the absence of calcium. 
However, addition of EGTA during detergent purification of the protein resulted in aggregation, 
we therefore attempted incubation of the nanodisc-reconstituted protein with high concentration 
of EGTA: 10 mM and 50 mM. While processing the data derived from the sample incubated with 
10 mM EGTA, ¼ of the particles were found to be bound to only one molecule of CaM. No density 
could be seen for the STRA6 CaMBPs when not bound to CaM. The rest of the structure was 
entirely similar to the original STRA6 in nanodisc structure, determined in the presence of calcium. 
The other ¾ of the particles had both molecules of CaM bound and calcium was bound in all four 
CaM sites. This was surprising given the high concentration of calcium chelator, that should have 
placed the sample below the range of calcium in which the N lobe of CaM would be calcium bound 
([158] and section 1.11), although free calcium concentration after incubation with chelator was 
not measured. This could be due to the high local concentration of calcium around the nanodisc, 
given that POPG can bind calcium [169, 170]. Similarly, data collected from the protein incubated 
with 50 mM EGTA still showed particles bound to CaM, but also had a class that had neither CaM 
molecule bound to the C termini of the STRA6 protomers in the dimer. However, this class did 
not go to high resolution, likely due to the lack of a soluble domain with which to align the particles. 
From a low-resolution map, the TMs did not appear grossly changed and the RBP interacting 
region was visible above the membrane. It appears that cryo-EM may not be the optimal technique 
to study the role of calcium in mediating RBP interaction as the most stable conformation of the 
protein appears to be bound to calcium-CaM. There are examples of calcium-binding proteins 
reconstituted in nanodisc and lacking calcium in the literature. For example, the calcium-
dependent lipid scramblase TMEM16 must bind calcium in order to move lipids between lipid 
bilayer leaflets, and structures of this protein with and without calcium have been determined 





and POPG lipid in a 7:3 molar ratio. In our case, this concentration of EGTA during purification 
causes STRA6 to aggregate and therefore this was not a viable approach for this particular 
protein.  
 Reconstitution in amphipol vs nanodisc as has been shown for other proteins did not affect 
the core structure and provided higher resolution in regions of the protein that interact with the 
membrane. We observed structural differences in the N terminal bundle, JM and the RBP-
interacting peptide in the nanodisc compared to the amphipol structure in addition to ordered lipids 
interacting with the protein. The high resolution of the nanodisc density map and the presence of 
the lipid bilayer environment supports the conclusion that this structure (compared to the amphipol 
one) could be closer to that found in the native milieu. The observation of a disulfide bond between 
highly conserved cysteine residues in the N terminus only in the nanodisc structure and not in the 
amphipol structure further supports this conclusion. Although both amphipol and nanodisc appear 
to be effective solubilization methods for this protein, nanodisc allowed us to develop a functional 
assay of retinol uptake in a purified environment that we can now utilize to measure binding to 












Chapter 3: Mammalian STRA6 structure determination 
The structure of zebrafish STRA6 provided the first major insight into the function of this 
vitamin A receptor at a molecular level. Although the overall structure does appear to be 
conserved based on sequence alignments between the zebrafish and mammalian STRA6, ([155] 
supplemental figure 7), the amino acid sequence of zebrafish STRA6 is only 61% similar to human 
STRA6 and the sequence identity of these two orthologs is 43%. This significant difference in 
sequence identity may be suggestive of functional differences between organisms with potential 
relevance to human health. From our studies of purified zebrafish STRA6, it appears that this 
homolog may not be as responsive to calcium concentration as the mammalian STRA6 (section 
2.4). We therefore determined it worthwhile to solve the structure of a mammalian STRA6.  
 3.1 Mouse and zebrafish STRA6 knockout studies and relevance to Matthew-Wood 
Syndrome 
Vitamin A is an essential nutrient, required for facilitating a wide variety of biological 
processes, as detailed in chapter 1. Mutations in STRA6 have been shown to cause the pleiotropic 
disorder Matthew-Wood Syndrome (MWS) which is characterized by congenital eye 
malformations in combination with major developmental defects in the lung and heart among other 
organs [133]. Rodent and zebrafish STRA6 knockout animal models in some ways recapitulate 
the effects seen in humans. Several studies on Stra6-/- mice showed that these animals are 
viable, but have decreased retinoid stores in the eye, malformed photoreceptors and poor visual 
responses [108, 109, 172-174]. When maintained on vitamin A deficient diet, Stra6-/- mice 
exhibited decreased retinoid stores in the brain and Sertoli cells of the testes, two other high 





in maintaining proper vitamin A homeostasis in the eye to support the visual cycle in addition to a 
role for mobilization of retinoid to peripheral tissues in times of dietary vitamin A insufficiency. The 
effects described in these studies however do not resemble the severe congenital defects 
observed in MWS patients, potentially pointing to perhaps a more vital role of STRA6 during 
human compared to mouse development. 
 In a zebrafish stra6 knockdown model, fish developed poorly, exhibiting defects 
reminiscent of MWS including microphthalmia and heart edema [125]. These outcomes appeared 
to be due to off-target effects of retinoic acid caused by excess circulating retinol-RBP. 
Knockdown of rbp4 expression rescued the phenotype, supporting an indirect role of STRA6 in 
the spatial and temporal regulation of retinoic acid during development [125]. Interestingly, two 
later studies in which zebrafish were treated with an RALDH inhibitor to decrease retinoic acid 
production during development, also caused microphthalmia and cardiac edema, suggesting that 
retinoic acid deficiency can also cause malformations associated with MWS in this species [175, 
176]. 
One major difference in zebrafish retinoid circulation that should be noted, is that RBP-
bound retinol, which serves as the rod photoreceptor visual chromophore source, does not 
circulate in complex with transthyretin [177]. Transthyretin is a homotetrameric protein that carries 
thyroxine in the bloodstream and in mammals circulates in a 2:1 complex of monomeric RBP to 
tetrameric TTR, serving to prevent the clearance of RBP by the kidney [178]. Differences in 
piscine TTR residues at the interface of the RBP-TTR complex compared to human homologs 
appear to be the reason for this lack of complex formation. For example, residue 99 of TTR is a 
T in fish and K in mammals, which appears to prevent the formation of a salt bridge in fish [179]. 
This difference in retinol mobilization in zebrafish compared to mammals may influence the 





Clearly our understanding of the function and importance of STRA6 in vivo is still, to a 
certain extent, lacking. Given these phenotypic differences in the described animal models and 
their relation to MWS, we proposed to solve a structure of a mammalian STRA6 closely related 
to the human homolog. Differences in a mammalian vs zebrafish STRA6 structure could be 
indicative of differences in functional properties and help us to understand the disparity in effects 
among Stra6-/- knockout model species. A structural genomics approach, utilizing sequence 
alignment followed by small scale expression testing was used to find a mammalian homolog 
amenable to structural characterization by single particle cryo-EM. The human STRA6 homolog 
itself, although ideal for structural study from a human health standpoint, did not express well in 
a heterologous system. This approach led us to sheep STRA6 which is 85% similar in sequence 
to the human STRA6 and has 80% sequence identity. We were able to purify this homolog and 
reconstitute it in nanodisc in order to better study its interaction with retinol and the membrane. 
We present here the 3D structures of sheep STRA6 in the presence and absence of retinol at 3.0 
and 3.4 Å resolution, respectively.  
 
3.2 Methods 
3.2.1 Structural genomics approach to determine optimal mammalian STRA6 target 
 Structural genomics refers to the combined use of bioinformatics and high-throughput 
protein expression and purification platforms to increase probability of protein structure 
determination by screening a large number of related proteins [180]. Our lab (and others) utilizes 
this strategy to narrow our focus on a particular membrane protein target to the homologs most 
likely to yield a structure. Previous studies in the lab revealed that the human STRA6 homolog 





heterologous systems. We next focused on the bovine STRA6 homolog as it is 80% similar to the 
human homolog and the identity of STRA6 as an RBP receptor was first discovered using bovine 
RPE cells [103]. Several papers on its potential mechanism of function have been published since 
then (reviewed in [123]). After several years of attempting to purify this high expressing, but 
unstable homolog, we decided to take the structural genomics approach to find a third STRA6 
homolog that might be more amenable to structural study. Using the NCBI’s Protein BLAST tool 
[181], we identified sequences that were no less than 80% similar to that of bovine STRA6, and 
six of the resulting sequences, evenly distributed amongst sequence space, were selected for 
small scale expression and stability testing. The six genes were synthesized and cloned into both 
transient mammalian expression (pME18) and baculovirus donor plasmid (pFastBac) vectors by 
COMPPÅ (the Center on Membrane Protein Production and Analysis) at the New York Structural 
Biology Center.  
 
Table 3.1: Mammalian STRA6 homologs screened for expression 




Bos taurus Cow   NP_001069198.1 
Ovis aries Sheep X2 95% XP_027813003.1 
Balaenoptera acutorostrata 
scammoni 
Minke whale X2 88% XP_007197782.1 
Vicugna pacos Alpaca X3 86% XP_015103025.1 
Orcinus orca Orca X3 86% XP_004276342.1 
Ceratotherium simum simum White rhinoceros X1 83% XP_014636398.1 
Felis catus Cat X2 82% XP_019687633.1 
Homo sapiens Human  80% AAQ89447.1 






3.2.2 Small and mid-scale expression and stability screening of mammalian homologs 
 The STRA6 homologs were cloned into the pME18 vector each with a C terminal GFP 
and 10x Histidine tag with a TEV cleavage site between the protein and the tags. The constructs 
were transiently transfected into 10 ml suspension cultures of HEK293F cells at a density of 2x106 
cells/ml using PEI transfection reagent. After 72 hours shaking in an 8% CO2 incubator at 37ºC, 
cells were collected and suspended in 400 µl buffer composed of 20 mM Hepes pH 7.5, 200 mM 
NaCl, 20 mM MgSO4, PMSF, cOmplete EDTA-free protease inhibitor, protease inhibitor cocktail 
set III, DNase and RNase. 1% beta-DDM detergent with 0.1% cholesteryl hemisuccinate (CHS) 
was added to solubilize the membrane proteins, after 2 hours rotating at 4ºC, the lysate was 
separated from the cell debris by centrifugation at 21000 x g in a tabletop centrifuge for 45 
minutes. 20 µl of the crude lysate was then injected on a Superdex 200 Increase 10/300 GL size 
exclusion chromatography (SEC) column attached to a Prominence UFLC instrument (Shimdazu) 
with an RF-10AXL fluorescence detector (Shimadzu).  
 Two of the top expressing homologs were chosen for further study and comparison with 
the original bovine construct. Sheep, cat and bovine STRA6 were transiently transfected into 100 
ml suspension cultures of HEK293F cells as described above for the small-scale cultures. 
Membranes were purified from the collected cells using one low salt wash (10 mM Hepes pH 7.5, 
10 mM KCl, 10 mM MgCl2, protease inhibitors, DNase and RNase) to osmotically break the cells 
and a high salt wash (same as low salt wash with the addition of 1M NaCl) to remove soluble 
proteins. The membranes were then solubilized in 20 mM Hepes pH 7.5, 200 mM NaCl, 10% 
glycerol, protease inhibitors, 1% DDM and 0.1% CHS for 2 hours rotating at 4°C. The solubilized 
membrane proteins were separated from the cell debris by centrifugation at 134,000 x g for 30 
minutes in a Beckman Coulter Optima L-90K ultracentrifuge. The supernatant was bound to Ni-





next day, the resin was washed with 10 column volumes of Wash buffer (20 mM Hepes pH 7.5, 
200 mM NaCl, 60 mM Imidazole, 10% glycerol, 0.1% DDM and 0.01% CHS). The protein was 
then eluted with Elution buffer (20 mM Hepes pH 7.5, 200 mM NaCl, 200 mM imidazole, 10% 
glycerol, 0.03% DDM and 0.003% CHS), concentrated and analyzed by FSEC, SDS-PAGE gel 
and western blot using a goat anti-rabbit GFP primary antibody (ThermoFisher A11122) followed 
by an HRP-conjugated anti-rabbit secondary antibody (Abcam 97051).  
 
3.2.3 Virus production and large-scale expression of STRA6 
 To increase yields of the STRA6 homologs to levels required for cryo-EM analysis, we 
switched from transient mammalian transfection to baculovirus infection of SF9 cells. The sheep 
and cat STRA6 homologs were cloned into the pFastBac vector with C-terminal 10x Histidine tag 
and a TEV cleavage site between the protein and tag by COMPPA as described earlier. The 
donor plasmid was transformed into DH10Bac competent cells for transposition of the STRA6 
gene into the bacmid [182]. The transformation was plated on LB agar plates containing 
kanamycin and gentamycin for selection along with X-gal and IPTG. Transposition of the gene 
from pFastBac vector by the Tn7 transposase (expressed on a separate plasmid in the DH10Bac 
cells) results in disruption of the reporter LacZ gene on the bacmid. White colonies are selected 
for PCR amplification to confirm transposition of the gene [183]. The bacmid was then transformed 
into SF9 cells for virus production following the protocol detailed in [183] and summarized here. 
0.9x106 cells/ml were plated in one well of a 6-well cell culture plate and allowed to adhere. 
Meanwhile, 8 µl of Cellfectin II (Gibco) was mixed with 100 µl of antibiotic-free SF9 media. 
Separately, 1 µg of bacmid DNA was mixed with another 100 µl of SF9 media. After five minutes, 
the Cellfectin and DNA dilutions were combined and incubated at room temperature for 30 





along with 2 ml of SF9 media. After 72 hours at 27°C, the supernatant was removed from the cells 
and filtered using a 0.2 µm filter. This P1 virus was then used to infect 50 ml of suspension SF9 
cells at 1.5x106 cells/ml in a 1:1000 dilution. After 96 hours, P2 was collected by centrifuging the 
cells at 2400 rpm for 17 minutes and filtering the supernatant. This amplification procedure was 
completed twice more to achieve a P4 virus. This final amplification was then used to infect SF9 
cells at 2x106 cells/ml in a 1:1000 dilution factor and cultured shaking at 27°C for 72 hours. 
Membranes were prepared from the collected SF9 cells following the published protocol [161] 
and summarized in section 3.2.2. Each cell pellet from an 800 ml SF9 culture was suspended in 
40 ml low salt buffer (described in 3.2.2) to osmotically lyse the cells. The supernatant was 
removed and the pellet was suspended in high salt buffer (described in 3.2.2) by rotor-stator 
homogenization (IKA® T25 digital ULTRA-TURRAX). The high salt wash was then repeated to 
ensure removal of all intracellular debris and soluble proteins. The final pellet was suspended in 
10 ml storage buffer consisting of 20 mM Hepes pH 7.5, 200 mM NaCl, 10% glycerol and protease 
inhibitors. 
 
3.2.4 Purification in detergent 
 Following membrane preparation, the volume of the final pellet suspension was brought 
up to 40 ml with additional storage buffer and 1% DDM with 0.01% CHS. The protein was 
solubilized with rotation at 4°C for two hours, then separated from the membrane and cell debris 
by ultracentrifugation at 134000 xg for 30 minutes in a Ti 45 rotor for a Beckman Coulter Optima 
L-90K ultracentrifuge. The solubilized protein was bound to Ni-NTA agarose resin (Qiagen) 
overnight in the presence of 30 mM imidazole to prevent nonspecific protein binding. The next 
day, the resin was washed with 10 column volumes of Wash Buffer and eluted with 3.5 column 





centrifugal concentrator (Millipore) to 500 µl, then filtered using a 0.22 µm cutoff PVDF centrifugal 
filter (Millipore) before being injected onto a Superdex 200 Increase 10/300 column attached to 
an AKTA gel purifier system. The SEC peak central fractions were collected, concentrated, 
measured to compare yield and analyzed for purity by SDS-PAGE gel.  
 
3.2.5 Reconstitution of STRA6 in nanodisc 
 After confirmation of protein purity and relative stability in detergent, the protein was 
reconstituted in nanodisc. Protein nanodisc reconstitution requires addition of exogenous lipid 
that forms a bilayer into which the detergent purified protein can partition and a membrane 
scaffolding protein (MSP) which forms a belt around the protein in the lipid bilayer [160]. After 2 
hours of incubation, the detergent is removed by addition of Biobeads (Bio-Rad) overnight. The 
next day, the protein is rebound to Ni-NTA agarose resin to separate empty nanodiscs from the 
protein incorporated nanodiscs. MSP 1E3D1 was used for all nanodisc incorporation testing since 
it was effective for zebrafish STRA6. The lipids used included POPG (Avanti) and porcine brain 
polar lipid extract (Avanti) either alone or in combination at different ratios. Lipids were prepared 
by weighing the dry powder, adding water to a final lipid concentration of 20 mM and then 
sonicating into solution in 15 second intervals alternating with 15 second incubations on ice. The 
molar ratio of protein to MSP to lipid was fixed at 1:5:225 as this again was effective for zebrafish 
STRA6. Lipid and MSP was added to detergent purified STRA6 and incubated with rotation for 2 
hours at 4°C at which point 90 mg Biobeads/1ml reaction volume was added to the 
protein/lipid/MSP mixture and rotated at 4°C overnight. The next day, the protein was removed 
from the Biobeads and rebound to Ni-NTA resin for 3 hours before eluting the nanodisc 
reconstituted protein into detergent free buffer. The resin was washed with 10 column volumes of 





with 3.5 column volumes of Detergent-free Elution Buffer (20 mM Hepes pH 7.5, 200 mM NaCl, 
200 mM Imidazole). The protein was then concentrated using a 100 kDa cutoff centrifugal filter 
(Millipore), filtered and then injected on a Superdex 200 increase 5/150 GL column attached to 
an Agilent 1200 Infinity Series LC instrument. The purity of the samples and presence of MSP 
protein was further verified by SDS-PAGE gel. After determining the optimal lipid ratio for 
reconstitution, the protein was purified from six 800 ml SF9 cultures and reconstituted using the 
predetermined conditions from the small-scale test.  
 
3.2.6 Loading of STRA6 in nanodisc with retinol  
 In order to load nanodisc-reconstituted STRA6 with retinol in a physiologically relevant 
manner, we utilized purified retinol-binding protein to deliver retinol to STRA6. The purification of 
retinol-bound RBP will be described in Section 4.2.1. Sheep STRA6 reconstituted in nanodisc, 
and purified by SEC was incubated with retinol-bound RBP for 12 minutes in a 1:13 molar ratio 
(STRA6:RBP) rotating at room temperature and protected from light. The sample was then filtered 
and injected on the same Superdex 200 Increase 10/300 column attached to the AKTA system 
to separate the now retinol-loaded STRA6 from the RBP. The STRA6 peak fractions were 
collected, concentrated and sent for retinol quantification by HPLC [161]. The fractions were also 
analyzed by SDS-PAGE gel to confirm separation of RBP from STRA6 due to SEC. 
 
3.2.7 Cryo-EM grid preparation and data collection  
 The nanodisc-reconstituted protein (by itself or loaded with retinol) was SEC purified and 
concentrated to 3 mg/ml. 3 µl of the protein solution was applied to a glow-discharged R 0.6/1 





4 seconds using a Vitrobot Mark IV (FEI) and plunge cooled in liquid nitrogen-cooled liquid ethane. 
Single particle cryo-EM data collection for the non-retinol-loaded sample was completed on a 
Titan Krios with 300 kV accelerating voltage and a K3 detector at the CUIMC Hammer EM facility. 
A total dose rate of exposure for the collection of 58 e-/A2 over 50 frames at a rate of 16 e- per 
pixel per second was used with raw pixel size of 0.83 Å and energy filter of slit width 20 eV. The 
defocus range of the collection was -0.8 to -1.8. 5505 images were collected over 24 hours. 
 Data for the retinol-loaded sample were collected on a Titan Krios at the New York 
Structural Biology Center with a K3 direct detector and energy filter with slit width 20 eV. The 
accelerating voltage was 300 kV, and raw pixel size of 0.844 Å. The total dose rate of exposure 
was 56.1 e-/A2 over 50 frames at a rate of 16 e- per pixel per second. 14240 images were collected 
over 2 days. Data are summarized in Table 3.2.  
 
3.2.8 CryoSPARC data processing and model building  
 For the sheep STRA6 in nanodisc dataset, movies were loaded into CryoSPARC V3.2.0, 
frames were aligned using patch motion correction with a B-factor of 500 followed by CTF 
estimation on the aligned frames. 373119 Particles were extracted from the aligned micrographs 
after inspection of blob picking with box size 320 and binning by 4. 2D classification was 
completed and classes showing protein in nanodisc with two CaM densities were selected as 
templates for template picker. 1574838 particles were extracted with box size 384 and binned by 
4 after template picking. A second round of 2D classification was performed to again sort protein 
particles in nanodisc with CaM bound. 4744 particles were extracted from 50 micrographs and 
used as input for the TOPAZ training algorithm. 1318215 Particles were extracted with box size 





were classified by 2D and then 3D ab intio. Reconstruction was performed The particles 
composing the best ab intio classes were then refined through a series of heterogeneous, non-
uniform, and local CTF refinements before arriving at a nominal resolution of 3.37 Å using 73409 
particles. The map was then submitted to the DeepEMhancer tool for sharpening before model 
building. 
 For the retinol-loaded dataset, particles were manually picked from 10 micrographs after 
frame alignment and CTF estimation in CryoSPARC V3.2.0 to begin crYOLO particle picking 
[184]. Due to the large number of micrographs, picking had to be completed in three batches. 
Particles binned by 6 were extracted from each batch then combined for 2D classification followed 
by 3D ab initio modeling (Figure 3.1). The best particles in the best ab initio classes were extracted 
from the micrographs this time binning by 4. Another round of ab initio reconstruction led to the 
final particle set that was then extracted from the micrographs without binning. Heterogeneous 
and non-uniform refinements were performed, leading to a final set of 363,684 particles reaching 
a nominal resolution of 3.03 Å. The map was then submitted to the DeepEMhancer tool for final 
sharpening. 
 Model building of the retinol-absent sheep STRA6 was completed in Coot, using the 
zebrafish STRA6 model as a starting point for real space refinement. Once this model was 
validated in Phenix, it was then used as the template for building of the retinol-loaded sheep 
STRA6 model in Coot. Current states of the structural data are summarized in Table 3.2. 









Figure 3.1 Data processing flowchart of retinol-loaded sheep STRA6  
Particle picking was performed using CrYOLO. Following initial 2D classification, particles were extracted 
using a box size of 384 and binned by 6. From a 3D ab initio reconstruction, 2 classes of particles were 
selected out of 3 to extract from the micrographs this time binning by 4. 3D ab intio reconstruction was 
again performed, resulting in 2 out of 4 classes visually approximating STRA6. Class 2 more resembled 
empty nanodisc, but was maintained in the data processing in order to utilize the largest amount of particles. 
These particles were then extracted from the micrographs without binning and subjected to heterogenous 
refinement, arriving at a final set of 363,684 particles. Non-uniform refinement was performed on the best 






Table 3.2 Cryo-EM data table for sheep STRA6 structures 
 
Structural Validations are still in progress, these are by no means final values. 





Microscope Hammer Krios 1 NYSBC Krios 1 Hammer Krios 1
Magnification 105000 105000 105000
Voltage (kV) 300 300 300
Electron exposure (e-/Å^2) 58 56.1 58.34
Dose rate (e-/pixel/s) 16 16 16
Defocus range (µm) 0.8-1.8 1 - 2 1 - 2
Pixel size (Å) 0.83 0.844 0.83
Symmetry imposed C2 C2 C1
Micrographs collected (no.) 5505 14240 5283
Initial particle images (no.) 373119 4 million 748,613
Final particle images (no.) 73409 363684 60847
Map resolution (Å) TMs/full protein 3.37 3.03 3.15
Map resolution (Å) CaM 1 - - 3.36
Map resolution (Å) CaM 2 - - 3.44
FSC threshold 0.143 0.143 0.143
Map sharpening B factor (Å2) 74.5 128.5 98.1
Map resolution (Å) CaM 1 - - 123.7
Map resolution (Å) CaM 2 - - 142.7
Residue range
Model composition:
Non-hydrogen atoms 9717 9848 11355
Protein residues 1233 1247 1425
B factors (Å2) 52.63 55.55 47.26
R.m.s deviations
Bond length (Å) 0.008 0.008 0.011
Bond angles (°) 1.076 1.11 1.422
Validation
MolProbity score 2.01 2.01 2.3
Clashscore 20.98 16.35 16.17
Rotamer outliers (%) 0.1 1.32 4.53
Ramachandran plot
Favored (%) 96.85% 96.73% 97.59%
Allowed (%) 3.15% 3.27% 2.41%





3.3 Results  
3.3.1 Determination of optimal mammalian homolog for large-scale study 
 FSEC results of the six STRA6 mammalian homologs with GFP fusions demonstrated that 
half of them expressed well with monodisperse fluorescence profile peaks (Figure 3.2 A) [185]. 
Of these three, two were chosen for further study by mid-scale culture purifications. The cat and 
sheep STRA6 homologs both expressed well compared to the bovine STRA6 in HEK293F cells 
and appeared relatively stable when purified in DDM/CHS (Figure 3.2 BC). The western blot 
showed that STRA6 runs as two bands (Figure 3.3 D), the zebrafish and bovine STRA6 also 
appear as two bands, the lower of which we found to be a degradation product of the full-length 
protein. The addition of Protease Inhibitor III (Sigma) decreases the formation of this product as 
is seen in future purifications. Both the sheep and cat STRA6 homologs seemed suitable 
candidates for structural study at this point given the indications of stability in detergent amenable 






Figure 3.3: Small scale expression screening of mammalian STRA6 homologs.  
A) FSEC of six mammalian STRA6 homologs in comparison to the unstable bovine STRA6 and zebrafish 
STRA6. Sheep and cat were the top expressing candidates based on this experiment. The top mammalian 
STRA6 homologs were expressed as GFP fusions in HEK293F cells by transient transfection. The proteins 
were purified by His tag and analyzed for purity by SDS-PAGE gel (B) and FSEC (C). Anti-GFP western 
blot was performed to confirm protein expression and TEV cleavage. Flow-thru (FT), Wash (W), Elution (E) 
of purified protein. Desalted protein (to remove imidazole) (D), TEV cleavage was performed to test stability 







3.3.2 Large-scale purification of sheep STRA6 
 Baculovirus was made for both the sheep and cat STRA6 to assay purity levels on a large 
scale. Both proteins when purified from SF9 cells in DDM/CHS detergent yielded more protein 
than the bovine STRA6 when using the same amount of cell cultures. The peaks from SEC were  
monodisperse and the SDS-PAGE gel showed that the protein was quite pure (Figure 3.3 AB). 
We observed a low molecular weight band on the SDS-PAGE gel and assumed it to be CaM 
binding to both sheep and cat STRA6. We confirmed this by western blot using an anti-CaM 
antibody (Figure 3.3 C). The sheep STRA6 seemed to express slightly better than the cat, so at 
this point sheep was determined the ideal candidate of the six homologs and we decided to move 










Figure 3.3: Sheep and Cat detergent purification from baculovirus-infected SF9 cells.  
800 ml SF9 cells were infected with STRA6 virus in a 1:1000 dilution. Purification in DDM with CHS was 
performed and the eluted proteins were analyzed by SEC (A), followed by SDS-PAGE gel (B). A low 
molecular weight band was observed on the gel migrating in the range of CAM, anti-CaM western was 
performed to confirm the identity of this protein. Flow-thru (FT), Wash (W) and Eluted protein (E) of the 
purification. Numbers above the gel and western correspond to the collected fractions from the SEC peak. 
CaM is a purified human CaM protein control (unfortunately overloaded on the gel, but clearly positive). 
Figure made in BioRender. 
 
 
3.3.3 Nanodisc incorporation of sheep STRA6 
 Nanodisc reconstitution of transmembrane proteins has become a common method of 
studying the protein in a close to physiological environment [186]. Of the four conditions tested, 
the mixtures of POPG and brain polar lipid appeared to allow for successful reconstitution of the 
protein into nanodisc (Figure 3.4 AB). The brain polar lipid alone gave a late peak on the SEC 
that indicated reconstitution was unsuccessful. The peak for the POPG lipid alone was much 
earlier than the detergent peak, suggesting that the protein had aggregated rather than 





injection on SEC was pure; bands for the MSP and CaM were the only ones visible on the gel in 
addition to that corresponding to STRA6 (Figure 3.4 B). Given the results of the small scale test, 
we decided to attempt reconstituting the protein in nanodisc using a 1:1 ratio of POPG:Brain polar 
lipid with MSP 1E3D1 in the 1:5:225 molar ratio of protein:MSP:lipid. The protein appeared pure 











Figure 3.4: Small scale sheep reconstitution in nanodisc and subsequent large-scale purification.  
A) Sheep STRA6 nanodisc was reconstituted in 1E3D1 MSP (Membrane Scaffolding Protein) nanodisc 
using the listed lipids. The gel filtration profiles were compared against the DDM/CHS detergent-purified 
protein. B) SDS-PAGE gel of two example nanodisc incorporations showing purity of the samples. C) Large-
scale purification of sheep STRA6 in nanodisc using MSP 1E3D1 and lipid mix POPG:Brain polar lipid in a 
1:1 ratio. D) SDS-PAGE gel of sheep STRA6 in nanodisc purification. Flow-thru (FT), Wash (W), Eluted 
protein (E) from the detergent purification (DDM/CHS) followed by the same series for the nanodisc nickel 





3.3.4 Structure of sheep STRA6 in nanodisc  
 
Figure 3.5: Sheep and zebrafish STRA6 amino acid sequence alignment.  
Sequence features are indicated above the alignment in colored rectangles corresponding to the model in 
figure 3.6. The first resolved residue in the map was P50 and the last was K655. The structural features of 
the species match overall. The location of the zebrafish JM helix (zJM) is indicated by a black rectangle. 






 Although the amino acid sequence identity of sheep STRA6 is only 43% similar to the 
zebrafish (Figures 3.5 and 3.6), the sequences in general appear conserved with the exception 
of the N and C termini and a stretch of 10 residues in the loop connecting TMs 2 and 3 that is 
missing in zebrafish but present in the sheep. Overall, the secondary structure is entirely 
conserved. The protein has the same N terminal bundle of 5 transmembrane helices, the RBP-
interacting loop is in the same position (between TMs 6 and 7), TMs 8, 9 and the intramembrane 
helix form a triangular lateral window opening from the large central cavity to the membrane, and 
calcium-bound-CaM is in complex with the C terminus of the protein (Figure 3.6). Some areas of 
the map are of low resolution and therefore the residues in these regions were deleted from the 
model and are represented as dotted lines. These mainly include linking sequences between 
alpha helices such as those connecting helices in the N terminal TM bundle, the loops connecting 
CaMBP0 to the rest of the structure, the connection between the end of the RBP-interacting loop 
to TM 7 in addition to the linker between CaMBP1 and 2 (the last of which is also missing from 






Figure 3.6: Model of sheep STRA6.  
One protomer in rainbow spectral coloring with CaM in cyan, the other in dark gray with CaM in light gray. 
A) Front view of sheep STRA6, approximate position of the membrane indicated in light yellow. B) Upper 
panel shows STRA6 rotated 90º to show a top view looking down onto the RBP interacting loops of the 
protein. Lower panel shows the protein rotated 90º in the plane of the membrane to show a side view facing 
the N terminal bundle of helices. 
 
 The density of the RBP-interacting loop is not well defined and therefore it was not possible 
to accurately place the side chains in the density map. This is likely indicative of inherent flexibility 
in this region. The backbones of the RBP interacting loops were placed based on the real space 
refinement restraints used in Coot and Phenix during model building. It does appear from the 
density map however that the zebrafish RBP loops (of each protomer) are closer to one another 






Figure 3.7: Sheep STRA6 and zebrafish STRA6 models differ in their interprotomer angles.  
Protomers of sheep STRA6 are at a larger angle to one another compared to zebrafish STRA6. Sheep 
STRA6 in red with bound CaM in yellow. Zebrafish STRA6 in green with bound CaM in blue. Distance 
between the alpha carbons of residue N112 of CaM on each protomer was measured in UCSF Chimera. 
B) Top views of each STRA6 showing a larger distance between the two RBP interacting peptides of each 
protomer. Figure made in BioRender.  
 
 
 The overall difference in the sheep compared to the zebrafish STRA6 structures is that 
the C termini of the protomers appear to be shifted away from one another. The distance between 
the C lobes of CaM bound to each protomer is indicated in figure 3.7 A. The difference responsible 
for this change may lie in one or multiple of the linking regions missing in our density map. For 





visible in the structure and connects Q209 of TM5 to S223 (listed residues are the last and first 
respectively of alpha helices). The loop is not straight, the center of it lies closer to the intracellular 
end of the N terminal bundle before connecting to CaMBP0 (Figure 3.8 BD). In comparing the 
sequence of the zebrafish and sheep loops, they are overall the same, with the exception of just 
four residues. Zebrafish has sequence TET where sheep has GA with the central residue missing. 
Later in the sequence, closer to CaMBP0, sheep has a G in place of zebrafish D (Figure 3.8 D). 
These differences do not appear to be significant enough to cause such a striking conformational 
change in the protein. The other sequence difference could be in the region connecting CaMBP0 
to TM6. In the zebrafish, a short JM helix lies parallel with the membrane. The density connecting 
CaMBP0 to the JM is missing in both maps, and the JM density itself appears more as a loop 
than an alpha helix in the sheep structure compared to the zebrafish one. After the JM helix, both 
models have a loop that descends towards CaMBP0, then turns sharply at a charged residue 
followed by a small hydrophobic one (in zebrafish: DV, in sheep: RG) before connecting laterally 
to the base of TM6 (Figure 3.8 C). The difference in the missing loops before the JM helix does 
not appear to be major, except that the zebrafish has three charged residues shortly before the 






Figure 3.8: STRA6 species comparison of loops connecting TM5, CaMBP0 and TM6.  
A) Zebrafish (in green) and sheep (in red) STRA6 aligned to one protomer, the other protomers and CaM 
in gray. B) Boxed region of panel A showing the connection between TM5 and CAMBP0, the loop 
connecting CaMBP0 and the JM helix of zebrafish STRA6. C) Boxed inset of panel B showing the sharp 
turn in the loop connecting the JM helix to TM6, the loop turns sharply at RG in the sheep and DV in the 
zebrafish. D) Indicated connecting region between TM5 and CaMBP0. Zebrafish has sequence TET where 
sheep has GA with second residue missing. Closer to CaMBP0, zebrafish has a D where sheep has a G. 
Figure made in BioRender. 
 
 A third source of the difference could be in the connection of TM9 to the IM and the IM 
itself. There are more charged residues in the loop connecting residues of TM9b to IMa in 
zebrafish compared to sheep. The connection from IMa to IMb in zebrafish is also more of a 
gradual curve than a sharp turn as it is in sheep that causes the first few residues of zebrafish 





and alpha 20 helix are aligned in the two structures. From CaMBP1 to the C terminus of the 
protein the two structures are misaligned, including the CaM molecules. However, the CaM and 
CaMBPs are actually in the same conformation in both species, this becomes clear if alignment 
to CaM rather than the STRA6 protomer is performed (Figure 3.9 C).  
 
 
Figure 3.9: Alignment of one zebrafish protomer to sheep STRA6.  
Aligned protomer of Sheep STRA6 in red and Zebrafish STRA6 in green. Second protomer and CaM 
molecules of sheep STRA6 in gray, the other protomer and CaMs of zebrafish STRA6 not shown. The 
difference in angle of protomers may lie in the sequence of specific regions of the sheep STRA6. A) Top 
view of overlaid sheep and zebrafish STRA6 protomer. TMs 1-7 align. The RBP-interacting loop is slightly 
offset in the two structures although the density is not well resolved. B) The IMa connection to IMb in 
zebrafish is at a more gradual angle than sheep which could contribute to the angle of the protomers with 
respect to one another. Panel has TM9b removed in order to view IM. C) When aligning to the STRA6 
protomer, CaMBPs 1 and 2 of zebrafish and sheep STRA6 appear offset, but alignment to CaM shows that 






3.3.5 Structure of sheep STRA6 in nanodisc loaded with retinol 
 STRA6 reconstituted in nanodisc and loaded with retinol structure overall appears very 
similar to the original sheep STRA6 structure. We confirmed retinol loading status by treating 
sheep STRA6 incorporated in nanodisc with purified retinol-bound RBP as described in section 
3.2.6, separating it from the RBP and analyzing it by HPLC at Rutgers University (Figure 3.10). 
The resulting amount of retinol per mg of protein was 40.6 ng. Empty nanodiscs (prepared using 
buffer in place of STRA6) were used as a negative control and the resulting retinol per mg of 










Figure 3.10 RBP purification and retinol-loading of STRA6 in nanodisc.  
A) Holo-RBP gel filtration profile. Excess protein was loaded on the column leading to saturation of the 280 
nm absorbance peak. B) Absorbance spectrum of RBP to confirm retinol binding of purified RBP. C) Sheep 
STRA6 in nanodisc was incubated with retinol-RBP to load the protein with retinol. RBP was separated 
from STRA6 by SEC – two distinct peaks corresponding to STRA6 were visible on the chromatogram. 
Fractions pertaining to the STRA6 peak were collected for retinol quantification of the nanodisc and cryo-
EM grid preparation. D) SDS-PAGE gel of STRA6 detergent purification (DDM/CHS – flow-thru FT, wash 
W and eluted protein E), reconstitution in nanodisc (FT, W, E), first injection of STRA6 in nanodisc on SEC 
(I1), collected STRA6 fractions from the first run (F1), second injection (retinol-loaded STRA6 I2), final 




 Despite this clear loading of the nanodisc with retinol, no evident changes in the structure 
were observed with the exception of a slight shift in the RBP-interacting loop of STRA6 (Figure 





it is difficult to confidently place the residues into the density. The RBP-interacting loop density is 
better in the retinol-loaded sheep STRA6 structure due to the overall higher resolution of the map, 
but the placement of the side chains still cannot be confidently compared in the two structures. 
The CaM bound to one protomer of retinol-loaded STRA6 also appears slightly offset from the 
original sheep STRA6. The source of this difference is unclear, but again it is likely related to the 
density map resolution improvement in the retinol-loaded vs retinol absent structure.  
 
 
Figure 3.11: Sheep STRA6 model overlay with sheep retinol-loaded STRA6 model.  
A) Front view of sheep STRA6 (in red with CaM in gray) and overlaid retinol-loaded sheep STRA6 (STRA6 
protomers in gold with CaM in olive). B) Top view of overlaid STRA6 with and without retinol, RBP-
interacting peptides are slightly closer in the retinol-loaded structure. C) Side view of overlaid sheep 






3.4 Discussion  
3.4.1 Insights from the comparison of zebrafish and mammalian STRA6 structures 
 Despite the relatively low conservation in sequence, the sheep STRA6 structure appears 
overall quite similar to the zebrafish one. From a biological perspective, this makes sense given 
the similar tissue expression pattern of STRA6 and its role in development and the visual process 
in both zebrafish and mammals [102, 125, 133, 173]. Sheep STRA6 is a dimer with the same 
central hydrophobic cavity, suggesting that our proposed mechanism of retinol uptake in zebrafish 
via the triangular opening formed by TMs 8, 9 and the IM directly into the membrane may be 
conserved across the board (section 1.10). The most obvious difference in the two proteins is in 
the interprotomer angle, which may be the result of sequence differences in linking regions of the 
protein. The source of these differences is unclear, as is their impact on STRA6 function. The 
disparity in distance between RBP interacting loops between the two species is also intriguing, 
especially since the density of the zebrafish STRA6 loops is more defined and therefore their 
conformation could be more stable in this state as compared to in sheep. 
 The fact that the CaM interaction is conserved in zebrafish and sheep is not surprising 
given sequence conservation in the regions of STRA6 that interact with CaM, and supports the 
importance of this calcium-binding protein having a role in STRA6 function. A recent paper from 
Dr. Sun’s group, which we co-authored, showed that CaM binding influences STRA6-mediated 
retinol uptake and RBP affinity in bovine RPE cells [158]. These assays have not been conducted 
using zebrafish STRA6, but the conservation of the structures would suggest a similar 
mechanism. It is of note that according to this publication, in a cell system, CaM only bound 
STRA6 in high calcium conditions. No calcium was added during the purification of sheep or 
zebrafish STRA6, suggesting that the calcium concentration in our buffers is above the 





the protein for detergent purification is in complex with calcium-bound CaM in all four sites. As 
described in 2.4, incubation of nanodisc reconstituted zebrafish STRA6 did result in a percentage 
of protein particles with one or both CaM molecules missing from the structure, but the CaMBPs 
were completely disordered such that no density beyond the TMs was visible. Perhaps purification 
of this protein with such a large disordered C terminal region is unfavorable. In an effort to replace 
the calcium-bound CaM with magnesium-bound CaM, we attempted to purify sheep STRA6 in 
the presence of EGTA and MgCl2. A magnesium-bound CaM in complex with STRA6 could be 
more likely to occur in the cell than an apo-CaM given the high resting intracellular magnesium 
concentration [187]. We also knew from structural studies of the zebrafish protein that excess 
EGTA alone was not enough to achieve a stable apo-CaM bound STRA6 and therefore tried for 
a milder condition than complete removal of calcium (section 2.4). However, the sheep protein 
aggregated under this condition. Further purification studies would be necessary to confirm this 
theory of CaM’s role as a stabilizing binding partner. 
  
3.4.2 Insights from a retinol-loaded sheep STRA6 structure 
 The high degree of similarity between the retinol-loaded and retinol absent structures of 
sheep STRA6 is not altogether surprising given that we observed a similar phenomenon with 
zebrafish STRA6 (section 2.3.2). It is likely that STRA6 conformational changes occurred in order 
to allow for RBP interaction and retinol uptake, but these intermediary states were not captured 
by cryo-EM. While processing the retinol-loaded STRA6 dataset, we performed 3D variability 
analysis in CryoSPARC in addition to 3D classification without alignment in Relion, but did not 
find a subset of particles that composed a STRA6 class with the RBP-interacting peptides in a 
different conformation. Our proposed mechanism of STRA6-mediated retinol uptake does not 





directly partitions into the membrane, and therefore no direct retinol binding to the protein nor 
associated conformational change is required. STRA6 appears to buffer the amount of retinol in 
the cell, maintaining proper levels of vitamin A and preventing toxicity. An energy-consuming 
conformational change upon retinol uptake by STRA6 could slow the receptor’s response to 
changes in retinol level in the membrane, making it a less sensitive retinol influx/efflux transporter.   
 It should also be mentioned that it is unclear if our retinol treatment conditions of STRA6 
in nanodisc were optimal for observing maximal retinol accumulation in the membrane. Treatment 
of STRA6 in a purified membrane environment with larger excess of retinol-bound RBP resulted 
in slower retinol uptake as compared to a lower concentration of retinol-RBP [127]. This is likely 
due to excess free retinol in the membrane, an effect that was mitigated by addition of LRAT. 
LRAT is an intracellular enzyme that converts retinol to retinyl esters, effectively removing free 
retinol from the membrane that could otherwise be loaded back onto apo-RBP for efflux. We were 
able to confirm retinol loading of the nanodisc lipid bilayer with holo-RBP, but a 1:13 molar ratio 
in a purified environment may be above the threshold at which retinol uptake is at its peak. It may 
be that some of the released retinol was loaded back onto RBP during the 12 minutes of 
incubation, although according to Dr. Sun’s work, when only STRA6 was present in the 
membrane, retinol release began to plateau around 20 minutes after addition of retinol-RBP. This 
would mean the 12 minutes of incubation used in our experiment would place the sample at the 
peak of retinol release rate. However, the molar ratio of STRA6:RBP used in Dr. Sun’s 
experiments is unclear as purified membranes of cells expressing STRA6 were used as opposed 
to purified protein. It is therefore difficult to compare the time points and concentrations used in 
our experiment with theirs.  
 Another important factor in loading STRA6 in nanodisc with retinol was the calcium 





concentration in our purification buffers must be high enough to allow for calcium-bound Cam 
binding to STRA6. Dr. Sun’s recent publication on the STRA6 interaction with CaM showed that 
increased intracellular calcium increased binding of CaM to STRA6 and decreased RBP binding 
[158]. With these data in mind, we could have perhaps increased retinol loading of STRA6 by 
adding a calcium chelator. According to his model of STRA6-CaM interaction, STRA6 in the 
absence of CaM has higher affinity for holo-RBP, while STRA6 in complex with CaM is more likely 
to bind apo-RBP. Our structure therefore fits in this model as the intermediary retinol-loaded 
STRA6 bound to CaM and prepared for retinol efflux via interaction with apo-RBP. This also 
applies to zebrafish STRA6 (chapter 2), assuming that its function is similarly calcium dependent. 
It is of note that a conformational change in the zebrafish RBP interacting loops upon retinol 
loading was observed, but not in the sheep. This is likely due to the lower resolution of the map 
in the RBP interacting loop region of the sheep density map, however it may also indicate a 
species difference in zebrafish and sheep STRA6 in how they recognize and bind RBP. 
 
3.4.3. Location of Matthew-Wood Syndrome mutations on mammalian STRA6  
 The reported STRA6 missense mutations known to cause MWS are located in the same 
regions of the protein in both zebrafish and sheep homologs. These include the double mutant 
P90L/T321P and single mutants P293L, G304K, T644M and R655C. P91 (P90 in human STRA6) 
is located in the loop connecting TM1 and 2 and the side chain is adjacent to the IMa (Figure 3.12 
B). The density for the loop connecting TMs 1 and 2 in the sheep STRA6 structure is not well 
resolved except for the center section of it, including P91. This may indicate the importance of 
this proline in ensuring structural stability. T322 (T321 in human) is located at the top of TM6, by 
itself this mutation allows for protein expression and folding (Figure 3.12 A). P294 (P293 in 





protein like P90. A third mutation in TM6, this one in the center of the helix, G305 (G304 in 
humans), faces the membrane and replacement with a charged residue at this position would 
likely destabilize the protein [176]. T643 (T644 in human) located in CaMBP2 and R654 (R655 in 
human) in the C terminus, appear to be important in maintaining the interaction of STRA6 with 
the C lobe of CaM (Figure 3.12 C). None of the human STRA6 mutants listed here when 
transfected into HEK293T cells expressed at the cell surface, with the exception of T321P, but 
only in the absence of P90L [133, 138]. The impact of a single mutation in the CaMBP2 is of 








Figure 3.12 Location of MWS mutations on the sheep STRA6 structure.  
A) Sheep STRA6 protomers shown in dark gray and CaM in yellow. MWS residues numbered as in the 
sheep structure. B) Inset of A showing P91 in the TM1-2 loop, P294 in the loop connecting CaMPB0 to TM6 
and G305 in TM6. B) Inset of A showing T643 in CaMBP2 and R654 in alpha C terminal helix. Figure made 
in BioRender. 
 
 With the successful reconstitution of sheep STRA6 in nanodisc, structure determination, 
and demonstration of retinol uptake in this native-like lipid bilayer, we can begin more nuanced 







Chapter 4: RBP-STRA6 complex formation 
The direct interaction of STRA6 with RBP is a unique feature to this system of cellular 
retinol uptake. The interaction has been reported to be rather strong (59 nM on cells [168]), 
however it must also be transient in order to maintain retinoid homeostasis in the STRA6-
expressing tissues. Complicating matters is the fact that RBP circulates in the bloodstream bound 
to TTR and must first dissociate from this complex in order to interact with STRA6. Specific 
residues of STRA6 and regions of RBP have been implicated in their interaction with one another, 
but the true nature of their contact interface remains unknown. We aimed to solve the structure 
of the complex of STRA6 in a native-like lipid bilayer with RBP in order to shed a molecular level 
light on the nature of this unique interaction.    
 
4.1 Introduction: STRA6 and RBP interacting residues 
The structure of human RBP in complex with all-trans retinol was first published in 1984 
[188], since then 33 other structures of this protein from various species and in complex with a 
number of substrates have been deposited in the PDB. The protein is a member of the lipocalin 
superfamily, small extracellular proteins characterized by an 8 anti-parallel stranded beta-barrel 
with a central ligand binding pocket [189]. Other lipocalins, such as beta-lactoglobulin have been 
shown to nonspecifically bind retinol, but RBP is considered the sole specific retinol transporter 
[190]. The protein, like most lipocalins, has an 8-stranded beta-barrel core with an alpha helix 
near the C terminus. The hydrophobic center of the beta-barrel houses one retinol molecule, 
providing hydrophobic and uncharged side chains in coordination with solvent molecules to hold 





The crystal structure of the human TTR in complex with chicken RBP, determined in 1995, 
revealed that two molecules of monomeric RBP bind one homotetramer of TTR. Each RBP 
molecule interacts with three out of the four TTR monomers [192]. The RBP-STRA6 interaction 
was predicted to be similar to the RBP-TTR one as both proteins would need to interact with the 
retinol exit end of RBP to facilitate retinol uptake in the case of STRA6, or protect it during 
circulation in the case of TTR. Three loops connecting strands of the RBP beta-barrel form the 
retinol exit end: residues 31-37, 60-70 and 92-98. Insight from mutational and deletional studies 
revealed that loops 60-70 and 92-98 in addition to the C terminus are needed for interaction with 
STRA6 (Figure 4.1 D). The RBP double mutant L63R and L64S could not bind placental 
membrane vesicles expressing the RBP receptor [193]. An antibody recognizing the same loop 
also prevented binding of RBP to the receptor [194] and deletion of residues 92-98 decreased 
binding of RBP to the receptor significantly [193]. The C terminus was implicated in receptor 
binding more indirectly as loss of some C terminal residues or addition of a C terminal tag on RBP 
each abrogated binding to the receptor [95, 103]. In a more recent study, two RBP mutations were 
identified in patients with congenital eye malformations including microphthalmia and 
anophthalmia. Biochemical studies of these mutations using recombinant RBP showed that they 
increased the Kon of RBP binding to STRA6, decreasing the Kd from 59 nM for wild-type RBP to 
1.9 nM for the A55T mutant and 1.5 nM for the A57T mutant [168]. These two residues are not 
located in the three regions shown to interact with STRA6, instead they form the retinol-binding 
pocket of the protein, interacting with the beta-ionone ring of retinol [168, 195]. This location is in 
line with the observation that these mutations result in less stable binding of retinol to RBP. The 
combination of these effects most likely results in an alteration in the retinoid homeostasis function 
of the RBP-STRA6 system; apo-RBP binds to STRA6 with high affinity, thus preventing 






Figure 4.1: Location of RBP and STRA6 interacting residues.  
A) Sheep STRA6 in nanodisc structure. Protomers in pink, CaM in gray and RBP essential ligand-binding 
domain as described by Dr. Sun’s group in yellow. B) Rotation of panel A 90. C) Rotation of panel A 90, 
viewing the essential ligand-binding domains from above the plane of the membrane. D) PDB ID 5NU7 in 
blue with predicted STRA6 interacting residues in yellow. Figure made in BioRender. 
 
The structure of sheep STRA6 reconstituted in nanodisc revealed that the essential ligand-
binding domain of the protein, as described by Dr. Sun’s group, is located at the apex of the 





abrogate RBP binding and retinol uptake when mutated, while maintaining cell-surface expression 
and therefore overall folding of the protein. These mutations included Y336A, G340L and G342L. 
How these residues on STRA6 may interact with loops 60-70, 92-98 and the C terminus of RBP 
could essentially only be guessed at without a structure of the complex of the two proteins. We 
present here the structure of nanodisc-reconstituted sheep STRA6 in complex with purified holo-
RBP bearing the A55T mutation.  
 
4.2 Methods  
4.2.1 Preparation of purified human RBP from E coli for complex formation 
 The human Rbp4 gene was ordered from IDT as gBlock gene fragments and cloned into 
a pET23 vector (COMPPÅ), providing an N terminal deca-Histidine tag and TEV protease 
cleavage site for purification purposes. Site-directed mutagenesis (kit from Agilent) was 
performed to generate the A55T mutation in the Rbp4 gene. The plasmid was transformed into 
BL21 E. coli cells with chloramphenicol and ampicillin resistance. Cells were grown at 37ºC until 
reaching an OD600 of 0.8-1.0 at which point expression of RBP was induced using 0.4 mM IPTG. 
The temperature was then decreased to 22ºC and the cells were cultured with shaking overnight. 
Cell pellets were collected the following day by centrifugation, the pellet was washed with PBS 
before pelleting the cells a second time and storing at -80ºC until inclusion body purification.  
 Inclusion bodies were prepared from the transformed E. coli following a protocol adapted 
from [197]. In brief, 6 ml of lysis buffer consisting of 50 mM Tris pH 8, 100 mM NaCl, 1% Triton-X 
100, 0.1% sodium azide, 10 mM DTT, and 1 mM PMSF was added per gram of cell pellet. The 
cells were disrupted using an EmulsiFlex C3 (Avestin) and then pelleted by centrifugation at 





resuspensions in Tris-EDTA-Triton-X buffer. The final pellet was resuspended in Tris-EDTA 
without Triton-X before final centrifugation and storage at -80ºC.  
 Refolding of RBP with retinol was carried following a protocol adapted from [198], 
beginning by adding 3 ml of 7.5 M guanidine hydrochloride to 1/6 of an inclusion body preparation 
from 1L of E. coli cells. The resuspended inclusion bodies were incubated at room temperature 
for 30 min and then added dropwise into 4 volumes of chilled refolding buffer consisting of 20 mM 
Hepes, 100 mM NaCl, 0.4 M L-arginine and 1 mM all-trans retinol. Retinol was prepared in ethanol 
and checked for purity by HPLC at Rutgers University. The refolding reaction was light protected 
and rotated at 4ºC overnight. The next day, insoluble material was pelleted by centrifugation and 
the supernatant was concentrated using a 10 kDa cutoff centrifugal concentrator (Millipore). 
Excess L-arginine and retinol were removed from the purification using a PD-10 desalting column 
(Cytiva) before binding the protein to Ni-NTA agarose (Qiagen) for 4 hours rotating at 4ºC. Resin 
was washed with 15 column volumes of Hepes-NaCl buffer with 10 mM Imidazole and eluted in 
3.5 column volumes of the same buffer but with 200 mM Imidazole. The eluted protein was mixed 
with TEV protease and placed in a dialysis cassette for His tag cleavage overnight. The next day, 
the protein was removed from dialysis and applied to Ni-NTA agarose three times to collect the 
cleaved protein. The protein was concentrated and filtered before applying to a Superdex 200 
increase 10/300 column on an AKTA gel filtration system. Fractions were collected, pooled and 
concentrated before measuring absorbance spectra over wavelength 250-400 nm, expecting 
peaks at 280 nm for protein and 325 nM to confirm presence of retinol in the protein sample [199]. 
Final protein concentration was measured by Bradford assay and aliquoted protein was stored at 






4.2.2 STRA6-RBP complex formation and sample preparation for cryoEM 
 Sheep STRA6 was purified and reconstituted in nanodiscs as described in sections 3.2.4 
and 3.2.5. Purity of the complex components were determined by SEC followed by SDS-PAGE 
gel (Figure 4.3). The absorbance spectrum of the purified A55T RBP protein across 250-400 nm 
was measured to confirm retinol refolding (Figure 4.3 B). Prior experiments showed that STRA6 
and RBP separate when injected together on SEC (see section 3.3.5). Each component was 
therefore purified separately, concentrated, and then incubated together just prior to cryo-EM grid 
preparation. STRA6 was concentrated to 3 mg/ml and purified holo-RBP A55T mutant was added 
in a 1:2 molar ratio (STRA6:RBP, assuming STRA6 to be a dimer). The mixture was incubated 
on ice for ~40 minutes before applying to the grid. R 0.6/1 holey carbon gold grids (QUANTIFOIL) 
were plasma cleaned using a Gatan Solarus instrument. 3 µl of the protein solution was applied 
to the grid, followed by a 60 second incubation period before blotting with force 9 for 4 seconds 
using a Vitrobot Mark IV (ThermoFisher). The grid was then plunge-cooled in liquid ethane, cooled 
by liquid nitrogen. The grids were clipped in liquid nitrogen and delivered to the Columbia 
University Hammer cryo-EM facility for data collection.  
 
4.2.3 STRA6-RBP complex data collection and processing 
 5238 micrographs were collected on a Krios G3i microscope at the Columbia University 
cryo-EM facility. The instrument has a 300 kV FEG, Gatan Quantum Life Science energy filters 
and a K3 direct electron detector. The total dose rate of exposure for the collection was 58.34 e-
/Å2 over 50 frames at a rate of 16 e- per pixel per second. A pixel size of 0.83 Å and a defocus 





 Micrographs were imported into CryoSPARC V3.2.0 for initial processing. Frames were 
aligned using patch motion correction with a B-factor of 500. CTF estimation was then performed 
on the aligned frames. 748,613 Particles were picked using the TOPAZ tool [200]. The particles 
were extracted using a box size of 384 pixels and were binned by 4. 2D classification followed by 
3D ab initio modeling of 3 classes was then performed on the extracted and binned particles in 
order to sort out the particles showcasing STRA6 in nanodisc as evidenced by presence of two 
CaM densities. A subset of 330,448 particles from this classification were then re-extracted 
without binning for further processing. Heterogeneous refinement was used to remove particles 
composed of empty nanodisc and STRA6 in nanodisc without the RBP density. Local refinement 
was performed using a mask encompassing the TMs and RBP density while excluding CaM. 3D 
classification without alignment was then performed, the best 3D class was then further processed 
using Bayesian polishing in Relion. Local refinements in CryoSPARC were then performed using 
masks for each separate CaM molecule in addition to a third mask again covering the TMs and 
RBP density. The three local refinement maps were then combined in Chimera and used for 
model building (Figure 4.2). 
 
4.2.4 STRA6-RBP complex model building 
 The previously solved structure of sheep STRA6 in nanodisc alone was used to create a 
model that could be fit into the corresponding density in the complex dataset. The human holo-
RBP (PDB ID 5NU7) was used as the template for the density corresponding to RBP. The model 
was then fit to the density in UCSF Chimera and then imported into Coot for adjustment. The 
resulting map revealed a density in the ligand binding pocket of RBP. A CIF file for retinol was 





GUI in Phenix. Structural refinement was performed iteratively using Coot and Phenix. Data are 
summarized in Table 3.2. 
 
Figure 4.2: Cryo-EM data processing of the STRA6-RBP complex.  
STRA6 and RBP separately purified then mixed prior to cryo-EM grid freezing. Data processing scheme 






4.3 Results: the STRA6-RBP complex structure 
The 2D class averages from the STRA6-RBP data collection showed presence of the 
nanodisc lipid bilayer, two densities for CaM on one side of the bilayer in addition to a new density 
on the opposite side in contact with the RBP binding peptide. During model building, holo-human 
RBP (PDB ID 5NU7) was modeled into this density and found to fit with minimal changes only in 
loops surrounding the exit end of the RBP binding site. Overall, STRA6 appears very similar to 
the model of the protein without retinol (Figure 4.4, sheep STRA6 described in chapter 3). Studies 
of STRA6-RBP interaction suggested the interaction to be 1:1 assuming STRA6 to be a monomer 
at the time [201]. Only one RBP monomer appeared to stably bind the STRA6 dimer in our 
structure, forming contacts with both protomers, not unlike the interaction with multiple protomers 
of tetrameric TTR. A density is present in the ligand-binding domain of RBP that could likely be 







Figure 4.3: Sheep STRA6 and human holo-RBP A55T purifications for complex formation.  
A) Holo-RBP A55T gel filtration profile. B) Absorbance spectrum of purified holo-RBP A55T demonstrating 
presence of retinol, absorbance maximum at 325 nm. Note that protein concentration was quite low in this 
spectrum but was concentrated before complex formation. C) Sheep STRA6 reconstituted in nanodisc (ND) 
gel filtration profile. D) Sheep STRA6 purification and complex formation SDS-PAGE gel. Flow-thru (FT), 
Wash (W), Eluted protein (E), Final sample applied to grids for cryo-EM analysis (Complex). Membrane 
Scaffolding Protein (MSP) used to form nanodiscs. Figure made in BioRender.  
 
 Consistent with previous studies, the primary contact points for the complex appear to be 
in the essential-ligand binding domain of STRA6 and in the retinol exit loops for RBP (Figure 4.4). 
One STRA6 protomer appears to be the primary contact point with RBP while the other may 
stabilize it. We will henceforth refer to the RBP interacting peptide that more directly faces the 
retinol exit end and interacts with all three loops of RBP (31-37, 60-70 and 92-98) as peptide A 
(part of STRA6 protomer A) and we will refer to the other RBP interacting peptide that interacts 






Figure 4.4: Model of sheep STRA6 in complex with RBP.  
A) Membrane indicated by yellow rectangle. One STRA6 protomer in red and in complex with CaM in 
yellow, the other protomer in green in complex with CaM in cyan. RBP in blue with retinol exit site loops 
indicated in yellow and labeled as STRA6-interacting loops. B) Model in panel A rotated counterclockwise 
90º. RBP interacting peptides of STRA6 labeled Peptide A, the protomer that interacts with all three STRA6 
interacting loops of RBP and Peptide B stabilizing the interaction mainly in contact with RBP loop 92-98. 
Figure made in BioRender. 
 
 The three retinol exit site loops make hydrophobic contacts with peptide A and also 
residues in TM 6 of STRA6 (Figure 4.5). Loop 60-70 actually comes in from below peptide A and 
interacts with the loop (residues 328-332) at the apex of TM 6 just before peptide A (Figure 4.6). 
Looking down on the interaction with peptide A it appears that STRA6 serves as the third side of 
a triangular retinol exit site, the other two sides being composed of the RBP loops 60-70 and 92-
98 with the 31-37 loop protecting retinol from above (Figure 4.6 C). The hydrophobic residues 





apparently protecting retinol from the solvent and making passage between the RBP ligand 
binding pocket and the STRA6 central cavity energetically favorable (Figure 4.6 C). On the 
exterior of the contact interface, the polar residues interact with one another and likely form 
hydrogen bonds with solvent molecules, although these are not visible in our structure (Figure 4.6 
D). A salt bridge between N66 and K325 is possible, although the density for the K325 sidechain 
is not visible in the density map, but based on the placement of the backbone, the NZ atom could 
be within range of this interaction. The density for the side chain of Y336 is quite strong, but those 
of E33 and K349 are not visible in the map. As is the case with K325, placement of the backbone 








Figure 4.5 Surface representation of RBP-STRA6 complex hydrophobicity.  
Color ranges from Orange hydrophobic molecules to Dodger Blue polar molecules. A) Front view of RBP-
STRA6, hydrophobic transmembrane regions clearly visible with outer edges of CaM and RBP covered by 
polar residues facing the solvent. B) Side views of STRA6 turned 90 in relation to panel A and turned 180 
degrees in relation to one another. Hydrophobic residues lining the STRA6 central cavity and interface of 
RBP with STRA6 visible. C) Top view (view from the extracellular side of the membrane) of STRA6-RBP 
complex rotated 90 in relation to panel A. D) Slice-through of panel C showing hydrophobic residues lining 
the STRA6 central cavity. E) Slice-through in the opposite direction of panel D, view into the retinol-binding 
site of RBP from the STRA6 cavity. Hydrophobic residues surrounding the retinol molecules in pink. Figure 







Figure 4.6: RBP interaction with protomer A of STRA6.  
A) STRA6 Peptide A in red, Peptide B in green, RBP in blue and retinol exit loops of RBP in yellow. B) 
Panel A represented by hydrophobicity ranging from hydrophobic Orange residues to polar Blue residues. 
View of panels C and D indicated. C) View of hydrophobic residues lining the retinol exit site of RBP and 
Peptide A of STRA6. D) Tilted view of panel C showing polar residues of loops 31-37 and 60-70 of RBP 
interacting with TM 6 and Peptide A of STRA6. Figure made in BioRender.  
  
 The opposite STRA6 protomer (B) appears to stabilize the RBP interaction through more 
polar contacts (Figure 4.7). The RBP loop, residues 48-52, presents a polar face that can interact 
with residues D333, Y336, and K349 of protomer B. This RBP loop is actually shifted downwards 
toward STRA6 when compared to the PDB file of holo human RBP (5NU7) although the density 
is really not well-defined for E49 and T50 in our structure. However, based on restraints used 





favorable position. Some hydrophobic interactions may also be present at this interface, above 
the membrane, as V74 of RBP is within 4 Å of A339 and G340. The hydrophobic residues of both 
peptides A and B face mainly downward toward the STRA6 cavity, following the observation in 
earlier structures that the outer cavity is lipid-filled. Other hydrophobic residues in loop 92-98 such 
as W91, G92 and V93 also face downward and are within 4 Å from peptide B and could 
hydrophobically interact with residues of STRA6.   
 
  
Figure 4.7: RBP interaction with protomer B of STRA6.  
A) Peptides A and B of STRA6 indicated in red and green respectively in contact with RBP (blue) with its 
retinol exit loops in yellow. B) Panel A translated into hydrophobicity color scheme as in previous figures, 
view of panel C indicated. C) Polar residues mediating contact of Peptide B with RBP loop 48-52. D) Side 
view of RBP-STRA6 interaction, STRA6 essential ligand-binding domain residues indicated in cyan. Figure 







 The structure of the STRA6-RBP complex supports previous hypotheses regarding the 
protein-protein interactions, at least in part. The predicted stoichiometry of 1:1 was partially correct 
– 1 monomer of RBP for 1 monomer of STRA6, however STRA6 is a dimer and each protomer 
interacts with the asymmetric exit end of RBP. This does not preclude the possibility of multiple 
RBP binding simultaneously, but the structure presented here is reminiscent of the RBP-TTR 
complex in which monomeric RBP binds a homotetramer of TTR (Figure 4.11). The 
homotetramer, like STRA6, is symmetrical in its binding interface for RBP and can allow for 
binding of RBP in either side. This could allow for more efficient recognition of the binding interface 
as compared to an asymmetrical binding site. RBP A55T mutant was used in these experiment 
as it has a Kon for STRA6 expressed in cells 25 to 50 fold higher than its wild-type counterpart 
[168]. Indeed, this mutant favored complex formation as most of the collected particles from 
TOPAZ picking had RBP bound. However, this mutant still binds TTR (0.2 uM) and retinol (80 
nM) with the same affinity as wildtype [168]. It should be noted that sheep RBP amino acid 
sequence is 92% identical to the human, and the differences are conservative in terms of amino 
acid type. The homologs are 100% identical in the regions of RBP found to interact with sheep 
STRA6. Sheep retinol-RBP circulates in the bloodstream and provides retinol to the developing 
tissues [202] and RPE cells secrete RBP in complex with TTR toward the retina. Therefore, the 
mammalian system of STRA6-RBP interaction, not surprisingly, would appear to be conserved in 






4.4.1 Direct interaction of STRA6 with RBP 
 The three retinol exit loops of RBP appear, as anticipated to be responsible for the major 
contacts with the RBP binding peptides on STRA6 [95, 103, 193, 194]. The C terminus was also 
expected to interact with STRA6, perhaps inserting itself into the interface of RBP and STRA6, 
as it does in the human TTR structure, however the last residue resolvable in our complex 
structure was N171. Therefore, the role of the C terminus in mediating the STRA6-RBP interaction 
remains unclear. Like TTR, STRA6 provides two identical sequence interfaces rotated 180° in 
relation to one another. The STRA6 monomer therefore interacts differently with each RBP 
interaction loop as the retinol exit end is not symmetrical.  
 Of the three retinol exit site loops, 31-37 was predicted to be the minor player based on 
mutational studies [193]. Indeed, G34 and L35 of RBP are closest to Y336 of protomer A, and it 
is unclear if they participate in any meaningful hydrophobic interaction with this residue. However, 
L35 participates in an important hydrophobic interaction with a glycine in the RBP-TTR complex 
[192]. Mutational and antibody binding studies of loop 60-70 indicated that these residues were 
vital to receptor interaction [193, 194]. It appears that this loop interacts both with peptide A and 
also with residues 326-332, on the upper end of TM 6 just before peptide A. L64, N66 and W67 
are all under 4 Å away from V326 of protomer A, potentially participating in hydrophobic 
interactions with this residue. The N65 sidechain is under 4 Å away from both T331 and N333 
perhaps forming a hydrogen bond or polar interaction with one or both of these residues. N66 of 
RBP is within 4 Å of K325 and V326 although it is unclear if these residues interact. It is of note 
that RBP W67 is one of the key contacts with TTR (and also the RS3 scaffolding protein, to be 
discussed in 4.4.6), but appears to be less involved in the STRA6 interaction, residues 64-66 are 
closer to STRA6 comparatively. In loop 92-98, L97 is the closest residue to protomer A and may 





to be two main interacting residues, the first is Y336 potentially interacting with several nearby 
residues including D48, S54, V74, T76, and W91 of RBP. The second is K349 which could 
potentially form salt bridges with RBP residues D48 or E49. Interestingly, these potential salt 
bridge-participating residues have not been implicated in previous mutational studies of the RBP-
STRA6 complex, suggesting that they may function more as cooperative stabilizing forces rather 
than compulsory interactions (if they are formed at all).  
 The residues composing the essential ligand-binding domain of STRA6 (Y336, G340 and 
G342) seem to serve similar functions on each protomer, although the interfaces are overall 
different. F341 of peptides A and B both face the STRA6 outer cavity, pointing away from the 
RBP interaction interface. It would appear that the significance of G340 and G342 as part of the 
binding domain would be in allowing for flexibility in the peptide to facilitate movement of F341 
out of the way of RBP interaction. F96 is located in the center of the 92-98 loop of RBP and also 
faces the STRA6 outer cavity, maintaining a continuous hydrophobic surface between the STRA6 
RBP binding peptides. This is also clear from the side view in figure 4.5, showing the continuous 
orange surface under RBP facing the STRA6 outer cavity. The hydrophobic residues of this loop 
(G92 and V93) are under 4 Å away from G340 and F341 of peptide B, and could potentially form 
interprotein hydrophobic interactions, further stabilizing the complex. The zebrafish RBP 
interacting residues of STRA6 are slightly different from the sheep, suggesting potential 
differences in the interaction interface with RBP. The corresponding residues of Y336, G340 and 
G342 in sheep are F314, G318 and N320 in zebrafish respectively (Figure 3.5). The Y to F 
difference is a conservative change as both are aromatic amphipathic residues that could interact 
similarly with RBP, given that the RBP interacting loops are also conserved in zebrafish. This 
does appear to be the case based on the residue alignment, although there is currently no 





G342 appears to be important in flexibility of the loop, but a polar residue like N does not usually 
play such a role. This suggests a potential difference in zebrafish RBP-STRA6 interaction. 
 It bears mentioning that hydrogen bonds coordinated by solvent molecules play a major 
role in maintaining the retinol in the ligand binding pocket, in addition to interaction with binding 
partners such as TTR and the RS3 scaffolding protein (PDB ID 6QBA). These other published 
structures were determined by X-ray crystallography and allowed for higher resolution of the 
structure including solvent molecules, while this complex structure via cryo-EM did not.  
 
4.4.2 Published observations of residues beyond the essential ligand-binding domain 
mediating STRA6-RBP interaction 
 It was previously reported that residues at the N terminus and in the loop connecting TMs 
4 and 5 of bovine STRA6 allowed cell surface expression, but prevented RBP interaction [104]. 
From our stabilized structure of the complex, it is unclear how these residues, which appear to be 
distant from the RBP interacting loop, participate in this interaction (Figure 4.8). However, the N 
terminal residues 1-48 in each protomer are missing from our structure, indicating a disordered N 
terminal tail that could play some role in RBP interaction. A myc tag inserted between residues 
16 and 17 of bovine STRA6 decreased RBP interaction and retinol, although it also decreased 
cell-surface expression to some extent [104]. C44 and C195 of sheep STRA6 are conserved in 
the zebrafish structure, and in chapter 2 we showed that a disulfide bridge is formed between the 
corresponding residues in the zebrafish nanodisc structure. Mutating each of these cysteines to 
alanines in the bovine protein allowed for cell-surface expression, but prevented RBP interaction 
and retinol uptake [104]. The loop housing C195 connects TMs 4 and 5 of STRA6 and is also 





complex, but the nature of its role could not be determined from this structure. The second 
instance reported in the publication from Dr. Sun’s group showed that a myc tag, when inserted 
between residues 461 and 462 of bovine STRA6, also blocked RBP interaction [104]. These 
residues are located between TMs 8 and 9, and are adjacent to the RBP interacting loop. Perhaps 
a myc tag in this region would prevent the movement of the RBP interacting loop or TM 7 needed 
for RBP interaction to occur.     
 In another publication, Dr. Sun’s group showed that mutation of S385C, located at the 
base of TM 7 had no effect on retinol uptake or RBP interaction. However, conjugation of an 
MTSEA biotin bead to this cysteine residue decreased retinol uptake and only partially blocked 
RBP binding [105]. Increasing the size of the bead had a larger effect on diminishing retinol 
uptake. 12 residues in TM 6 and 8 residues in TM 7 had a similar effect when mutated to cysteine 
and coupled to a large bead. Previous to our structural work, Dr. Sun’s group surmised that these 
residues potentially faced one another and formed a pore through which retinol could pass. 
Analyzing the structure, a pore does not appear to be present in this region. For example, the 
residues in TM 6 L293, L297, S300, V319 and V320 face TM 7, as they might in a pore, but TM 
7 residues M381, S385 and H389 face the IM and the loop connecting the IM to the alpha 20 
helix. Additionally, L295, L299 and L303 in TM 6 all face TM 2, potentially mediating hydrophobic 
interactions between these two helices (Figure 4.8 B). We hypothesize that the effect of coupling 
a bead to these residues could not so much block a retinol pore, but instead inhibit movement of 
these helices, a requirement for the RBP interacting loop to trigger the release of retinol from RBP 
into the hydrophobic cavity of STRA6. In another publication they demonstrated that calcium-
bound CaM partially alleviated the effect of the MTSEA-bead on retinol uptake, supporting the 
conclusion that CaM binding to STRA6 causes a conformational change in the protein [158]. The 





STRA6 according to their model of CaM influence on STRA6 function, although efflux was not 
assayed in the presence of the bead. 
 
Figure 4.8: Location of STRA6 residues beyond the essential ligand-binding domain associated with 
RBP complex formation.  
A) Loop connecting TM 4-5 indicated which contains a cysteine that can form a disulfide bridge with the N 
terminal tail. Loop connecting TMs 8-9 indicated where an inserted myc tag interfered with RBP-STRA6 
complex formation. B) STRA6 protomers in dark gray and CaM in light sea green in order to better indicate 
residues. Residues in red when mutated to cysteine and chemically modified by attachment of an MTSEA 
bead allowed RBP interaction but blocked retinol uptake. Figure made in BioRender. 
 
4.4.3 Comparison of the sheep STRA6 structure in nanodisc with the complex structure  
 As expected, the structure of STRA6 in complex with RBP is highly similar to the original 





complex structure to the original sheep nanodisc structure (Figure 4.9). The differences described 
here are mirrored if instead they are aligned to protomer B. The most striking observation is that 
TMs 6 and 7 of each protomer appear to have shifted apart, making space for the RBP monomer 
to interact with the two RBP interacting peptides. When aligning to protomer A of STRA6, the two 
structures overlap well until residues 349-365 at the apex of TM 7. This section of the helix is 
slightly, but clearly, shifted away from the RBP molecule, perhaps moving the RBP interacting 
peptide into optimal position for interaction with RBP. Peptide A itself is in a very similar position 
in both structures, but just offset in terms of alpha helices. The density for the loop connecting 
peptide A to TM 7 is unfortunately not present in sheep STRA6 structure absent RBP, so we 
cannot compare these loops. Protomer B also overlaps completely with the original sheep STRA6 
structure, with the exception of the same residues in TM 7 (349-365) in addition to residues 321-
332 of TM 6. These helices, in addition to the RBP interacting peptide, are more dramatically 
shifted in protomer B compared to those in protomer A. Indeed, peptide B in the original structure 
intersects with the 92-98 loop of RBP in the complex structure. TMs 8 and 9 (residues 456-465) 
of this protomer is also shifted away from the opposite protomer. The movement could potentially 
support our hypothesis in section 4.4.2 that a myc tag between 461 and 462 would impede 
movement of this loop. These shifts suggest a model in which RBP recognizes one peptide of 
STRA6 while the other contorts in response, allowing for full docking of the protein. 
 The C termini and CaM of each STRA6 protomer in the complex with RBP appear to align 
with the original structure, and calcium is bound in all four binding sites of CaM. This conformation 
of STRA6 with CaM makes sense in light of observations published in a recent paper from Dr. 
Sun’s group [158]. This work showed, through cell-based studies of bovine STRA6, that increased 
intracellular calcium increased binding of CaM to STRA6, and also the affinity of STRA6 for RBP. 





but we can surmise that at least nanomolar level calcium is present in the utilized buffers. Our 
previous structures of sheep STRA6 clearly demonstrated that under our purification conditions, 
calcium-bound CaM remains in complex with STRA6. Dr. Sun’s group also showed that the affinity 
for apo-RBP is increased over holo-RBP in the presence of calcium. We prepared cryo-EM grids 
of the complex using A55T mutant apo-RBP. The initial 2D class averages showed that the 
complex was indeed formed, but the grid conditions were not optimal for collection. It may be of 
interest in the future to revisit this complex and study potential differences in the orientation of the 









Figure 4.9: Comparison of RBP-STRA6 complex with STRA6 structure in the absence of RBP. 
 STRA6 complex in gray, STRA6 alone in pink. B) Top view of STRA6 RBP interacting peptides overlaid 
with one another. C) Side view of STRA6 and RBP-STRA6 complex overlay with RBP in blue and retinol 
exit loops in yellow. Shifted TMs between the two structures indicated by curved arrows. D) Panel C rotated 
200º counterclockwise, providing a more angled view of the shifted peptides. Peptide B of STRA6 alone 
shown intersecting with loop 92-98 of RBP. Figure made in BioRender. 
 
 
4.4.4 Presence of a lipid density in the RBP binding pocket 
 A density, tentatively assigned as retinol, is present in the binding pocket of RBP in our 
structure (Figure 4.10). However, this density lies closer to the exit end of RBP compared to the 
published holo-RBP structures, and is not continuous, indicating poor density resolution in this 





5NU7) in our figures as we are not confident in the fitting of the molecule in the density in our 
structure. It is possible that retinol may have been transferred into the STRA6 cavity and that a 
lipid present in the nanodisc has been exchanged. It is notable that the shape of the density 
(although lower resolution comparatively) is similar to the densities found interacting with the 
intramembrane helices in the center of the hydrophobic cavity. These densities are present in the 
zebrafish and sheep nanodisc structures, as well as in the RBP-STRA6 complex structure (see 
figure 1.8 D for location of these densities in the zebrafish amphipol structure). We predicted that 
forming the complex using the A55T RBP mutant at 4°C would encourage binding, but not retinol 
uptake [112, 168]. The A55T mutation has been shown to increase the Kon of RBP for STRA6, 
making the complex of the two proteins more stable. The affinity of A55T RBP for retinol was 
found to be the same as for WT (80 nM) unless in the presence of detergents, ethanol or lipids, 
in which case it can more easily lose retinol compared to wild-type RBP [168]. It is possible that 
the density viewed in the structure is retinol, potentially shifted due to the presence of the 
mutation, or poised to be deposited into the outer cavity, or perhaps loaded back onto RBP after 
deposition in the cavity. There does not appear to be a structure of the A55T mutant RBP in the 
literature to which we could compare our structure. This topic will be revisited in section 4.4.7. 
 The key difference in apo vs holo human RBP crystal structures was found to be in 
residues 34-37 [204]. Overlaying the structure of RBP in complex with STRA6 with human holo-
RBP from plasma (PDB ID 5NU7), the backbone and side chains of these residues match almost 
exactly. The apo structure from this same publication (5NTY) shows that the protein purified from 
plasma was actually in complex with palmitic acid. Residues L35 and F36 have side chains that 
are completely displaced in the apo structure compared to the holo-RBP structure. L35 points 
downwards toward the retinol exit end. In the 5NU7 structure this sidechain potentially mediates 





closer to Y336 of STRA6 protomer A, perhaps mediating a hydrophobic interaction between the 
two proteins. F36 appears to be closer to the orientation of the holo-RBP structure in terms of 
placement of the backbone (Figure 4.10 C), although the density of the sidechain is not well 
resolved, it could be pointing into the ligand-binding pocket, mediating an interaction with retinol. 
Additionally, K29 in the apo structure interacts with palmitic acid and points into the binding site 
coordinating the ligand, but our structure matches the position of the holo-RBP in which this lysine 
faces outwards from RBP (Figure 4.10 C).   
 Y90 and L97 also coordinate the retinol in the ligand binding pocket, but are displaced in 
our structure (Figure 4.10 CD). In the complex structure, Y90 points upwards into the cavity rather 
than sideways towards the retinol exit end in 5NU7 (blue Y90 vs. sky blue Y90 in Figure 4.10 C). 
L97 is also shifted apparently out of range of coordination with the retinol molecule and closer to 
the RBP interacting loop of protomer A in the complex structure compared to in 5NU7. These 
effects could be related to the movement of the loop containing residues 93-98 being pulled up 
toward the cavity and into more of an alpha helix form than a flexible loop [204]. Two residues in 
the 92-98 loop in addition to several water molecules coordinate the alcohol end of the retinol in 
the ligand binding site in the 5NU7 structure. The O of F96, the N of Q98 and water molecules 
290, 295, 311, 381 and 425 support the hydrogen bonding [191]. The participation of Q98 is 
confusing considering that the downloaded model has the residue 5 Å away from the alcohol 
group as opposed to 2.99 Å as reported in the publication [204]. Of course, movement of the side 
chain can allow for this hydrogen bond to form. In our complex structure, the residue is closer to 
6 Å away from the alcohol group, suggesting that this bond may not be formed in our structure, 
however we cannot be sure of the placement of the alcohol group given that the density for retinol 
is so weak. Similarly, F96 is shifted farther away from the retinol exit site in our complex structure 





complex structure of holo-RBP with TTR, the alcohol end of retinol itself participates in the protein-
protein interface, if retinol is in the same position in our structure, then it does not appear to be 
within range of bonding similarly to STRA6. The density we observed however could put it in 
range of interaction with peptide A. Other residues participating in the retinol interaction include 
L37, M73, M88, V61, H104, R121, and F135 [191]. The sidechains of all of these residues appear 
to overlap with our complex structure, supporting the notion that retinol could still be bound in the 
binding pocket. The listed water molecules that may participate in hydrogen bonding between 









Figure 4.10: Presence of a lipid density in the ligand binding site of RBP in complex with STRA6.  
A) STRA6 in complex with RBP, RBP in blue with retinol exit loops in yellow. B) Closer view of RBP ligand 
binding site, retinol in pink from 5NU7 PDB file overlaid with density found in the ligand-binding site. C) 
Overlay of 5NU7 (sky blue) with RBP in complex with STRA6. Indicated residue side chains overlap with 
5NU7 structure, suggesting retinol present, or at least that the density is not palmitic acid as in the human 
apo-RBP structure. D) 5NU7 overlaid with RBP from RBP-STRA6 complex structure. Red arrows begin at 




4.4.5 Comparison of the RBP-TTR complex to the RBP-STRA6 complex 
 The interface of the holo-RBP TTR complex in some ways resembles that of RBP-STRA6 
(Figure 4.11). However, the holo-RBP, while circulating in the bloodstream bound to TTR, must 





above that the binding sites of RBP for each of these partners are overlapping but perhaps not 
identical. The RBP-TTR interface is mainly composed of a hydrophobic core and charged 
residues on the outer edges of the contact site. Taking for example the interaction of one RBP 
(labeled E in the 1QAB PDB); V20, A81 and I84 residues of TTR monomers A and D are at the 
center of the binding interface. The I84S TTR mutation found in patients would appear to severely 
impede the hydrophobic interactions occurring on both protomers in contact with RBP. Monomer 
A interacts with loop 60-70 of RBP while monomer D interacts with loop 92-98 [205]. The two TTR 
monomers present identical but 180 degree flipped interfaces, much like the two RBP interacting 
loops of STRA6, although a third monomer also stabilizes the interaction. This third monomer 
appears to participate in mainly polar interactions with RBP much like protomer B does. For 
example, K89 and K99 of RBP form hydrogen bonds with D99 of this protomer as does RBP W91 
with S100 of the same protomer [192]. Additionally, the retinol alcohol group appears to be within 
range of hydrogen bonding directly with G83 of TTR. This same residue also appears to form the 
only contact with RBP loop 31-37, suggesting that this retinol exit loop of RBP is less important 
to the RBP-TTR complex than the other two [192]. Indeed, replacement of loops 60-70 and 92-
98 into rat epidydimal retinoic acid binding protein gave the protein the ability to bind TTR [206]. 
Replacing retinol with palmitic acid [207] or N-ethyl retinamide [208] causes RBP to lose affinity 
for TTR, likely due to the lack of alcohol group in the tail. Lastly, the C terminus of RBP E, residues 
L182 and L183 in the PDB file 1QAB, is located between monomer A of the TTR tetramer and 
the 60-70 loop of RBP [205]. This supports the observation that RBP with a truncated C terminus 
is cleared from the circulation more readily [209]. The affinity of TTR for holo-RBP is 0.2 µM as 
compared to 1.2 µM for apo-RBP [167]. This could be in part due to the vital role the alcohol group 
of the retinol molecule plays in forming this complex [192]. G83, S85 and Y114 of TTR are close 






Figure 4.11: Human RBP-TTR interaction from PDB ID 1QAB.  
A) Two RBP monomers in complex with one homotetramer of TTR. B) Close up of the interaction of retinol 
loop 60-70 with TTR monomer A and loop 92-98 with TTR monomers C and D. C) Hydrophobic residues 
in panel C shown in orange at the center of the interface between the two proteins. D) Panel B rotated 180 
to show RBP loop 92-98 interacting with TTR monomer C. E) Panel D in hydrophobic representation (polar 
residues in blue, nonpolar in orange), to indicate polar interactions of RBP loop 92-98 with TTR monomer 
C. Figure made in BioRender.  
 
4.4.6 Comparison of the RBP-STRA6 complex to the RBP engineered binding scaffold 
6QBA 
 A second structure of RBP4 in complex with another protein exists in the PDB – that of a 
scaffolding protein that could function as a molecular ON switch for CAR (chimeric antigen 
receptor) T cells (Figure 4.12) [211]. CAR T cells secrete cytokines in response to an antigen, but 
have many off-target effects. A specific ON switch could therefore allow more control over this 
therapy. In this case, the scaffold protein RS3 would be attached to the CAR T cell and A1120 (a 





retinol exit end since it lacks a tail hydroxyl group, compared to the natural apo or retinol bound 
state, serving to provide higher specificity for binding to the engineered scaffold protein. 
 The crystallized structure of RBP in complex with RS3 reveals some overlap with the 
STRA6 interaction. RS3 is composed of two short N terminal beta strands, connected to three 
longer beta sheets that form a lid across the retinol exit loop while a C terminal alpha helix folds 
under this beta sheet. The most striking feature is the presence of 4 tyrosines arranged in a line 
across the beta-sheet with the hydroxyl group of each pointing up into the A1120 binding site 
(Figure 4.12 A). This is not altogether surprising given that tyrosine is an amphipathic molecule 
and its versatility allows it to interact with both hydrophobic residues and polar molecules. This 
residue also provides specificity to an engineered binding site by virtue of its rigidity [212]. The 
tyrosines in this complex structure appear to form both hydrophobic interactions with the retinol 
exit loops for example, L35, L63 V69, A71 and F96 in addition to more polar interactions via the 
hydroxyl group within the ligand binding site (Figure 4.12 B). The key residue of the RBP-STRA6 
interaction is also a tyrosine, mediating interaction with the outer edge of the binding site. The 
tyrosines in this structure are involved both in contacts such as this with the outer edge in addition 
to within the ligand binding site. Other polar residues on the outer edge of the RBP-RS3 binding 
interface such as N66, D72, and S95 of RBP help to maintain the interaction, similar to the 
interaction of RBP with protomer B of STRA6 (Figure 4.12 C). In general, this scaffold protein is 
much different from the natural TTR or STRA6 interactions with RBP since it is an engineered 
site made specifically for interaction with antagonist-bound RBP, but the interactions described 






Figure 4.12: Human A1120-bound RBP in complex with RS3 scaffolding protein  
(PDB file 6QBA). A) RBP in red, scaffolding protein in gray, the four tyrosine residues of RS3 are in yellow 
with inset of close up of the four tyrosines with hydroxyls facing into the ligand binding cavity of RBP. B) 
RBP in hydrophobic spectral coloring (orange for hydrophobic, blue for polar) indicating hydrophobic 
interactions of RBP loops with the tyrosines of RS3. C) Panel B rotated to show polar interactions of RS3 
tyrosines with RBP residues. Figure made in BioRender. 
 
 
4.4.7 Contextualization of the STRA6-RBP complex in the current literature  
 Several papers from Dr. Noy’s group at Case Western Reserve University have put forth 
the hypothesis that holo-RBP interaction with STRA6 transduces an insulin signaling cascade 





putative SH2 domain in the C terminus of STRA6 [133, 146]. This SH2 domain includes residues 
642-645 of the sheep STRA6 structure with sequence YTLL. This sequence, as in the zebrafish 
and sheep STRA6 in nanodisc structures is in direct contact with the C lobe of CaM, preventing 
interaction with any tyrosine kinases (Figure 4.13 C). It is of course possible that a transient 
unbinding of calcium from CaM could cause this sequence to become available for 
phosphorylation and subsequent recruitment of JAK2 and STAT5. In the model of calcium-CaM 
regulation of STRA6 function put forth by Dr. Sun’s group, STRA6 under physiological calcium 
concentrations is not bound to CaM and can bind holo-RBP, mediating retinol uptake. Interaction 
of holo-RBP with CaM-free STRA6 would then, in Dr. Noy’s model, result in the phosphorylation 
of the tyrosine in the SH2 domain. Upon a calcium signaling event, CaM would then associate 
with STRA6, increasing the affinity of STRA6 for apo-RBP and mediating retinol efflux from the 
cell. This would mean that insulin signaling transduction via this pathway would only occur under 
physiological calcium concentration conditions and not during a calcium signaling event. It does 
not appear that Dr. Noy’s group investigated the potential role of intracellular calcium 
concentration on this signaling cascade.    
 Whether STRA6 must interact with CRBP-I for retinol uptake has been a debated subject 
in the literature. Sun’s group showed that CRBP-I independent cellular retinol uptake can occur 
and that LRAT can increase retinol uptake as well as CRBP-I [127]. Dr. Noy’s paper in 2012 
however provided evidence for the direct interaction of STRA6 with CRBP-I. They show through 
co-IP experiments that a transfected STRA6 associates with CRBP-I when the cells are treated 
with RBP [215]. They then narrowed down the potential binding region of STRA6 to residues 235-
295 and expressed this peptide separately and showed binding to only apo and not holo-CRBP1 
through fluorescence anisotropy experiments. They suggest the protein-protein interaction 





These residues are located in CaMBP0, only arginine faces toward the solvent while the other 
four residues appear to mediate the interaction with the N lobe of CaM. Specifically, mutation of 
L255A resulted in decreased CRBP-I interaction in addition to retinol uptake but retained cell-
surface expression. Given Sun’s model of retinol uptake, CaM would not be bound during STRA6 
interaction with holo-RBP and therefore it is possible a rearrangement of STRA6 could allow for 
CRBP-I interaction with this residue. However it must be noted that the Noy paper utilized a His-
tagged CRBP-I for their purified protein interaction studies and this has been shown to destabilize 









Figure 4.13: Location of putative CRBP1 and JAK2 interacting residues in STRA6.  
A) Sheep STRA6 protomers in gray and CaM in light sea green. B) Protein-protein recognition sequence 
LRTLL in CaMBP0 of STRA6 shown in red. Residue L255 labeled as the key interacting amino acid. C) 
SH2 binding domain sequence YTLL located in CaMBP2 of STRA6. Y642 labeled as target of 
phosphorylation for signal cascade transduction.  
 
 
 The stable structure of mammalian STRA6 has provided unique insight into the required 
functional interaction of these two proteins, but many questions still remain. We hypothesize that 
the structure presented here is not the initial complex formation in which retinol-bound RBP first 
interacts with STRA6 to release retinol to the cell, but is instead the “second” phase in which 





[158]. This follows the observations that A55T mutant readily loses its bound retinol when exposed 
to lipids (in this case the nanodisc), that it forms a more stable complex with STRA6 compared to 
wild-type RBP, and that apo-RBP is more likely to remain bound to STRA6 than holo-RBP [158, 
168]. However, a publication from 1988 observed that human placental membranes when 
incubated with RBP at 0°C exhibited binding, but no retinol uptake [113]. We formed the RBP-
STRA6 complex in a similar manner, by incubating the two components on ice for an extended 
period. Ultimately, we cannot know which phase we are in, without some method of labeling the 
retinol, or covalently attaching the retinol to the RBP (without disrupting the STRA6 interaction), 
but the calcium-bound state of CaM would suggest the retinol efflux phase (Figure 4.14).  
 
 
Figure 4.14: STRA6-RBP interaction in relation to CaM binding.  
A) STRA6 at physiological calcium levels is not bound to CaM. B) During a calcium signaling event, calcium 
increases, encouraging CaM binding. C) apo-RBP has increased affinity for STRA6 in complex with CaM. 
D) Retinol is loaded onto apo-RBP. E) The now holo-RBP departs, allowing the cycle to continue. Figure 







 The inevitably static nature of this structure unfortunately does not shed light on the 
conformational changes needed for retinol release from RBP or loading onto STRA6. It is clear 
however from previous studies, that TMs 6 and 7 play a vital role in mediating retinol release from 
RBP [105]. These helices are also clearly shifted in our structure of the complex, supporting the 
notion that conformational changes beyond the RBP-interacting loop of STRA6 mediate the retinol 
influx and efflux functions of the protein. TM 6 is connected by a flexible loop to CaMBP0 which 
mediates interaction with the N lobe CaM in conjunction with CaMBP1. One hypothesis is that the 
calcium-bound status of CaM influences the conformation of this loop and thus TMs 6 and 7 which 
are themselves connected by the RBP interacting loop [156]. For example, a decrease in calcium 
could trigger unbinding of the N lobe of CaM from STRA6, resulting in a conformational change 
dramatic enough to influence the distant interaction of RBP with the RBP-interacting loop. The 
change could then favor the release of the now holo-RBP.   
 It does not appear from our structure that retinol directly interacts with STRA6, as it does 
in the RBP-TTR complex, and this follows the observation that apo-RBP cannot interact with TTR. 
How then do conformational changes in one or both of the two proteins make it more energetically 
favorable for release of retinol from RBP or loading of retinol to RBP? The retinol density in our 
structure is shifted compared to PDB ID 5NU7. This could be indicative of an intermediary state 
between full retinol binding and unbinding from the pocket while in complex with STRA6. This 
could also be a result of the A55T mutation, and a structure of this RBP mutant does not appear 
in the literature as of yet. Yet a third possibility is that a fatty acid or other lipid has exchanged 
with retinol and is present in the ligand-binding cavity of RBP in our structure. The resolution of 
this density is quite low so it is difficult to draw any conclusion solely based on the density shape 
and position. The direction of the key side chains of residues interacting with retinol would suggest 





palmitic acid as in the PDB 5NTY file. Adding to the confusion is the new position of some of the 
retinol interacting residues in the 92-98 loop which is no longer a loop at all in the complex 
structure, but an alpha helix. It is of note that we were able to form a stable complex of STRA6 
with the apo-RBP A55T mutant even in the absence of retinol (although some small percentage 
of RBP did still have retinol bound as evidenced by native mass spectrometry), perhaps solution 
of this structure could provide answers in regards to the interaction of these two proteins. Although 
this structure may prove to be, like the apo vs holo structure of RBP, not significantly different, 
but instead indicative of potentially dramatic conformational changes needed for retinol binding 
and release [191]. It is clear in comparing our complex structure with apo and holo forms of RBP 
alone that potentially dramatic conformational changes in the two proteins are needed to trigger 
release of retinol, but may not be effectively studied by static cryo-EM structure resolution.   
    














Chapter 5: Future STRA6 experiments and open questions 
The structure of mammalian STRA6 has provided insight into how this protein might 
function at a molecular level. However, biochemical assays aimed at characterizing the interaction 
of STRA6 with RBP and retinol uptake are still lacking. First, we plan to utilize Surface Plasmon 
Resonance (SPR) to measure the binding affinity of STRA6 in nanodisc for RBP. This technique 
has been utilized in the past for this system, but the stable reconstitution of STRA6 in a purified 
lipid bilayer environment will provide greater insight into this interaction than the previously used 
membrane or membrane mimetic systems consisting of placental membrane vesicles and 
detergent, respectively. The optimization of this technique will then allow us to study, for example, 
the impact of calcium concentration on STRA6-RBP affinity in a purified environment. Second, 
we aim to characterize the kinetics of retinol uptake by STRA6 into nanodisc utilizing a scintillation 
proximity assay. The kinetics of STRA6-mediated retinol uptake have been studied in membrane 
vesicles, but utilizing a controlled environment consisting of purified STRA6 in nanodisc will allow 
us more insight into the direct interaction of these proteins. 
The second part of this chapter will address the open questions as to the importance of 
the STRA6-RBP interaction in the context of whole organism retinoid homeostasis, what we can 
learn about the importance of this retinol uptake mechanism from animal knockout models and 
the similarities and differences between the STRA6 and RBPR2 systems. 
 
5.1 Future experiments 
5.1.1 STRA6-RBP Surface Plasmon Resonance 
The STRA6-RBP affinity has been measured in a number of systems, however a 





still lacking. We are currently optimizing conditions for a Biacore study of binding kinetics for sheep 
STRA6 reconstituted in nanodisc and human RBP.  
In 1988, Sivaprasadarao and Findlay showed that there are two RBP populations 
interacting with a receptor in human placenta [112]. A high affinity (3 nM) and a low affinity (80 
nM) component. Their assay utilized radiolabeled RBP to detect binding to membrane vesicles 
prepared from human placental microvilli. The labeled RBP was incubated with the prepared 
membrane vesicles at 22ºC for a total of 15 minutes and aliquots of the mixture were removed 
and counted at select time points. Interestingly, when the assay was performed at 37ºC for 1hr, 
the Kd of RBP for the receptor was measured to be 79 nM. It appears that the high affinity, slow-
dissociating form of RBP was not being detected under this second set of conditions. In the paper, 
it is proposed that this high affinity, slow dissociating RBP is retinol bound and that once it has 
delivered RBP to the membrane, has decreased affinity for the receptor. They also show another 
temperature dependent effect on affinity; at 0ºC, RBP immediately associates with the receptor, 
and dissociates very slowly. They attribute this to the inability of the receptor to take up retinol at 
this below-physiological temperature. However, at 22ºC, RBP binding increases beyond that 
measured at 0ºC and decreases over time, likely due to the retinol uptake reaction occurring and 
the apo-RBP subsequently dissociating from the receptor. These data may explain the high 
percentage of STRA6-RBP complex formation in chapter 4 observed after incubation at 4ºC for 
40 minutes. A density that could potentially be retinol was present in the binding pocket of RBP, 
suggesting that retinol uptake did not occur under these conditions. However, it is possible, that 
the stabilized complex observed by cryo-EM is the efflux state of the protein in which the added 
RBP had already deposited retinol and was now reassociating with STRA6 to remove retinol from 





SPR has been performed on STRA6 using membrane vesicles and also detergent purified 
human STRA6. In the first scenario, RBP was fixed to a CM5 Biacore chip which traps exposed, 
free amine groups on the protein [217]. Membrane vesicles prepared from HEK293 cells or 
placental microvilli were then flowed over immobilized RBP. An interaction was observed in SPR 
but an affinity measurement could not be performed, given the membrane environment and 
unknown size of the receptor. It is of interest to note that HEK293 cells only minimally express 
STRA6 according to the Human Protein Atlas and other reports [56], but this publication mentions 
unpublished data indicating that STRA6 is endogenously expressed by this cell line.  It is therefore 
unclear what protein was responsible for the interaction observed. STRA6 however is highly 
expressed in placental microvilli and membranes from this cell type have been clearly shown to 
bind RBP [112]. Interestingly, in this system, interaction was only observed with holo-RBP, but 
interaction was not detected when apo-RBP was affixed to the chip. Cellular and membrane 
studies have demonstrated that STRA6 interacts with both forms of RBP, and again it is unclear 
why there was no detected interaction of apo-RBP. The 50 µM EDTA addition to the flow buffer 
would be expected to increase affinity of STRA6 for apo-RBP [158], but this was not the case in 
this study.     
In 2015, the same group that performed the earlier SPR study performed SPR using 
detergent purified human STRA6 expressed in yeast to measure affinity for human holo and apo-
RBP. The protein was fixed to a chip with an anti-myc antibody, recognizing a C-terminal Myc tag 
on STRA6. They measured the Kd of STRA6 for holo and apo-RBP to be 19 and 22 µM, 
respectively. These low affinity measurements may be explained by the purification conditions, 
as we know from the structures reported here that the interface of the two proteins also includes 
lipids in the hydrophobic cavity. The detergent solubilizing the protein may prevent or inhibit, at 





receptor purification may negatively affect the RBP affinity, as a previous study showed that RBP 
binding was reduced by 44% with the addition of DTT as compared to without, although this was 
on placental membrane vesicles rather than purified STRA6 [112]. We now know from Dr. Sun’s 
publication that the disulfide bond between C44 and C195 is needed for optimal RBP binding 
[138]. From the sheep STRA6 structure, this N terminal disulfide bridge appears to be the only 
one in the structure. Therefore, the reason for this decrease in affinity after reducing agent 
treatment remains unclear, but should be recognized. 
The Biacore experiments we have begun in collaboration with a group at the University of 
Siena, Italy utilize a biotinylated nanodisc to fix the protein to a streptavidin chip. We biotinylated 
the MSP protein that forms the nanodisc following a protocol detailed by the Kossiakoff lab [218]. 
Sheep STRA6 is then reconstituted in the biotinylated nanodisc and fixed to the chip. Prior to this 
immobilization strategy, we attempted to use a CM5 chip that binds available lysines on STRA6, 
however this approach showed no interaction with RBP likely due to the presence of a lysine 
adjacent to the RBP interacting loop. The fixation from the nanodisc rather than from STRA6 itself 
ensures that the RBP interacting loop is available for binding. At this point, we have achieved a 
low level of nanodisc fixation to the chip and are working to increase binding. From the previously 
mentioned paper in which SPR was performed on detergent purified STRA6, we learned that the 
affinity of the purified components of this system may have lower affinity in the absence of 
interacting partners present in the cell [201]. We anticipate the affinity measured in our system 
may be in the micromolar range rather than the nanomolar as measured in a cell or membrane 
vesicle environment. We are attempting to conduct SPR both at 4ºC, the condition under which 
RBP-STRA6 stable complex is formed and also at 22ºC in which physiologically relevant retinol 
uptake can occur. Once we have determined the optimal conditions for this assay, we will 





publication with Dr. Sun’s group, we expect an increase in affinity for apo-RBP in the presence of 
high calcium [158]. The 2015 paper appears to have utilized buffer with minimal calcium present, 
indeed no chelator was added, suggesting nanomolar calcium levels. This paper showed no 
difference in affinity of STRA6 for holo vs apo-RBP, which may suggest that the described effect 
of calcium on STRA6 affinity is mediated by a player absent from this purified system. 
 
5.1.2 Retinol uptake kinetics of purified STRA6 and influence of calcium 
 We recently published an assay to measure zebrafish STRA6-mediated retinol uptake into 
proteoliposomes composed of brain polar lipid [161]. We are currently in the process of optimizing 
liposome reconstitution of sheep STRA6 into liposomes to similarly measure retinol uptake in a 
purified system. Retinol uptake into nanodisc demonstrated that indeed RBP interaction and 
subsequent retinol uptake occur in a purified system, however a closed liposome will allow us to 
control the amount of calcium present inside vs outside of the proteoliposome and therefore help 
to elucidate the effect of this divalent ion on retinol uptake by purified STRA6. This assay can be 
conducted as with the zebrafish STRA6, measuring retinol uptake by HPLC, or a 3H-retinol bound 
RBP (prepared as in [124]) can be used and 3H-retinol incorporation into the liposomes can be 
measured using a scintillation counter. 3H-retinol bound RBP will be added to the liposomes and 
the counts per minute (cpm) of the STRA6-incorporated liposomes will be measured at time points 
following addition of RBP to determine retinol incorporation kinetics (not unlike the procedure 
used with placental membrane vesicles with natively expressed STRA6 in [113]). We will utilize 
this proteoliposome system to begin defining the rate characteristics of retinol uptake by STRA6. 
Due to our inability, thus far, to purify a calcium-free STRA6 for structural studies, it is unclear 
whether we will be able to accurately assay the effect of calcium on protein function in a purified 





liposome will be sufficient to mimic a low calcium state of the cell and measure retinol uptake in 
this context. Another option would be to utilize a CaM with a point mutation in each of the calcium 
binding sites, preventing it from binding calcium. STRA6 could either be expressed as a fusion to 
this stable apo-CaM or the mutant CaM could be encapsulated in the liposome at high 
concentration in order to compete off the wild-type CaM purified from the SF9 cells [219, 220].  
 In the event that sheep STRA6 liposome incorporation is unsuccessful, we can plan to 
use a scintillation proximity assay (similar to the one conducted in [221]) on STRA6 incorporated 
nanodiscs to measure retinol uptake kinetics from purified RBP. A scintillation proximity assay 
(SPA) utilizes a bead that emits light when in close vicinity to a radiolabeled molecule [222, 223]. 
In this assay, a C-terminal His tag on STRA6 will be utilized to attach the protein to a YSi-copper 
bead (Yiitrium silicate bead from Perkin Elmer). A series of purified 3H-retinol-bound RBP 
concentrations will then be added to this fixed STRA6 in nanodisc. The proximity of the 3H-retinol 
to the bead will be indicative of retinol uptake into the nanodisc and will be measured in cpm, 
which can then be readily converted to determine molar amounts of ligand in the nanodisc. This 
assay can be conducted in the presence and absence of calcium in order to gain insight into the 
role of calcium in STRA6-mediated retinol uptake, although it will not fully recapitulate the cell 
environment as the sides of the membrane cannot be separated as they can in a liposome.  
 
5.1.3 The STRA6-CaM interaction 
 The potential role of CaM in regulating STRA6 function in a cellular context has only 
recently been reported and therefore requires further study. In the publication from Dr. Sun’s 
group, it was demonstrated that CaM interaction with bovine STRA6 is calcium dependent and 





Our structural studies of sheep STRA6 were all in complex with CaM, suggesting either that the 
calcium concentration in our purification buffers is high enough to facilitate this interaction or that 
the CaM-bound state of STRA6 is the most stable for high yield protein purification purposes. In 
an upcoming publication in collaboration with Dr. Weber’s group (submitted to JMB), we show 
that CaM when bound to zebrafish STRA6 CaMBP2 has sufficiently high affinity for calcium that 
the C lobe of CaM would be calcium bound under resting conditions in the cell. The N lobe of 
CaM however would only bind calcium during a calcium signaling event (when intracellular 
calcium concentrations rise above 100 nM). This supposed species difference in affinity of CaM 
for STRA6 CaMBP2 could be due to sequence differences in mammalian STRA6 compared to 
zebrafish. Dr. Weber’s group is currently in the process of measuring the binding affinities of 
sheep CaMBP2 for CaM in the presence of calcium so that we can compare between species 
and witness if indeed mammalian STRA6 does not bind CaM at resting calcium concentrations 
unlike zebrafish. The importance of the CaM regulation of STRA6 in an organism context can only 
be speculated on at this point, but a potential relationship could exist for example in the retina 
between light, calcium release and STRA6-mediated retinol uptake.  
 
5.2 The value of the STRA6 retinol-uptake system 
 Although 95% of circulating vitamin A in the fasting state is in the form of retinol bound to 
RBP [87], the importance of STRA6 does not appear to be in maintaining total body retinoid 






5.2.1 STRA6-independent vitamin A tissue uptake: other ways in 
 As described in section 1.4, there are a variety of mechanisms through which tissues can 
obtain vitamin A. Retinol, for example, can reach target tissues through uptake from RBP by 
STRA6 or RBPR2, the latter of which is mainly expressed in the liver and intestine (see section 
5.2.3). Megalin can endocytose RBP, although this pathway appears to be more important for 
retinol-RBP re-uptake by the kidney in order to prevent its excretion into urine rather than for 
tissue specific use of the retinol [224]. Retinol can also circulate bound to proteins other than RBP 
such as serum amyloid A. Expression of serum amyloid A increases during bacterial infection 
when RBP levels are decreased [225, 226]. Beta-lactoglobulin can also carry retinol in the 
circulation at much lower levels compared to RBP and can be internalized by endocytic receptors 
such as LIMR (Lipocalin-Interacting Membrane Receptor) [227]. The affinity of serum amyloid A 
and beta-lactoglobulin for retinol are 259 nM and approximately 25 nM respectively as compared 
to 80 nM for RBP [228, 229]. Albumin can also transport retinol in the bloodstream, but the affinity 
of this protein for retinol is 30-fold lower compared to RBP [230]. Lastly, retinol can freely diffuse 
across the cell membrane for example, recently ingested retinol generally diffuses into the 
enterocytes [54].  
 Other forms of vitamin A aside from retinol can also cross the cell membrane through 
different mechanisms. Firstly, these include lipoprotein receptor-mediated uptake of retinoids and 
carotenoids incorporated in lipoproteins. As described in section 1.4, retinyl esters and 
carotenoids can be incorporated into lipoproteins in the intestine and secreted into the lymphatic 
system for tissue uptake. The concentration of retinyl esters secreted from the liver in very low-
density lipoproteins (VLDL) in the human fasting circulating is usually <244 nmol/L [231], although 
after a meal, this concentration can increase to above that of retinol-RBP (1.4 umol/L) [232]. It 





placenta, but they do not appear to be the preferred source of vitamin A [115, 233, 234]. Secondly, 
endocytosis of albumin bound retinoic acid. Indeed, the fatty acid binding protein, albumin is the 
most abundant protein in the circulation and as such is important in transporting a variety of 
ligands [235]. Retinoic acid can bind albumin nonspecifically for transport in the circulation, 
however this metabolite can be toxic and as such does not appear to be the ideal retinoid transport 
form [111]. The level of circulating retinoic acid is generally low (4-14 nmol/L), supporting the 
notion that it is not a primary source of tissue retinoid uptake [72]. Thirdly, retinoyl beta-
glucuronide (RAG – produced from retinoic acid), a soluble metabolite of retinoic acid [236] can 
circulate in the bloodstream. Although this metabolite is less toxic compared to retinoic acid, it is 
present in very low levels and therefore not a primary source of retinoids for peripheral tissues 
[237]. Appreciable cellular uptake of RAG does not appear to occur in rodent models if maintained 
on a vitamin A sufficient diet [238]. It can however serve as a source of retinoic acid in vitamin A 
depleted tissues. When administered orally, RAG is absorbed by the intestine and converted to 
retinoic acid and retinoyl esters. RAG, although similar to retinoic acid, cannot bind CRABP [239] 
nor RARs [240]. Furthermore, it is neither toxic nor teratogenic unlike retinoic acid when 
administered orally [241]. Investigations of its potential use as a less toxic retinoid in treating acne 
and other illnesses are ongoing [242], however its importance in maintaining retinoid homeostasis 
does not appear to be significant. 
 Despite the existence of all of these different routes of cellular vitamin A uptake, the 
STRA6-RBP mechanism appears to play a specific role in the tissues where STRA6 is abundantly 
expressed and where maintain a tight regulation of vitamin A levels is of crucial importance, that 






5.2.2 Alternative pathways of retinoid uptake by tissues that express STRA6 
 STRA6 is highly expressed in blood-tissue barriers such as the placenta, RPE and choroid 
plexus of the brain. The question remains as to why Stra6-/- and Rbp-/- mice develop normally 
with the exception of eye defects. There are in fact other forms of circulating vitamin A as 
described in 5.5.1 that may be able to adequately compensate for lack of these components in 
mammals. For example, Rbp-/- mice maintained on a vitamin A sufficient diet for the most part 
develop normally. Lipoprotein incorporated retinyl esters appear to compensate for lack of this 
transport protein, crossing the maternal-fetal barrier via lipoprotein receptors [115]. Retinol, 
transported by albumin could also potentially compensate for lack of RBP. In a study of retinol 
uptake by a perfused human placenta, retinol (introduced in the “maternal perfusate”) was 
transferred less efficiently from RBP than from albumin. This suggests that the system of placental 
retinol uptake from RBP is more regulated compared to albumin [243]. Albumin, being a less 
specific transporter of retinol and also having a lower affinity for this molecule, therefore does not 
appear to be the preferred transport protein for placental retinol uptake [115]. Retinoic acid 
circulating in the bloodstream could be another source of compensatory retinoid, however in this 
study of Rbp-/- mice, concentrations of retinoic acid in the sera were very low and not increased 
in the knockout animals. These data suggest that although the STRA6-RBP system is an 
important route of retinol uptake for the developing tissues, the lipoprotein system of retinoid 
uptake may be able to compensate, at least partially, when necessary.  
 The eye, unlike other tissues however appears to heavily rely on retinol-bound RBP as a 
stable vitamin A source. Rbp-/- mice maintained on a vitamin A deficient diet were unable to 
mobilize hepatic retinoid stores and visual function declined (as measured by electroretinogram). 
On a vitamin A sufficient diet however, ingested retinoids from the diet were enough to maintain 





mice on a vitamin A sufficient diet initially had poor vision that improved to wild-type level over 
time, likely due to compensatory pathways such as lipoprotein incorporated retinyl esters. These 
data suggest that RBP may not be essential in the adult organism if dietary vitamin A is adequate 
[244]. The RPE itself can secrete RBP into the interphotoreceptor matrix although the role it plays 
in transporting all-trans and 11-cis retinol to the rod photoreceptors appears to be minimal [245]. 
This role is mainly filled by Interphotoreceptor Retinol-Binding Protein (IRBP) [246]. RBP 
expressed from the eye also does not appear to be vital to maintaining retinoid stores for the 
visual cycle itself. Visual defects and decreased retinoid levels in the eye observed in Rbp-/- mice 
on vitamin A deficient diet [244] are ameliorated by expression of human RBP ectopically 
expressed from muscle [247]. The eye appears to strongly prefer vitamin A delivered as retinol-
bound RBP compared to retinol-bound albumin or retinyl esters in lipoproteins. Albumin-bound 
retinoic acid was not taken up by the RPE [85] and although the RPE expresses LDLr [248], 
lipoprotein incorporated retinyl esters were also not a significant source of retinoid in this tissue 
[232]. The RPE has been shown to take up cholesterol in LDL from the circulation via LDLr and it 
is surmised that beta-carotene can be obtained from the circulation in a similar fashion [249, 250]. 
BCO1 expressed in the RPE can cleave this carotenoid and thereby provide all-trans 
retinaldehyde for the visual cycle, however the contribution of this pathway appears to be minimal 
[251]. Patients with RBP mutations have been reported in the literature, including I41N and G75D, 
residues located in the retinol binding pocket of RBP. These patients had extremely low retinol 
(0.19 µmol/L) and circulating RBP (<0.6 µmol/L), but their only symptoms were night blindness 
and some retinal dystrophy [252]. These mutations caused misfolding and aggregation of the 
protein, resulting in decreased secreted holo-RBP. Alternative pathways such as lipoprotein-
incorporated retinyl esters however appeared to compensate for the lack of functional RBP, 





 Stra6-/- animals as described in 1.7.1 and 3.1 mainly have issues in eye development and 
visual function although the effects vary between species models. In a mouse model of Stra6-/- 
for the most part the animals were normal if maintained on a vitamin A sufficient diet, except for 
eye defects including shortened photoreceptors [108, 174] and decreased retinoid stores in the 
eye [109, 214]. Retinyl palmitate especially was decreased in the retina, pointing to an important 
role of STRA6 in providing retinoid stores for this tissue [109]. Developing mouse embryos also 
showed normal retinoic acid expression with exception of the RPE which showed highly 
decreased retinoic acid levels. This suggests that STRA6 is only essential for providing retinoic 
acid to the developing RPE, but not for full body spatial and temporal distribution during mouse 
embryonic development [214]. On a vitamin A deficient diet in this study however, knockout 
animals had decreased retinoid stores in the brain and Sertoli cells of the testes, two organs that 
highly express STRA6 [108]. Another study showed that hepatic retinoid levels did not decrease 
while Stra6-/- mice were maintained on vitamin A deficient diet, suggesting that since vitamin A 
could not be effectively targeted to peripheral tissues, it remained in this storage organ [174]. 
These data support the function of STRA6 in maintaining retinoid stores especially in the eye 
during times of dietary vitamin A insufficiency. STRA6 could also play a role in mediating efflux of 
retinol from the developing tissues in order to prevent retinoid toxicity. In Lrat-/-Rbp-/- mice, a 
model for vitamin A deficiency, STRA6 was upregulated in the placenta and embryo when 
maintained on vitamin A sufficient or excess diet. This transcriptional increase could be a 
mechanism whereby retinol efflux is increased from the developing tissues due to a lack of LRAT 
which would normally convert retinol to retinyl esters [253, 254]. Zebrafish stra6-/- have more 
widespread symptoms like those seen in MWS patients and seem to be caused by excess retinol-
RBP that cannot be cleared by the embryo efficiently, leading to RA excess [125]. stra6-/- 





retinoid levels in the developing eye. These effects were rescued by decreasing expression of 
RBP, supporting the conclusion that STRA6 plays an important role in regulating retinoic acid 
expression in the developing zebrafish embryo. 
 Overall these effects in the Stra6-/- animal models point to a specific role of the STRA6-
RBP system in maintaining sufficient vitamin A acquisition in tissues that express STRA6, the eye 
in particular. Without this pathway, the animal must constantly consume vitamin A in order for the 
lipoprotein pathway (among others) to efficiently compensate for the inability of retinoid stores to 
be mobilized from storage tissues. The reason for the species differences remains unclear, but 
could be related to the differences in structure between the zebrafish and mammalian STRA6 
homologs. However, it has been shown that a large percentage of the retinoid stored in the 
zebrafish yolk sac is trafficked to the eye, and therefore inherent differences in retinoid distribution 
among developing tissues may be to blame for the species differences, rather than a STRA6 
structural difference [125, 255]. Further studies on the activity of the two proteins are needed to 
confirm this hypothesis. 
 
5.2.3 Potential parallels in STRA6 and RBPR2 function 
 The recently discovered retinol-binding protein receptor 2 (RBPR2) is overall less than 
18% similar to STRA6, but appears to play a similar role in that it transports retinol from RBP into 
the cell. It is predicted to have a similar topology to STRA6 based on sequence alignments with 
an N terminal bundle of helices (that can be expressed separately [56]) and a C terminal domain 
that could bind CaM [155]. An RBP binding domain was mapped on the structure using sequence 
similarity and molecular dynamics modeling [256]. The affinity of RBP as measured by alkaline 





and 52.6 nM for RBPR2. The major difference in these two proteins is in their tissue expression, 
the high liver and intestinal expression of RBPR2 are indicative of a role of this protein in whole 
organism retinoid homeostasis. Another difference is that while STRA6 is, as its name indicates, 
upregulated by retinoic acid, while RBPR2 expression and subsequent retinol uptake is 
decreased by treatment with retinoic acid, retinol and fetal bovine serum. This could suggest the 
presence of a feedback mechanism aimed at preventing retinoid toxicity in these tissues. In terms 
of activity, STRA6 and RBPR2 seem to function similarly in that they both can couple to LRAT for 
uptake of retinol specifically from RBP and not from albumin [56]. In a zebrafish model of rbpr2 
knockout, eye defects and developmental malformations in brain and heart such as cardiac 
edema were observed, not unlike the defects seen in vitamin A deficiency and in stra6-/- studies 
[257]. This is consistent with MWS effects, suggesting that RBPR2 could play a global role in 
retinoid homeostasis during development. Retinoic acid treatment of the knockout developing 
zebrafish rescued the phenotype, unlike in zebrafish where decreasing RBP rescued a similar 
phenotype [125]. A frameshifted RBPR2 mutant was also generated to effectively change the 
RBP binding residues and introduce a premature stop codon shortly after the putative binding 
domain [256]. The vitamin A deficiency-like effects of this frameshift mutant zebrafish make sense 
in this context as this type of truncation would prevent dimerization (if indeed RBPR2 dimerizes 
like STRA6) and also remove the C terminus which is likely to bind CaM, although any connection 
of RBPR2 to cellular calcium concentration has yet to be observed.  
 Studies of Rbpr2-/- mice in the literature so far are lacking, however a meeting abstract 
published online stated that these mice, when maintained on a vitamin A sufficient diet, had lower 
retinoid content in the eye, similar to Stra6-/- suggesting the importance of this protein in trafficking 





homeostasis outside of the eye. It will be of interest to learn the importance of this protein in the 
liver and intestine in the future, in addition to whether it is similarly regulated by calcium. 
 
5.3 Conclusions 
 The importance of the RBP-STRA6 interaction appears to be in tightly controlling vitamin 
A uptake in STRA6-expressing tissues such as the eye which depends on a supply of circulating 
retinoid. After a vitamin A-rich meal, the concentration of lipoprotein-incorporated retinoid 
increases, but STRA6 maintains tissue retinoid homeostasis in the face of this increase as it only 
accepts retinol from RBP. During times of dietary vitamin A insufficiency, retinol stores are 
released from the liver bound to RBP, ensuring uptake by STRA6 expressing cells. RBP is 
therefore a regulated source of vitamin A for the tissues where STRA6 is expressed. An 
unregulated source of vitamin A has been shown to result in adverse effects such as in the case 
of medications that supply retinoids unbound to RBP [259, 260]. The mouse and zebrafish Stra6-
/- knockout animals although phenotypically different both support the role of STRA6 in 
maintaining retinoid homeostasis in the eye and promoting proper eye development. The 
development of such an eye specific pathway of retinol trafficking clearly points to the evolutionary 
importance of maintaining retinoid stores for vision in the event of vitamin-A poor diet. The 
regulation of STRA6 by CaM although unclear at present may prove to play a specific role in 
providing adequate retinol for the visual cycle.  
 The closest relative to the RBP/STRA6 retinol uptake mechanism is likely SR-B1 which 
mediates incorporation of cholesteryl esters transported in HDLs (High Density Lipoproteins) to 
the plasma membrane [261]. The structure of LIMP-1, which shares high similarity with SR-B1 





concentration in a lipoprotein particle to lower concentration in the outer leaflet of the plasma 
membrane [262, 263]. SR-B1 has two TMs with a large luminal domain that directly interacts with 
the HDL particle. This is akin to the STRA6 interaction with RBP on the extracellular side of the 
membrane, triggering the release of retinol from RBP into a membrane of lower retinol 
concentration. Indeed CRBP-1 and LRAT, which transport retinol out of the membrane and 
convert it to retinyl esters, thereby decreasing the retinol content of the plasma membrane, 
increase uptake of retinol by STRA6. Both proteins (STRA6 and SR-B1) are therefore mediating 
membrane incorporation of a lipidic molecule into the plasma membrane from a specific 
transporter. Further studies are required to elucidate the mechanism of STRA6 (and RBPR2) 
















 The structural characterization of STRA6 in complex with calmodulin and RBP provide 
atomic-level insight into the function of this unique protein, while many questions still remain. In 
this work, we showed the structure of zebrafish STRA6 in a lipid bilayer environment at high 
resolution, illuminating molecular details previously unseen in the initial structure determined in 
amphipol. This 3.0 Å resolution structure showed the disulfide linkage thought to be needed for 
RBP interaction in the N terminus, movement of specific loops and helices in a lipid bilayer 
environment and distinct lipid densities interacting with the protein. The structure of the retinol-
loaded zebrafish although similar overall showed distinct movement in the RBP-interacting 
helices, supporting the role of a structural change in altering affinity of STRA6 for apo vs holo-
RBP. The structure of sheep STRA6 presented here represents the first full-length mammalian 
STRA6 structure solved to date. The core of the protein structure is conserved compared to 
zebrafish, but the protomers are angled such that the bound CaM molecules are farther apart in 
the sheep structure. The regions of the protein responsible for this difference and its relevance in 
terms of retinol uptake function remain unclear. The retinol-loaded structure of sheep STRA6 is 
similar to the zebrafish in that it appears highly similar overall to the structure in the absence of 
retinol. Movement in the RBP interacting loops may be possible, but the low resolution of this 
region of the protein prevents us from making a direct comparison. It is possible that this region 
is more disordered in the mammalian STRA6 compared to zebrafish, potentially signifying a 
difference in RBP interaction. Finally, we presented here a structure of sheep STRA6 in complex 
with RBP. In analyzing the contact points of our complex structure, the main interacting residues 
do seem to be in the predicted regions. Our structure therefore supports published observations 





binding pocket of RBP, the identity of which is predicted to be retinol, but further studies are 
needed to confirm this. CaM is also bound to STRA6 in complex with RBP, suggesting, based on 
Dr. Sun’s model of calcium-CaM regulation of STRA6 function, that the structure we have trapped 
represents the efflux state of STRA6 in which retinol has been loaded onto RBP and prepared for 
dissociation.  
 Further studies of the interaction of STRA6 with holo-RBP, apo-RBP and CaM are needed 
to understand the mechanism of retinol uptake. The stable structures of STRA6 in complex with 
CaM solved by cryo-EM, although enlightening, are only a snapshot of what is likely a very 
dynamic process. The study of the STRA6 interaction with CaM may finally provide answers as 
to how this unique protein is regulated and why it is needed for vitamin A uptake by such specific 
tissues. We are just beginning to discern the details of this fascinating and distinctive system of 















1. Thoreson, W.B. and E. Margalit, Night Blindness☆, in Reference Module in Biomedical 
Sciences. 2015, Elsevier. 
2. Dowling, J.E. and G. Wald, VITAMIN A DEFICIENCY AND NIGHT BLINDNESS. 
Proceedings of the National Academy of Sciences, 1958. 44(7): p. 648-661. 
3. Lanska, D.J., Chapter 29: historical aspects of the major neurological vitamin deficiency 
disorders: overview and fat-soluble vitamin A. Handb Clin Neurol, 2010. 95: p. 435-44. 
4. Wolf, G., A history of vitamin A and retinoids. The FASEB Journal, 1996. 10(9): p. 1102-
1107. 
5. Ebbell, B., The Papyrus Ebers: the greatest Egyptian medical document. 1937: Levin & 
Munksgaard. 
6. Littré, E., Oeuvres complètes d'Hippocrate. Vol. 3. 1841: JB Baillière. 
7. McLaren, D.S., BITOT'S SPOTS: A REVIEW OF THEIR SIGNIFICANCE AFTER 100 
YEARS. Br Med J, 1963. 2(5362): p. 926. 
8. Bitot, Lésion conjonctivale non encore décrite: coïncidant avec l'héméralopie. 1863: Imp. 
G Gounouilhou. 
9. Wolf, G., The Discovery of the Visual Function of Vitamin A. The Journal of Nutrition, 2001. 
131(6): p. 1647-1650. 
10. Mori, M., Über den sog. Hikan (Xerosis conjunctivae infantum ev. Keratomalacie). Jahrb 
Kinderheilk Phys Erzieh, 1904. 59: p. 175-195. 
11. Sommer, A., Nutritional blindness. Xerophthalmia and keratomalacia. 1982: New York, 
USA; Oxford University Press. 
12. McCollum, E.V. and M. Davis, THE NECESSITY OF CERTAIN LIPINS IN THE DIET 
DURING GROWTH. Journal of Biological Chemistry, 1913. 15(1): p. 167-175. 
13. Hopkins, F.G., Feeding experiments illustrating the importance of accessory factors in 
normal dietaries. The Journal of physiology, 1912. 44(5-6): p. 425-460. 
14. Osborne, T.B., et al., The relation of growth to the chemical constituents of the diet. Journal 
of Biological Chemistry, 1913. 15(2): p. 311-326. 
15. Karrer, P., R. Morf, and K. Schöpp, Zur Kenntnis des Vitamins-A aus Fischtranen II. 
Helvetica Chimica Acta, 1931. 14(6): p. 1431-1436. 
16. Semba, R.D., On the ‘Discovery’ of Vitamin A. Annals of Nutrition and Metabolism, 2012. 
61(3): p. 192-198. 
17. Petkovich, M., et al., A human retinoic acid receptor which belongs to the family of nuclear 
receptors. Nature, 1987. 330(6147): p. 444-50. 
18. Balmer, J.E. and R. Blomhoff, Gene expression regulation by retinoic acid. J Lipid Res, 
2002. 43(11): p. 1773-808. 
19. Baleato, R.M., R.J. Aitken, and S.D. Roman, Vitamin A regulation of BMP4 expression in 
the male germ line. Developmental biology, 2005. 286(1): p. 78-90. 
20. Sun, H. and R. Kawaguchi, The membrane receptor for plasma retinol-binding protein, a 
new type of cell-surface receptor. International review of cell and molecular biology, 2011. 
288: p. 1-41. 
21. NIH. Vitamin A Fact Sheet for Health Professionals. 2021 March 26 2021 [cited 2021 May 
18]; Available from: https://ods.od.nih.gov/factsheets/VitaminA-HealthProfessional/#en2. 
22. Coates, P.M., et al., Encyclopedia of Dietary Supplements, Second Edition (Print). 2010: 





23. van den Broek, N., et al., Vitamin A supplementation during pregnancy for maternal and 
newborn outcomes. Cochrane Database Syst Rev, 2010(11): p. Cd008666. 
24. Vitamin A deficiency. Nutrition Landscape Information System 2009  [cited 2021 June 5]; 
Available from: https://www.who.int/data/nutrition/nlis/info/vitamin-a-deficiency. 
25. UNICEF. Vitamin A deficiency. 2019 February 2019 June 6, 2021]; Available from: 
https://data.unicef.org/topic/nutrition/vitamin-a-deficiency/. 
26. Russell, R.M., The vitamin A spectrum: from deficiency to toxicity. The American Journal 
of Clinical Nutrition, 2000. 71(4): p. 878-884. 
27. 2001, I.o.M., Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, 
Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, 
and Zinc. National Academies Press: Washington (DC). 
28. Stevens, G.A., et al., Trends and mortality effects of vitamin A deficiency in children in 138 
low-income and middle-income countries between 1991 and 2013: a pooled analysis of 
population-based surveys. The Lancet Global Health, 2015. 3(9): p. e528-e536. 
29. WHO. Global prevalence of vitamin A deficiency in populations at risk 1995-2005. WHO 
Global Database on Vitamin A Deficiency, 2009. 
30. Huang, Z., et al., Role of Vitamin A in the Immune System. Journal of clinical medicine, 
2018. 7(9): p. 258. 
31. WHO, Guideline: Vitamin A supplementation in infants and children 6-59 months of age. 
2011: Geneva. 
32. Imdad, A., et al., Vitamin A supplementation for preventing morbidity and mortality in 
children from six months to five years of age. Cochrane Database of Systematic Reviews, 
2017(3). 
33. SWAMINATHAN, M.C., T.P. SUSHEELA, and B.V.S. THIMMAYAMMA, Field 
Prophylactic Trial with a Single Annual Oral Massive Dose of Vitamin A. The American 
Journal of Clinical Nutrition, 1970. 23(1): p. 119-122. 
34. UNICEF, Coverage at a Crossroads: New directions for vitamin A supplementation 
programmes. 2018: New York. 
35. WHO guideline: Use of multiple micronutrient powders for point-of-use fortification of foods 
consumed by infants and young children aged 6-23 monts and children aged 2-12 years. 
2016. 
36. Talsma, E.F., A. Melse-Boonstra, and I.D. Brouwer, Acceptance and adoption of 
biofortified crops in low-and middle-income countries: a systematic review. Nutrition 
reviews, 2017. 75(10): p. 798-829. 
37. Nkhata, S.G., et al., Biofortification of maize and sweetpotatoes with provitamin A 
carotenoids and implication on eradicating vitamin A deficiency in developing countries. 
Journal of Agriculture and Food Research, 2020. 2: p. 100068. 
38. Aman, R., A. Schieber, and R. Carle, Effects of heating and illumination on trans− cis 
isomerization and degradation of β-carotene and lutein in isolated spinach chloroplasts. 
Journal of Agricultural and Food Chemistry, 2005. 53(24): p. 9512-9518. 
39. Rodriguez-Amaya, D.B., M.R. Nutti, and J.L. Viana de Carvalho, Chapter 28 - Carotenoids 
of Sweet Potato, Cassava, and Maize and Their Use in Bread and Flour Fortification, in 
Flour and Breads and their Fortification in Health and Disease Prevention, V.R. Preedy, 
R.R. Watson, and V.B. Patel, Editors. 2011, Academic Press: San Diego. p. 301-311. 
40. Vitamin A supplementation: A statistical snapshot, UNICEF, Editor. 2016: New York. 
41. Livny, O., et al., Beta-carotene bioavailability from differently processed carrot meals in 





42. Rock, C.L., et al., Bioavailability of beta-carotene is lower in raw than in processed carrots 
and spinach in women. J Nutr, 1998. 128(5): p. 913-6. 
43. Canene-Adams, K. and J.W. Erdman, Absorption, transport, distribution in tissues and 
bioavailability, in Carotenoids. 2009, Springer. p. 115-148. 
44. Moore, T., LXXIX. Vitamin A and carotene. VI. The conversion of carotene to vitamin A in 
vivo. Nutrition Reviews, 1982. 40(9): p. 275-278. 
45. Britton G., L.-J.S., Pfander H. , Special Molecules, Special Properties, in Carotenoids. 
2008: Birkhauser Basel. 
46. Olson, J.A., Carotenoids and human health. Archivos Latinoamericanos de Nutrición, 
1999. 49(3 Suppl 1): p. 7S-11S. 
47. Grune, T., et al., Beta-carotene is an important vitamin A source for humans. The Journal 
of nutrition, 2010. 140(12): p. 2268S-2285S. 
48. Eroglu, A. and E.H. Harrison, Carotenoid metabolism in mammals, including man: 
formation, occurrence, and function of apocarotenoids. Journal of lipid research, 2013. 
54(7): p. 1719-1730. 
49. Burri, B.J., M.R. La Frano, and C. Zhu, Absorption, metabolism, and functions of β-
cryptoxanthin. Nutrition reviews, 2016. 74(2): p. 69-82. 
50. Harrison, E.H., Mechanisms involved in the intestinal absorption of dietary vitamin A and 
provitamin A carotenoids. Biochimica et biophysica acta, 2012. 1821(1): p. 70-77. 
51. Lindqvist, A. and S. Andersson, Biochemical Properties of Purified Recombinant Human 
β-Carotene 15,15′-Monooxygenase*. Journal of Biological Chemistry, 2002. 277(26): p. 
23942-23948. 
52. World Carrot Museum: Carrots and night vision - WW2.  [cited 2021 June 15]; Available 
from: http://www.carrotmuseum.co.uk/ww2seeinthedark.html. 
53. During, A. and E.H. Harrison, Mechanisms of provitamin A (carotenoid) and vitamin A 
(retinol) transport into and out of intestinal Caco-2 cells. Journal of Lipid Research, 2007. 
48(10): p. 2283-2294. 
54. Wongsiriroj, N., et al., The molecular basis of retinoid absorption: a genetic dissection. 
The Journal of biological chemistry, 2008. 283(20): p. 13510-13519. 
55. Dew, S.E. and D.E. Ong, Specificity of the retinol transporter of the rat small intestine 
brush border. Biochemistry, 1994. 33(40): p. 12340-5. 
56. Alapatt, P., et al., Liver retinol transporter and receptor for serum retinol-binding protein 
(RBP4). Journal of Biological Chemistry, 2013. 288(2): p. 1250-1265. 
57. Reboul, E., Absorption of vitamin A and carotenoids by the enterocyte: focus on transport 
proteins. Nutrients, 2013. 5(9): p. 3563-3581. 
58. van Bennekum, A.M., et al., Hydrolysis of retinyl esters by pancreatic triglyceride lipase. 
Biochemistry, 2000. 39(16): p. 4900-4906. 
59. Reboul, E., et al., Pancreatic lipase and pancreatic lipase-related protein 2, but not 
pancreatic lipase-related protein 1, hydrolyze retinyl palmitate in physiological conditions. 
Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 2006. 1761(1): 
p. 4-10. 
60. Herr, F.M. and D.E. Ong, Differential interaction of lecithin-retinol acyltransferase with 
cellular retinol binding proteins. Biochemistry, 1992. 31(29): p. 6748-55. 
61. Yen, C.-L.E., et al., The triacylglycerol synthesis enzyme DGAT1 also catalyzes the 
synthesis of diacylglycerols, waxes, and retinyl esters. Journal of Lipid Research, 2005. 





62. O'Byrne, S.M., et al., Retinoid Absorption and Storage Is Impaired in Mice Lacking 
Lecithin:Retinol Acyltransferase (LRAT)*. Journal of Biological Chemistry, 2005. 280(42): 
p. 35647-35657. 
63. Goodman, D.W., H.S. Huang, and T. Shiratori, TISSUE DISTRIBUTION AND 
METABOLISM OF NEWLY ABSORBED VITAMIN A IN THE RAT. J Lipid Res, 1965. 6: 
p. 390-6. 
64. Nayak, N., E.H. Harrison, and M.M. Hussain, Retinyl ester secretion by intestinal cells: a 
specific and regulated process dependent on assembly and secretion of chylomicrons. J 
Lipid Res, 2001. 42(2): p. 272-80. 
65. Cooper, A.D., Hepatic uptake of chylomicron remnants. J Lipid Res, 1997. 38(11): p. 2173-
92. 
66. Bellovino, D., et al., Retinol Binding Protein and Transthyretin Are Secreted as a Complex 
Formed in the Endoplasmic Reticulum in HepG2 Human Hepatocarcinoma Cells. 
Experimental Cell Research, 1996. 222(1): p. 77-83. 
67. Melhus, H., et al., Retinol-binding protein and transthyretin expressed in HeLa cells form 
a complex in the endoplasmic reticulum in both the absence and the presence of retinol. 
Exp Cell Res, 1991. 197(1): p. 119-24. 
68. Ronne, H., et al., Ligand-dependent regulation of intracellular protein transport: effect of 
vitamin a on the secretion of the retinol-binding protein. J Cell Biol, 1983. 96(3): p. 907-
10. 
69. Blaner, W.S., et al., Vitamin A Absorption, Storage and Mobilization, in The Biochemistry 
of Retinoid Signaling II: The Physiology of Vitamin A - Uptake, Transport, Metabolism and 
Signaling, M.A. Asson-Batres and C. Rochette-Egly, Editors. 2016, Springer Netherlands: 
Dordrecht. p. 95-125. 
70. Blaner, W.S., et al., Retinoids, retinoid-binding proteins, and retinyl palmitate hydrolase 
distributions in different types of rat liver cells. J Lipid Res, 1985. 26(10): p. 1241-51. 
71. Wongsiriroj, N., et al., Genetic dissection of retinoid esterification and accumulation in the 
liver and adipose tissue. J Lipid Res, 2014. 55(1): p. 104-14. 
72. Blaner, W. and J. Olson, Retinol and retinoic acid metabolism Sporn MB Roberts AB 
Goodman DS eds.. The Retinoids: Biology, Chemistry, and Medicine: 229-256. 1994, 
Raven Press New York. 
73. Chen, W. and G. Chen, The Roles of Vitamin A in the Regulation of Carbohydrate, Lipid, 
and Protein Metabolism. Journal of clinical medicine, 2014. 3(2): p. 453-479. 
74. Gesto, M., et al., Retinol Metabolism in the Mollusk Osilinus lineatus Indicates an Ancient 
Origin for Retinyl Ester Storage Capacity. PLOS ONE, 2012. 7(4): p. e35138. 
75. Sahu, B. and A. Maeda, Retinol Dehydrogenases Regulate Vitamin A Metabolism for 
Visual Function. Nutrients, 2016. 8(11): p. 746. 
76. Harper, A.R., et al., Identification of active retinaldehyde dehydrogenase isoforms in the 
postnatal human eye. PloS one, 2015. 10(3): p. e0122008-e0122008. 
77. Fujii, H., et al., Metabolic inactivation of retinoic acid by a novel P450 differentially 
expressed in developing mouse embryos. The EMBO Journal, 1997. 16(14): p. 4163-
4173. 
78. Ray, W.J., et al., CYP26, a Novel Mammalian Cytochrome P450, Is Induced by Retinoic 
Acid and Defines a New Family*. Journal of Biological Chemistry, 1997. 272(30): p. 18702-
18708. 
79. Adams, M.K., et al., The retinaldehyde reductase activity of DHRS3 is reciprocally 
activated by retinol dehydrogenase 10 to control retinoid homeostasis. J Biol Chem, 2014. 





80. O'Byrne, S.M. and W.S. Blaner, Retinol and retinyl esters: biochemistry and physiology. 
Journal of lipid research, 2013. 54(7): p. 1731-1743. 
81. Zhong, M., et al., Retina, retinol, retinal and the natural history of vitamin A as a light 
sensor. Nutrients, 2012. 4(12): p. 2069-2096. 
82. Nakamura, M., et al., A high association with cone dystrophy in Fundus albipunctatus 
caused by mutations of the RDH5 gene. Invest Ophthalmol Vis Sci, 2000. 41(12): p. 3925-
32. 
83. Imanishi, Y., et al., Noninvasive two-photon imaging reveals retinyl ester storage 
structures in the eye. The Journal of cell biology, 2004. 164(3): p. 373-383. 
84. Dowling, J.E. and G. Wald, THE BIOLOGICAL FUNCTION OF VITAMIN A ACID. Proc 
Natl Acad Sci U S A, 1960. 46(5): p. 587-608. 
85. Chen, C.C. and J. Heller, Uptake of retinol and retinoic acid from serum retinol-binding 
protein by retinal pigment epithelial cells. Journal of Biological Chemistry, 1977. 252(15): 
p. 5216-5221. 
86. Wang, J.-S. and V.J. Kefalov, The cone-specific visual cycle. Progress in retinal and eye 
research, 2011. 30(2): p. 115-128. 
87. Blaner, W. and J. Olson, The retinoids: biology, chemistry, and medicine. New York: 
Raven Press. p, 1994: p. 229-255. 
88. Mallia, A.K., J.E. Smith, and D.W. Goodman, Metabolism of retinol-binding protein and 
vitamin A during hypervitaminosis A in the rat. J Lipid Res, 1975. 16(3): p. 180-8. 
89. The Pathophysiological Basis of Vitamin a Toxicity. Nutrition Reviews, 1982. 40(9): p. 272-
274. 
90. Heller, J., Interactions of plasma retinol-binding protein with its receptor. Specific binding 
of bovine and human retinol-binding protein to pigment epithelium cells from bovine eyes. 
J Biol Chem, 1975. 250(10): p. 3613-9. 
91. Heller, J. and D. Bok, A Specific Receptor for Retinol Binding Protein as Detected by the 
Binding of Human and Bovine Retinol Binding Protein to Pigment Epithelial Cells. 
American Journal of Ophthalmology, 1976. 81(1): p. 93-97. 
92. Sundaram, M., et al., The transfer of retinol from serum retinol-binding protein to cellular 
retinol-binding protein is mediated by a membrane receptor. J Biol Chem, 1998. 273(6): 
p. 3336-42. 
93. Futterman, S. and J. Heller, The Enhancement of Fluorescence and the Decreased 
Susceptibility to Enzymatic Oxidation of Retinol Complexed with Bovine Serum Albumin, 
&#x3b2;-Lactoglobulin, and the Retinol-binding Protein of Human Plasma. Journal of 
Biological Chemistry, 1972. 247(16): p. 5168-5172. 
94. N'Soukpoé-Kossi, C.N., et al., Retinol and retinoic acid bind human serum albumin: 
Stability and structural features. International Journal of Biological Macromolecules, 2007. 
40(5): p. 484-490. 
95. Rask, L. and P.A. Peterson, In vitro uptake of vitamin A from the retinol-binding plasma 
protein to mucosal epithelial cells from the monkey's small intestine. J Biol Chem, 1976. 
251(20): p. 6360-6. 
96. Sivaprasadarao, A., M. Boudjelal, and J.B. Findlay, Solubilization and purification of the 
retinol-binding protein receptor from human placental membranes. The Biochemical 
journal, 1994. 302 ( Pt 1)(Pt 1): p. 245-251. 
97. Shingleton, J.L., M.K. Skinner, and D.E. Ong, Retinol esterification in Sertoli cells by 





98. Hagen, E., et al., Uptake of vitamin A in macrophages from physiologic transport proteins: 
role of retinol-binding protein and chylomicron remnants. The Journal of nutritional 
biochemistry, 1999. 10(6): p. 345-352. 
99. Båvik, C.O., C. Busch, and U. Eriksson, Characterization of a plasma retinol-binding 
protein membrane receptor expressed in the retinal pigment epithelium. J Biol Chem, 
1992. 267(32): p. 23035-42. 
100. Ward, S.J., et al., A retinol-binding protein receptor-mediated mechanism for uptake of 
vitamin A to postimplantation rat embryos. Biology of reproduction, 1997. 57(4): p. 751-
755. 
101. Bouillet, P., et al., Efficient Cloning of cDNAs of Retinoic Acid-Responsive Genes in P19 
Embryonal Carcinoma Cells and Characterization of a Novel Mouse Gene, Stra1 (Mouse 
LERK-2/Eplg2). Developmental Biology, 1995. 170(2): p. 420-433. 
102. Bouillet, P., et al., Developmental expression pattern of Stra6, a retinoic acid-responsive 
gene encoding a new type of membrane protein. Mech Dev, 1997. 63(2): p. 173-86. 
103. Kawaguchi, R., et al., A Membrane Receptor for Retinol Binding Protein Mediates Cellular 
Uptake of Vitamin A. Science, 2007. 315(5813): p. 820-825. 
104. Kawaguchi, R., et al., Mapping the membrane topology and extracellular ligand binding 
domains of the retinol binding protein receptor. Biochemistry, 2008. 47(19): p. 5387-95. 
105. Zhong, M., et al., Vitamin A Transport and the Transmembrane Pore in the Cell-Surface 
Receptor for Plasma Retinol Binding Protein. PLOS ONE, 2013. 8(11): p. e73838. 
106. Naylor, A., et al., Tight Junctions of the Outer Blood Retina Barrier. International journal 
of molecular sciences, 2019. 21(1): p. 211. 
107. Daruwalla, A., et al., Structural biology of 11-cis-retinaldehyde production in the classical 
visual cycle. The Biochemical journal, 2018. 475(20): p. 3171-3188. 
108. Kelly, M., et al., Transport of vitamin A across blood-tissue barriers is facilitated by STRA6. 
The FASEB Journal, 2016. 30(8): p. 2985-2995. 
109. Ruiz, A., et al., Retinoid Content, Visual Responses, and Ocular Morphology Are 
Compromised in the Retinas of Mice Lacking the Retinol-Binding Protein Receptor, 
STRA6. Investigative Ophthalmology & Visual Science, 2012. 53(6): p. 3027-3039. 
110. Clagett-Dame, M. and H.F. DeLuca, The role of vitamin A in mammalian reproduction and 
embryonic development. Annu Rev Nutr, 2002. 22: p. 347-81. 
111. Rothman, K.J., et al., Teratogenicity of high vitamin A intake. New England Journal of 
Medicine, 1995. 333(21): p. 1369-1373. 
112. Sivaprasadarao, A. and J.B. Findlay, The interaction of retinol-binding protein with its 
plasma-membrane receptor. Biochem J, 1988. 255(2): p. 561-9. 
113. Sivaprasadarao, A. and J.B. Findlay, The mechanism of uptake of retinol by plasma-
membrane vesicles. The Biochemical journal, 1988. 255(2): p. 571-579. 
114. Quadro, L., et al., Pathways of vitamin A delivery to the embryo: insights from a new 
tunable model of embryonic vitamin A deficiency. Endocrinology, 2005. 146(10): p. 4479-
90. 
115. Quadro, L., et al., Transplacental delivery of retinoid: the role of retinol-binding protein and 
lipoprotein retinyl ester. Am J Physiol Endocrinol Metab, 2004. 286(5): p. E844-51. 
116. Lun, M.P., E.S. Monuki, and M.K. Lehtinen, Development and functions of the choroid 
plexus–cerebrospinal fluid system. Nature Reviews Neuroscience, 2015. 16(8): p. 445-
457. 
117. Libien, J. and W.S. Blaner, Retinol and retinol-binding protein in cerebrospinal fluid: can 
vitamin A take the "idiopathic" out of idiopathic intracranial hypertension? J 





118. Lohnes, D., et al., Function of the retinoic acid receptors (RARs) during development (I). 
Craniofacial and skeletal abnormalities in RAR double mutants. Development, 1994. 
120(10): p. 2723-2748. 
119. Dräger, U.C., Retinoic acid signaling in the functioning brain. Science Signaling, 2006. 
2006(324): p. pe10-pe10. 
120. Misner, D.L., et al., Vitamin A deprivation results in reversible loss of hippocampal long-
term synaptic plasticity. Proc Natl Acad Sci U S A, 2001. 98(20): p. 11714-9. 
121. Maret, S., et al., Retinoic acid signaling affects cortical synchrony during sleep. Science, 
2005. 310(5745): p. 111-3. 
122. Olson, C.R. and C.V. Mello, Significance of vitamin A to brain function, behavior and 
learning. Molecular nutrition & food research, 2010. 54(4): p. 489-495. 
123. Kawaguchi, R., et al., Vitamin A Transport Mechanism of the Multitransmembrane Cell-
Surface Receptor STRA6. Membranes, 2015. 5(3): p. 425-453. 
124. Kawaguchi, R., et al., STRA6-catalyzed vitamin A influx, efflux, and exchange. J Membr 
Biol, 2012. 245(11): p. 731-45. 
125. Isken, A., et al., RBP4 disrupts vitamin A uptake homeostasis in a STRA6-deficient animal 
model for Matthew-Wood syndrome. Cell metabolism, 2008. 7(3): p. 258-268. 
126. Mills, J.P., H.C. Furr, and S.A. Tanumihardjo, Retinol to retinol-binding protein (RBP) is 
low in obese adults due to elevated apo-RBP. Experimental biology and medicine 
(Maywood, N.J.), 2008. 233(10): p. 1255-1261. 
127. Kawaguchi, R., et al., Receptor-Mediated Cellular Uptake Mechanism That Couples to 
Intracellular Storage. ACS Chemical Biology, 2011. 6(10): p. 1041-1051. 
128. Kawaguchi, R., et al., Differential and isomer-specific modulation of vitamin A transport 
and the catalytic activities of the RBP receptor by retinoids. The Journal of membrane 
biology, 2013. 246(8): p. 647-660. 
129. Heller, J. and J. Horwitz, Conformational Changes following Interaction between Retinol 
Isomers and Human Retinol-binding Protein and between the Retinol-binding Protein and 
Prealbumin. Journal of Biological Chemistry, 1973. 248(18): p. 6308-6316. 
130. Kane, M.A., F.V. Bright, and J.L. Napoli, Binding affinities of CRBPI and CRBPII for 9-cis-
retinoids. Biochim Biophys Acta, 2011. 1810(5): p. 514-8. 
131. Zanotti, G., R. Berni, and H.L. Monaco, Crystal structure of liganded and unliganded forms 
of bovine plasma retinol-binding protein. J Biol Chem, 1993. 268(15): p. 10728-38. 
132. Berni, R., et al., Retinoids: in vitro interaction with retinol-binding protein and influence on 
plasma retinol. The FASEB Journal, 1993. 7(12): p. 1179-1184. 
133. Pasutto, F., et al., Mutations in STRA6 cause a broad spectrum of malformations including 
anophthalmia, congenital heart defects, diaphragmatic hernia, alveolar capillary dysplasia, 
lung hypoplasia, and mental retardation. American journal of human genetics, 2007. 80(3): 
p. 550-560. 
134. Golzio, C., et al., Matthew-Wood syndrome is caused by truncating mutations in the 
retinol-binding protein receptor gene STRA6. American journal of human genetics, 2007. 
80(6): p. 1179-1187. 
135. West, B., K.E. Bove, and A.M. Slavotinek, Two novel STRA6 mutations in a patient with 
anophthalmia and diaphragmatic eventration. American journal of medical genetics. Part 
A, 2009. 149A(3): p. 539-542. 
136. Casey, J., et al., First implication of STRA6 mutations in isolated anophthalmia, 
microphthalmia, and coloboma: a new dimension to the STRA6 phenotype. Human 





137. Chassaing, N., et al., Phenotypic spectrum of STRA6 mutations: from Matthew-Wood 
syndrome to non-lethal anophthalmia. Hum Mutat, 2009. 30(5): p. E673-81. 
138. Kawaguchi, R., et al., An essential ligand-binding domain in the membrane receptor for 
retinol-binding protein revealed by large-scale mutagenesis and a human polymorphism. 
The Journal of biological chemistry, 2008. 283(22): p. 15160-15168. 
139. Altucci, L. and H. Gronemeyer, The promise of retinoids to fight against cancer. Nature 
Reviews Cancer, 2001. 1(3): p. 181-193. 
140. Szeto, W., et al., Overexpression of the Retinoic Acid-responsive Gene 
<strong><em>Stra6</em></strong> in Human Cancers and Its Synergistic Induction by 
Wnt-1 and Retinoic Acid. Cancer Research, 2001. 61(10): p. 4197-4205. 
141. Berry, D.C., L. Levi, and N. Noy, Holo-retinol-binding protein and its receptor STRA6 drive 
oncogenic transformation. Cancer Res, 2014. 74(21): p. 6341-51. 
142. Karunanithi, S., et al., RBP4-STRA6 Pathway Drives Cancer Stem Cell Maintenance and 
Mediates High-Fat Diet-Induced Colon Carcinogenesis. Stem cell reports, 2017. 9(2): p. 
438-450. 
143. Wu, J.M., A.M. DiPietrantonio, and T.C. Hsieh, Mechanism of fenretinide (4-HPR)-induced 
cell death. Apoptosis, 2001. 6(5): p. 377-88. 
144. Yang, Q., et al., Serum retinol binding protein 4 contributes to insulin resistance in obesity 
and type 2 diabetes. Nature, 2005. 436(7049): p. 356-62. 
145. Berry, D.C. and N. Noy, Signaling by vitamin A and retinol-binding protein in regulation of 
insulin responses and lipid homeostasis. Biochimica et biophysica acta, 2012. 1821(1): p. 
168-176. 
146. Berry, D.C., et al., Signaling by vitamin A and retinol-binding protein regulates gene 
expression to inhibit insulin responses. Proceedings of the National Academy of Sciences 
of the United States of America, 2011. 108(11): p. 4340-4345. 
147. Darnell, J.E., Jr., I.M. Kerr, and G.R. Stark, Jak-STAT pathways and transcriptional 
activation in response to IFNs and other extracellular signaling proteins. Science, 1994. 
264(5164): p. 1415-21. 
148. Emanuelli, B., et al., SOCS-3 is an insulin-induced negative regulator of insulin signaling. 
J Biol Chem, 2000. 275(21): p. 15985-91. 
149. Beg, M., et al., Distinct Akt phosphorylation states are required for insulin regulated Glut4 
and Glut1-mediated glucose uptake. eLife, 2017. 6: p. e26896. 
150. Kersten, S., B. Desvergne, and W. Wahli, Roles of PPARs in health and disease. Nature, 
2000. 405(6785): p. 421-4. 
151. Shimabukuro, M., et al., Direct antidiabetic effect of leptin through triglyceride depletion of 
tissues. Proc Natl Acad Sci U S A, 1997. 94(9): p. 4637-41. 
152. Dentelli, P., et al., Formation of STAT5/PPARgamma transcriptional complex modulates 
angiogenic cell bioavailability in diabetes. Arterioscler Thromb Vasc Biol, 2009. 29(1): p. 
114-20. 
153. Motani, A., et al., Identification and characterization of a non-retinoid ligand for retinol-
binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo. The Journal 
of biological chemistry, 2009. 284(12): p. 7673-7680. 
154. Muenzner, M., et al., Retinol-binding protein 4 and its membrane receptor STRA6 control 
adipogenesis by regulating cellular retinoid homeostasis and retinoic acid receptor α 
activity. Molecular and cellular biology, 2013. 33(20): p. 4068-4082. 
155. Chen, Y., et al., Structure of the STRA6 receptor for retinol uptake. Science (New York, 





156. Young, B.D., Varney, K.M., Wilder, P.T., Costabile, B.K., Pozharski, E., Cook, M.E., 
Godoy-Ruiz, R., Clarke, O.B., Mancia, F., Weber, D.J., Physiologically relevant free Ca2+ 
ion concentrations regulate STRA6-calmodulin complex formation via the BP2 region of 
STRA6. 2021: Submited to JMB. 
157. Berridge, M.J., P. Lipp, and M.D. Bootman, The versatility and universality of calcium 
signalling. Nature Reviews Molecular Cell Biology, 2000. 1(1): p. 11-21. 
158. Zhong, M., et al., Regulatory mechanism for the transmembrane receptor that mediates 
bidirectional vitamin A transport. Proceedings of the National Academy of Sciences, 2020. 
117(18): p. 9857-9864. 
159. Tribet, C., R. Audebert, and J.-L. Popot, Amphipols: Polymers that keep membrane 
proteins soluble in aqueous solutions. Proceedings of the National Academy of Sciences, 
1996. 93(26): p. 15047-15050. 
160. Bayburt, T.H., J.W. Carlson, and S.G. Sligar, Reconstitution and imaging of a membrane 
protein in a nanometer-size phospholipid bilayer. Journal of structural biology, 1998. 
123(1): p. 37-44. 
161. Costabile, B.K., et al., Chapter Five - Sample preparation for structural and functional 
analyses of the STRA6 receptor for retinol-binding protein, in Methods in Enzymology, E. 
Pohl, Editor. 2020, Academic Press. p. 95-117. 
162. Gao, Y., et al., TRPV1 structures in nanodiscs reveal mechanisms of ligand and lipid 
action. Nature, 2016. 534(7607): p. 347-351. 
163. Liao, M., et al., Structure of the TRPV1 ion channel determined by electron cryo-
microscopy. Nature, 2013. 504(7478): p. 107-112. 
164. Etzkorn, M., et al., Cell-free Expressed Bacteriorhodopsin in Different Soluble Membrane 
Mimetics: Biophysical Properties and NMR Accessibility. Structure, 2013. 21(3): p. 394-
401. 
165. Mazhab-Jafari, M.T., et al., Atomic model for the membrane-embedded VO motor of a 
eukaryotic V-ATPase. Nature, 2016. 539(7627): p. 118-122. 
166. Roh, S.-H., et al., The 3.5-Å CryoEM Structure of Nanodisc-Reconstituted Yeast Vacuolar 
ATPase V(o) Proton Channel. Molecular cell, 2018. 69(6): p. 993-1004.e3. 
167. Malpeli, G., C. Folli, and R. Berni, Retinoid binding to retinol-binding protein and the 
interference with the interaction with transthyretin. Biochimica et Biophysica Acta (BBA) - 
Protein Structure and Molecular Enzymology, 1996. 1294(1): p. 48-54. 
168. Chou, C.M., et al., Biochemical Basis for Dominant Inheritance, Variable Penetrance, and 
Maternal Effects in RBP4 Congenital Eye Disease. Cell, 2015. 161(3): p. 634-646. 
169. Mao, Y., et al., Binding competition to the POPG lipid bilayer of Ca2+, Mg2+, Na+, and K+ 
in different ion mixtures and biological implication. J Phys Chem B, 2013. 117(3): p. 850-
8. 
170. Macdonald, P.M. and J. Seelig, Calcium binding to mixed phosphatidylglycerol-
phosphatidylcholine bilayers as studied by deuterium nuclear magnetic resonance. 
Biochemistry, 1987. 26(5): p. 1231-40. 
171. Kalienkova, V., et al., Stepwise activation mechanism of the scramblase nhTMEM16 
revealed by cryo-EM. eLife, 2019. 8: p. e44364. 
172. Terra, R., et al., To Investigate the Necessity of STRA6 Upregulation in T Cells during T 
Cell Immune Responses. PLOS ONE, 2014. 8(12): p. e82808. 
173. Kelly, M. and J. von Lintig, STRA6: role in cellular retinol uptake and efflux. Hepatobiliary 
Surgery and Nutrition, 2015. 4(4): p. 229-242. 
174. Amengual, J., et al., STRA6 is critical for cellular vitamin A uptake and homeostasis. 





175. Le, H.-G.T., J.E. Dowling, and D.J. Cameron, Early retinoic acid deprivation in developing 
zebrafish results in microphthalmia. Visual neuroscience, 2012. 29(4-5): p. 219-228. 
176. Casey, J., et al., First implication of STRA6 mutations in isolated anophthalmia, 
microphthalmia, and coloboma: A new dimension to the STRA6 phenotype. Human 
Mutation, 2011. 32(12): p. 1417-1426. 
177. Shidoji, Y. and Y. Muto, Vitamin A transport in plasma of the non-mammalian vertebrates: 
isolation and partial characterization of piscine retinol-binding protein1. Journal of Lipid 
Research, 1977. 18(6): p. 679-691. 
178. Episkopou, V., et al., Disruption of the transthyretin gene results in mice with depressed 
levels of plasma retinol and thyroid hormone. Proceedings of the National Academy of 
Sciences, 1993. 90(6): p. 2375-2379. 
179. Folli, C., et al., Distinctive binding and structural properties of piscine transthyretin. FEBS 
Letters, 2003. 555(2): p. 279-284. 
180. Mancia, F. and J. Love, High throughput platforms for structural genomics of integral 
membrane proteins. Current Opinion in Structural Biology, 2011. 21(4): p. 517-522. 
181. Altschul, S.F., et al., Basic local alignment search tool. J Mol Biol, 1990. 215(3): p. 403-
10. 
182. Luckow, V.A., et al., Efficient generation of infectious recombinant baculoviruses by site-
specific transposon-mediated insertion of foreign genes into a baculovirus genome 
propagated in Escherichia coli. Journal of virology, 1993. 67(8): p. 4566-4579. 
183. Goehring, A., et al., Screening and large-scale expression of membrane proteins in 
mammalian cells for structural studies. Nature Protocols, 2014. 9(11): p. 2574-2585. 
184. Wagner, T., et al., SPHIRE-crYOLO is a fast and accurate fully automated particle picker 
for cryo-EM. Communications Biology, 2019. 2(1): p. 218. 
185. Hattori, M., R.E. Hibbs, and E. Gouaux, A fluorescence-detection size-exclusion 
chromatography-based thermostability assay for membrane protein precrystallization 
screening. Structure, 2012. 20(8): p. 1293-9. 
186. Efremov, R.G., C. Gatsogiannis, and S. Raunser, Lipid Nanodiscs as a Tool for High-
Resolution Structure Determination of Membrane Proteins by Single-Particle Cryo-EM. 
Methods Enzymol, 2017. 594: p. 1-30. 
187. Romani, A.M.P., Cellular magnesium homeostasis. Archives of biochemistry and 
biophysics, 2011. 512(1): p. 1-23. 
188. Newcomer, M.E., et al., The three-dimensional structure of retinol-binding protein. The 
EMBO journal, 1984. 3(7): p. 1451-1454. 
189. Flower, D.R., The lipocalin protein family: structure and function. The Biochemical journal, 
1996. 318 ( Pt 1)(Pt 1): p. 1-14. 
190. Pérez, M.D. and M. Calvo, Interaction of β-Lactoglobulin with Retinol and Fatty Acids and 
Its Role as a Possible Biological Function for This Protein: A Review. Journal of Dairy 
Science, 1995. 78(5): p. 978-988. 
191. Zanotti, G. and R. Berni, Plasma Retinol-Binding Protein: Structure and Interactions with 
Retinol, Retinoids, and Transthyretin, in Vitamins & Hormones. 2004, Academic Press. p. 
271-295. 
192. Monaco, H., M. Rizzi, and A. Coda, Structure of a complex of two plasma proteins: 
transthyretin and retinol-binding protein. Science, 1995. 268(5213): p. 1039-1041. 
193. Sivaprasadarao, A. and J.B. Findlay, Structure-function studies on human retinol-binding 






194. Melhus, H., et al., Epitope mapping of a monoclonal antibody that blocks the binding of 
retinol-binding protein to its receptor. Biochemical and biophysical research 
communications, 1995. 210(1): p. 105-112. 
195. Calderone, V., R. Berni, and G. Zanotti, High-resolution structures of retinol-binding 
protein in complex with retinol: pH-induced protein structural changes in the crystal state. 
J Mol Biol, 2003. 329(4): p. 841-50. 
196. Zhong, M. and H. Sun, A Genetic Clog in the Vitamin A Transport Machinery. Cell, 2015. 
161(3): p. 435-437. 
197. Thomson, C.A., et al., A Simplified Method for the Efficient Refolding and Purification of 
Recombinant Human GM-CSF. PLOS ONE, 2012. 7(11): p. e49891. 
198. Kawaguchi, R. and H. Sun, Techniques to study specific cell-surface receptor-mediated 
cellular vitamin A uptake. Methods Mol Biol, 2010. 652: p. 341-61. 
199. Kawaguchi, R., M. Zhong, and H. Sun, Real-time analyses of retinol transport by the 
membrane receptor of plasma retinol binding protein. Journal of visualized experiments : 
JoVE, 2013(71): p. e50169-e50169. 
200. Bepler, T., et al., Positive-unlabeled convolutional neural networks for particle picking in 
cryo-electron micrographs. Nature methods, 2019. 16(11): p. 1153-1160. 
201. Breen, C.J., et al., Production of Functional Human Vitamin A Transporter/RBP Receptor 
(STRA6) for Structure Determination. PLOS ONE, 2015. 10(3): p. e0122293. 
202. Donoghue, S., et al., Placental transport of retinol in sheep. J Nutr, 1982. 112(11): p. 2197-
203. 
203. Jaworowski, A., et al., Protein synthesis and secretion by cultured retinal pigment 
epithelia. Biochimica et Biophysica Acta (BBA) - General Subjects, 1995. 1245(1): p. 121-
129. 
204. Perduca, M., et al., High resolution crystal structure data of human plasma retinol-binding 
protein (RBP4) bound to retinol and fatty acids. Data in brief, 2018. 18: p. 1073-1081. 
205. Naylor, H.M. and M.E. Newcomer, The Structure of Human Retinol-Binding Protein (RBP) 
with Its Carrier Protein Transthyretin Reveals an Interaction with the Carboxy Terminus of 
RBP. Biochemistry, 1999. 38(9): p. 2647-2653. 
206. Sundaram, M., et al., The transfer of transthyretin and receptor-binding properties from 
the plasma retinol-binding protein to the epididymal retinoic acid-binding protein. The 
Biochemical journal, 2002. 362(Pt 2): p. 265-271. 
207. Perduca, M., et al., Human plasma retinol-binding protein (RBP4) is also a fatty acid-
binding protein. Biochim Biophys Acta Mol Cell Biol Lipids, 2018. 1863(4): p. 458-466. 
208. Zanotti, G., G. Malpeli, and R. Berni, The interaction of N-ethyl retinamide with plasma 
retinol-binding protein (RBP) and the crystal structure of the retinoid-RBP complex at 1.9-
A resolution. Journal of Biological Chemistry, 1993. 268(33): p. 24873-24879. 
209. Rask, L., A. Vahlquist, and P.A. Peterson, Studies on two physiological forms of the human 
retinol-binding protein differing in vitamin A and arginine content. Journal of Biological 
Chemistry, 1971. 246(21): p. 6638-6646. 
210. Zanotti, G., et al., Structural and mutational analyses of protein-protein interactions 
between transthyretin and retinol-binding protein. Febs j, 2008. 275(23): p. 5841-54. 
211. Zajc, C.U., et al., A conformation-specific ON-switch for controlling CAR T cells with an 
orally available drug. Proceedings of the National Academy of Sciences, 2020. 117(26): 
p. 14926-14935. 
212. Koide, S. and S.S. Sidhu, The importance of being tyrosine: lessons in molecular 






213. Berry, D.C., et al., Transthyretin blocks retinol uptake and cell signaling by the holo-retinol-
binding protein receptor STRA6. Mol Cell Biol, 2012. 32(19): p. 3851-9. 
214. Berry, D.C., et al., The STRA6 receptor is essential for retinol-binding protein-induced 
insulin resistance but not for maintaining vitamin A homeostasis in tissues other than the 
eye. J Biol Chem, 2013. 288(34): p. 24528-39. 
215. Berry, D.C., et al., Cross talk between signaling and vitamin A transport by the retinol-
binding protein receptor STRA6. Molecular and cellular biology, 2012. 32(15): p. 3164-
3175. 
216. Menozzi, I., et al., Structural and molecular determinants affecting the interaction of retinol 
with human CRBP1. J Struct Biol, 2017. 197(3): p. 330-339. 
217. Redondo, C., et al., Identification of the retinol-binding protein (RBP) interaction site and 
functional state of RBPs for the membrane receptor. Faseb j, 2008. 22(4): p. 1043-54. 
218. Dominik, P.K. and A.A. Kossiakoff, Chapter Eleven - Phage Display Selections for Affinity 
Reagents to Membrane Proteins in Nanodiscs, in Methods in Enzymology, A.K. Shukla, 
Editor. 2015, Academic Press. p. 219-245. 
219. Starovasnik, M.A., et al., A series of point mutations reveal interactions between the 
calcium-binding sites of calmodulin. Protein science : a publication of the Protein Society, 
1992. 1(2): p. 245-253. 
220. Piazza, M., et al., Structural Consequences of Calmodulin EF Hand Mutations. 
Biochemistry, 2017. 56(7): p. 944-956. 
221. Kim, J., et al., Structure and drug resistance of the Plasmodium falciparum transporter 
PfCRT. Nature, 2019. 576(7786): p. 315-320. 
222. Bosworth, N. and P. Towers, Scintillation proximity assay. Nature, 1989. 341(6238): p. 
167-8. 
223. Xia, L., et al., Scintillation proximity assay (SPA) as a new approach to determine a 
ligand's kinetic profile. A case in point for the adenosine A1 receptor. Purinergic signalling, 
2016. 12(1): p. 115-126. 
224. Christensen, E.I., et al., Evidence for an essential role of megalin in transepithelial 
transport of retinol. J Am Soc Nephrol, 1999. 10(4): p. 685-95. 
225. Rosales, F.J., et al., Effects of acute inflammation on plasma retinol, retinol-binding 
protein, and its mRNA in the liver and kidneys of vitamin A-sufficient rats. Journal of lipid 
research, 1996. 37(5): p. 962-971. 
226. Ivanov, I.I., et al., Induction of intestinal Th17 cells by segmented filamentous bacteria. 
Cell, 2009. 139(3): p. 485-498. 
227. Fluckinger, M., et al., Lipocalin-interacting-membrane-receptor (LIMR) mediates cellular 
internalization of β-lactoglobulin. Biochimica et Biophysica Acta (BBA) - Biomembranes, 
2008. 1778(1): p. 342-347. 
228. Derebe, M.G., et al., Serum amyloid A is a retinol binding protein that transports retinol 
during bacterial infection. eLife, 2014. 3: p. e03206-e03206. 
229. Ciuciu, A.-M.S., et al., Thermally driven interactions between β-lactoglobulin and retinol 
acetate investigated by fluorescence spectroscopy and molecular modeling methods. 
Dairy Science & Technology, 2016. 96(3): p. 405-423. 
230. Noy, N. and Z.J. Xu, Interactions of retinol with binding proteins: implications for the 
mechanism of uptake by cells. Biochemistry, 1990. 29(16): p. 3878-83. 
231. Ballew, C., D. Galuska, and C. Gillespie, High Serum Retinyl Esters Are Not Associated 
with Reduced Bone Mineral Density in the Third National Health and Nutrition Examination 





232. Vogel, S., et al., Retinol-binding protein-deficient mice: biochemical basis for impaired 
vision. Biochemistry, 2002. 41(51): p. 15360-8. 
233. Harrison, E.H., Mechanisms of Transport and Delivery of Vitamin A and Carotenoids to 
the Retinal Pigment Epithelium. Molecular Nutrition & Food Research, 2019. 63(15): p. 
1801046. 
234. Wassef, L. and L. Quadro, Uptake of Dietary Retinoids at the Maternal-Fetal Barrier: IN 
VIVO EVIDENCE FOR THE ROLE OF LIPOPROTEIN LIPASE AND ALTERNATIVE 
PATHWAYS*. Journal of Biological Chemistry, 2011. 286(37): p. 32198-32207. 
235. Bern, M., et al., The role of albumin receptors in regulation of albumin homeostasis: 
Implications for drug delivery. Journal of Controlled Release, 2015. 211: p. 144-162. 
236. Barua, A.B. and N. Sidell, Retinoyl β-Glucuronide: A Biologically Active Interesting 
Retinoid. The Journal of Nutrition, 2004. 134(1): p. 286S-289S. 
237. Barua, A.B. and J.A. Olson, Chemical synthesis of all-trans-[11-3H] retinoyl β-glucuronide 
and its metabolism in rats in vivo. Biochemical Journal, 1989. 263(2): p. 403-409. 
238. Barua, A.B., P.K. Duitsman, and J.A. Olson, The Role of Vitamin A Status in the 
Conversion of All-Trans Retinoyl β-Glucuronide to Retinoic Acid in Male Sprague-Dawley 
Rats. The Journal of Nutritional Biochemistry, 1998. 9(1): p. 8-16. 
239. Mehta, R., et al., Retinoid glucuronides do not interact with retinoid binding proteins. 
International journal for vitamin and nutrition research. Internationale Zeitschrift fur 
Vitamin-und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 
1992. 62(2): p. 143-147. 
240. Sani, B.P., et al., Retinoyl β-glucuronide: lack of binding to receptor proteins of retinoic 
acid as related to biological activity. Biochemical pharmacology, 1992. 43(4): p. 919-922. 
241. Gunning, D.B., A.B. Barua, and J.A. Olson, Comparative teratogenicity and metabolism 
of all-trans retinoic acid, all-trans retinoyl β-glucose, and all-trans retinoyl β-glucuronide in 
pregnant Sprague-Dawley rats. Teratology, 1993. 47(1): p. 29-36. 
242. Gunning, D., et al., Retinoyl β-glucuronide: A nontoxic retinoid for the topical treatment of 
acne. Journal of Dermatological Treatment, 1994. 5(4): p. 181-185. 
243. Dancis, J., et al., Transfer and metabolism of retinol by the perfused human placenta. 
Pediatr Res, 1992. 32(2): p. 195-9. 
244. Quadro, L., et al., Impaired retinal function and vitamin A availability in mice lacking retinol-
binding protein. Embo j, 1999. 18(17): p. 4633-44. 
245. Ong, D.E., et al., Synthesis and secretion of retinol-binding protein and transthyretin by 
cultured retinal pigment epithelium. Biochemistry, 1994. 33(7): p. 1835-42. 
246. Gonzalez-Fernandez, F., C.A. Baer, and D. Ghosh, Module structure of interphotoreceptor 
retinoid-binding protein (IRBP) may provide bases for its complex role in the visual cycle 
- structure/function study of Xenopus IRBP. BMC biochemistry, 2007. 8: p. 15-15. 
247. Quadro, L., et al., Muscle expression of human retinol-binding protein (RBP). Suppression 
of the visual defect of RBP knockout mice. J Biol Chem, 2002. 277(33): p. 30191-7. 
248. Hayes, K.C., et al., Retinal pigment epithelium possesses both LDL and scavenger 
receptor activity. Investigative Ophthalmology & Visual Science, 1989. 30(2): p. 225-232. 
249. Tserentsoodol, N., et al., Uptake of cholesterol by the retina occurs primarily via a low 
density lipoprotein receptor-mediated process. Mol Vis, 2006. 12: p. 1306-18. 
250. Thomas, S.E. and E.H. Harrison, Mechanisms of selective delivery of xanthophylls to 
retinal pigment epithelial cells by human lipoproteins. Journal of lipid research, 2016. 





251. Chichili, G.R., et al., β-Carotene Conversion into Vitamin A in Human Retinal Pigment 
Epithelial Cells. Investigative Ophthalmology & Visual Science, 2005. 46(10): p. 3562-
3569. 
252. Biesalski, H.K., et al., Biochemical but not clinical vitamin A deficiency results from 
mutations in the gene for retinol binding protein. Am J Clin Nutr, 1999. 69(5): p. 931-6. 
253. Kim, Y.-K., et al., Retinyl ester formation by lecithin: retinol acyltransferase is a key 
regulator of retinoid homeostasis in mouse embryogenesis. The Journal of biological 
chemistry, 2008. 283(9): p. 5611-5621. 
254. Spiegler, E., et al., Maternal-fetal transfer and metabolism of vitamin A and its precursor 
β-carotene in the developing tissues. Biochimica et biophysica acta, 2012. 1821(1): p. 88-
98. 
255. Lampert, J.M., et al., Provitamin A conversion to retinal via theβ, β-carotene-15, 15′-
oxygenase (bcox) is essential for pattern formation and differentiation during zebrafish 
embryogenesis. 2003. 
256. Solanki, A.K., et al., A Functional Binding Domain in the Rbpr2 Receptor Is Required for 
Vitamin A Transport, Ocular Retinoid Homeostasis, and Photoreceptor Cell Survival in 
Zebrafish. Cells, 2020. 9(5): p. 1099. 
257. Shi, Y., et al., The Retinol Binding Protein Receptor 2 (Rbpr2) is required for Photoreceptor 
Outer Segment Morphogenesis and Visual Function in Zebrafish. Scientific Reports, 2017. 
7(1): p. 16207. 
258. LOBO, G., et al., Mice lacking the Vitamin A transporter RBPR2 show decreased Ocular 
Retinoid Content and Photoreceptor Phenotypes. Investigative Ophthalmology & Visual 
Science, 2020. 61(7): p. 4010-4010. 
259. Goodman, D.S., Overview of current knowledge of metabolism of vitamin A and 
carotenoids. J Natl Cancer Inst, 1984. 73(6): p. 1375-9. 
260. David, M., E. Hodak, and N.J. Lowe, Adverse effects of retinoids. Med Toxicol Adverse 
Drug Exp, 1988. 3(4): p. 273-88. 
261. Sun, H., Membrane receptors and transporters involved in the function and transport of 
vitamin A and its derivatives. Biochimica et biophysica acta, 2012. 1821(1): p. 99-112. 
262. Neculai, D., et al., Structure of LIMP-2 provides functional insights with implications for 
SR-BI and CD36. Nature, 2013. 504(7478): p. 172-176. 
263. Rodrigueza, W.V., et al., Mechanism of scavenger receptor class B type I-mediated 
selective uptake of cholesteryl esters from high density lipoprotein to adrenal cells. J Biol 
Chem, 1999. 274(29): p. 20344-50. 
 
